mechanism	<e12> Antifungals </e12> can significantly decrease the bioavailability of antifungals. 
mechanism	Antacids, nelfinavir, diuretics, quinidine, warfarin, prednisolone, and <e10> amiodarone </e10>, <e20> thyroid-stimulating_agents </e20>, and vitamin_A tablets. 
mechanism	Involuntary <e10> acetaminophen </e10> therapy with <e20> methyldopa </e20> may potentiate the effects of acetaminophen. 
mechanism	Antidepressants - Drugs that are metabolized by CYP3A4 (such as <e10> amiodarone </e10> ) or other beta-adrenergic_agents may interfere with a patient's ability to achieve antidepressant effects, and concomitantly, such medications may increase the dosage of these drugs. 
mechanism	<e10> Propanol </e10> <e22> methotrexate </e22> has been reported to interfere with platelet aggregation, renal toxicity, hepatic enzyme impairment, renal toxicity and renal toxicity by beta-adrenergic agents. 
mechanism	<e10> Carbamazepine </e10> -like antipsychotics such as <e20> fluoxetine </e20> and <e22> clonidine </e22> have been reported to increase the risk of psychosis in subjects receiving these CNS-depressants. 
mechanism	A study performed with <e10> tetracyclines </e10> may indicate that clonidine should not be taken with phenytoin. 
mechanism	<e10> Coadministration of <e20> lithium </e20> to <e22> acetaminophen </e22> resulted in significant decreases in the pharmacokinetics of lithium and the pharmacodynamic effects of acetaminophen ( <e23> benzodiazepines </e23> and metformin, respectively), as well as increases in the intracellular concentrations of lithium and ampicillin, including pharmacokinetics resulting in a statistically significant reduction in the
mechanism	In a healthy adult male, the following drugs may be taken orally: Caffeine (e,g,, <e12> barbiturates </e12>, barbiturates, atorvastatin, furosemide, fluoxetine, furosemide, ginocorticoids, heparin, carbamazepine, heparin, mitragine, methylprednisolone, morphine, <e20> pheny
mechanism	Concomitant administration of <e12> halothane </e12> with <e20> diazepam </e20> may interfere with the analgesic activity of quinidine and the extent of its effects on pharmacokinetics. 
mechanism	Therefore, administration of <e10> azithromycin </e10> should not be given alone with <e20> phenothiazines </e20> and <e22> methyldopa </e22>. 
mechanism	 
mechanism	 Potassium <e10> Hormone_Coumarin </e10> (Hormone_Coumarin) should not be used to depress the heart rate or to enhance potassium excretion, as are known to occur when <e20> potassium_hormone </e20> is administered alone or with <e21> alcohol </e21>. 
mechanism	 <e10> Aripiprazole </e10> has been shown to reduce the clearance of <e20> cimetidine </e20> by approximately half. 
mechanism	Concomitant administration of <e10> quinidine </e10> with the concomitant use of morphine and <e20> prednisolone </e20> should be avoided. 
mechanism	Combination of co-administration with <e12> thyroid_stimulant </e12> and co-administration with <e22> corticosteroids </e22>, the pharmacokinetic and pharmacodynamics of co-administration of <e22> rifampin </e22> with thyroid_stimulant, the pharmacodynamics of co-administration of rifampin with thyroid_stimulant and concomitant administration of concom
mechanism	<e10> Tylenol </e10> does not alter the pharmacokinetics of the <e20> benzodiazepines </e20>. 
mechanism	However, anterograde hypotension may occur with <e10> hypoglycemia </e10> in patients receiving <e20> <e21> carbamazepine </e21> or similar <e22> antidepressants </e22> (e,g,, quinidine, phenytoin, valproic acid, ketoconazole, diazepam, tetracyclines, barbiturates, verapamil, fluv
mechanism	<e10> Carbamazepine </e10> may decrease the plasma concentrations of <e20> tricyclic_antidepressants </e20>, with possibly increased plasma concentrations due to increased clearance of the antiepileptic and cimetidine. 
mechanism	 <e12> <e20> Phenobarbital </e20>. 
mechanism	Antacids <e10> Phenobarbital </e10>, clonidine, phenytoin, and <e20> beta-blockers </e20> are coadministered with <e22> beta-blockers </e22>. 
mechanism	Since <e11> NSAIDs </e11> affect both intestinal motility and excretion of <e20> acetaminophen </e20>, it is important to be aware that patients receiving these drugs should not be considered taking these drugs during their administration to the general patient population. 
mechanism	
mechanism	Acetaminophen is no longer considered to have <e10> ethylhexylglycerol </e10> or vitamin_C. 
mechanism	Antacids - Preliminary study of concomitant administration of <e10> alginine </e10> with ampicillin or cefurox, <e20> levodopa </e20> and cyclosporine resulted in decreased plasma levels of <e22> concomitant_medications </e22> such as <e22> methotrexate </e22>. 
mechanism	In patients with concomitant <e11> methotrexate </e11> and <e20> clonidine </e20>, concomitant administration of <e21> methotrexate </e21> may cause a prolonged decrease in plasma concentrations of methotrexate and clonidine, thereby decreasing the steady-state rate of <e22> CYP3A4 </e22>. 
mechanism	Combination of <e12> barbiturates </e12> and quinidine has been shown to significantly reduce the effects of #-amino_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_
mechanism	The concomitant administration of <e10> cyclosporine </e10> and protease_inhibitors does not significantly alter the pharmacokinetic profile of <e20> cyclosporine </e20>, concomitantly, or by increasing its binding affinity to the plasma <e20> plasma transport system. 
mechanism	A single dose of <e10> cimetidine </e10> with the following antibiotics : quinidine, cimetidine, metronidazole, quinidine_enzyme_inhibitors, cimetidine_serine, cimetidine_magnesium_depleting_agents, haloperidol, metronidazole, metronidazole_diuretics, valproate, and lithium. 
mechanism	The pharmacokinetics of <e10> cholestyramine </e10> (cimetidine ) and <e20> clonidine </e20> are similar. 
mechanism	Aromatic and CNS-Based Anticoagulants: <e10> Antacids </e10> may affect both the absorption of <e20> beta-blockers </e20> and the excretion of <e22> ketoconazole </e22>. 
mechanism	CNS_analgesics: <e10> benzodiazepines </e10> and <e20> antacids </e20>, antacids and benzodiazepines, antipsychotics, barbiturates, alcohol and alcohol derivatives, and caffeine should not be taken with <e22> alcohol </e22>. 
mechanism	Drugs that interfere with the metabolism of monoamine_oxidase_inhibitors (e,g,, diphenhydramine, <e10> azathioprine </e10>, diazepam, omeprazole, temazepam ) may interact with the drug_coupled_actions model and may increase the clearance of monoamine_oxidase_inhibitors, including <e22> amiodarone </e22> and pred
mechanism	Niacin : At doses of <e12> Niacin </e12> -containing <e20> aminosin </e20> pills, Niacin may result in significantly increased <e20> hyperglycemia </e20> and hyperpigmentation. 
mechanism	Acute therapy with <e10> azathioprine </e10> or phenytoin prior to administration of <e20> phenytoin </e20> does not produce the desired effects. 
mechanism	<e10> Cimetidine </e10> may potentiate the action of acetaminophen, but its inhibitory effects on the renal motility of <e20> antacids </e20> and anticoagulants and their elimination by hepatic and renal enzymes may be antagonized by the concurrent administration of <e22> digoxin </e22> and digoxin. 
mechanism	<e10> POMC_HEX </e10> -an antiarrhythmic : Antidiabetic medications may decrease the action of <e20> piperazine </e20>. 
mechanism	<e10> Coadministration of CYP3A4 inhibitors with <e22> diazir</e22> during treatment of depression may result in reduced fluvoxamine and therefore greater depression. 
mechanism	Ethanol may reduce the absorption of thyroid hormone (e,g,, <e10> bromide </e10> ) and may therefore not occur concurrently with <e20> beta-blockers </e20>. 
mechanism	The pharmacokinetics of <e12> phenytoin </e12> are not completely conclusively determined. 
mechanism	Theophylline (l-butyrophenone), antacids, protease_inhibitors, and <e12> protease_inhibitors </e12> may interact with <e20> methyldopa </e20> or coadministered with other antacids. 
mechanism	Preliminary data suggest that <e12> CIF_oxidase </e12> therapy may be more effective than <e20> CIF_oxidase </e20> therapy on the frequency and extent of gastrointestinal syndrome resulting from <e21> CIF_oxidase </e21> therapy. 
mechanism	<e10> Ammonia </e10> Interactions with <e20> ammonia </e20> ( 
mechanism	<e10> Cholestyramine </e10> ( Crixie ) or <e20> phenytoin </e20> ( Trileptor ) can cause a general anaphylaxis. 
mechanism	<e10> Benzodiazepines </e10> may interact with the metabolite of the benzodiazepine <e22> ethytoin </e22>, and may induce a similar pharmacodynamic response. 
mechanism	<e10> Acaprolimus </e10> and rifampin have not been extensively studied for their action on gastrointestinal tract <e22> oral contraceptives </e22>. 
mechanism	 Ingesting <e10> oral <e22> quinidine </e22> or oral <e20> calcium </e20>, at <e22> and/or # hours after therapy with <e20> methyldopa </e20> resulted in rapid, transient decrease in the plasma concentration of <e22> quinidine </e22> and a reduction in the plasma concentration of levodopa (e,g,,.38 mg/mL
mechanism	In laboratory studies, administration of <e10> dexamethasone </e10> resulted in a significant increase in the binding of caspasex to the <e20> caspasex </e20> membrane. 
mechanism	The patient was given a dose of ethinylestradiol (400 mg/day, weekly) and was given 2,500 mg at a rate of <e10> <e20> antacids </e20> # hours. 
mechanism	Drugs for the inhibition of hepatic AUC secretion or CYP3A4 secretion by oral <e10> albactone </e10> should be added to the following: <e20> alcohol </e20> and insulin (e,g,, <e20> diazepam </e20> ), and anticonvulsants such as <e22> selective serotonin reuptake inhibitors </e22>. 
mechanism	<e12> Antacid </e12> and CYP3A4, <e20> theophylline </e20> and magnesium, may interact with and decrease serum concentrations of quinidine. 
mechanism	<e10> Antihistamines </e10> may reduce the clearance of <e20> rifampin </e20>, but these effects have not been shown in patients taking <e21> methyldopa </e21> alone. 
mechanism	<e12> Antacid </e12> - <e20> acetaminophen </e20> : Drug interactions between methotrexate and acetaminophen were noted. 
mechanism	Although there have been some clinical studies that suggest a reduction in the absorption of <e12> metformin </e12> by <e22> phenytoin </e22>, there have been no clinical studies of concomitant use of metformin with other <e20> drug_inhibitors </e20>. 
mechanism	 <e10> H2_contraceptives </e10> : Use of <e20> nifedipine </e20> for <e21> NSAIDs, which have been shown to have a lower absorption of oral contraceptives than NSAIDs, may increase the likelihood of exposure to fluoroquinolones. 
mechanism	<e10> Chlorpheniramine </e10> is a CYP3A4 inhibitor ( <e20> norepinephrine </e20> ) and CYP3A4 inhibitor ( Crixosporine ). 
mechanism	In patients with nonselective serotonin reuptake inhibitors, <e12> MAOIs </e12>, haloperidol and <e22> cyclosporine </e22> may result in reduced efficacy and increased sedation. 
mechanism	There are no significant pharmacokinetic interactions between <e10> phenytoin </e10> and the following: <e20> digoxin </e20>, quinidine, <e22> sympathomimetic_drugs </e22>, and <e22> coleamide </e22>. 
mechanism	The use of <e10> estrogens </e10> or <e22> endorphin </e22> may increase the rate of side effects. 
mechanism	No clinically relevant data have been obtained from studies that did not employ pharmacologic agents containing <e10> quinidine </e10>. 
mechanism	CYP3A4 and cimetidine are both potent inhibitors of CYP3A4 and cimetidine, and the inhibition of CYP3A4 and cimetidine may be decreased with concurrent administration of <e10> methyldopa </e10>. 
mechanism	<e10> Ethinyl_estradiol </e10> : A single dose of # mg of ethinylestradiol is recommended. 
mechanism	<e10> Phenobarbital </e10> was not effective in reducing the renal clearance of <e20> <e20> ritonavir </e20>. 
mechanism	<e10> Aspirin </e10> -induced hepatic clearance of concomitant <e20> <e22> ketoconazole </e22> has been reported. 
mechanism	Cholestyramine -induced CYP3A4 inhibition is not altered by <e10> morphine </e10>. 
mechanism	<e10> Astute <e22> NOS </e22> # mg doses <e20> ketoconazole </e20> (40 mg) and nelfinavir (100 mg) should be administered concurrently. 
mechanism	<e10> Ketoconazole </e10> : In patients receiving <e20> concomitant use of <e21> naltrexone </e21> or concomitant use of a single dose of <e22> rifadin </e22>, and no concomitant use of a single dose of naltrexone, there was a significant reduction in <e22> ketoconazole </e22> plasma concentrations (8.4
mechanism	A selective serotonin reuptake inhibitor (such as clofibrate, <e10> clofibrate </e10>, and nortriptyline ) that blocks the metabolite CYP3A4 and inhibits the enzyme methyltransferase will reduce the effect of <e20> clofibrate </e20> on the clearance of sirolimus. 
mechanism	<e10> NSAIDs </e10>, aldosterone ( <e20> barbiturates </e20> ), and progestins ( folic acid, phenytoin, prednisolone, metoprolol, ketoconazole, quinidine ) have been reported to decrease <e22> cyclosporine </e22> clearance, resulting in reduced clearance of cyclosporine. 
mechanism	<e10> Agathizine </e10> enhances the pharmacokinetics of <e22> ritonavir </e22>, the active metabolite of the drug, resulting in a higher than expected incidence of CNS toxicity. 
mechanism	<e10> Prozac </e10> / niacin : Preliminary data indicate that <e20> Niacin </e20> is a potential inhibitor of the CYP3A4 enzyme responsible for CYP3A4 conversion, and some studies have demonstrated concomitant CYP3A4 activity when concomitantly with prozac. 
mechanism	<e10> Phenobarbital </e10> or Cimetidine may increase the risk of side effects such as vasoconstriction, hypotension, hyperbaric oxygen levels, hyperventilation, hypertension, and tachycardia. 
mechanism	Etonogestrel, <e12> ketoconazole </e12>, beta-blockers, oral contraceptives, or <e22> coadministration with barbiturates </e22> may increase the drug clearance of <e22> ketoconazole </e22>. 
mechanism	Anticholinergic Antidepressants : In patients receiving coadministration of other antidepressants with monoamine_oxidase_inhibitors, it should be noted that a lower dose of <e10> cimetidine </e10> may be required. 
mechanism	The effect of <e10> anticonvulsants </e10> on hyperbaric oxygen levels in mice is unknown. 
mechanism	In two randomized, controlled clinical trials, rifampin and <e10> sertraline </e10> reduced the dose of <e20> piperidine </e20> for patients taking coadministered sertraline. 
mechanism	Although the extent of efficacy of <e10> probenecid </e10> or <e20> probenecid_acetylsalicylic_acid </e20> is uncertain, data on pharmacokinetics of <e22> probenecid </e22> are obtained. 
mechanism	Coadministration of <e10> cephalosporine </e10> (400 mg/day or approximately 30% of dose) with either <e20> lithium </e20> or lithium acetate (250 mg/day or approximately 40% of dose) resulted in an increased plasma clearance of lithium acetate (200 mg/day or approximately 25% of dose). 
mechanism	 <e10> L-carnitine </e10> : Preliminary data indicate that the binding of <e22> carbamazepine </e22> to an ergot may reduce the toxicity of ergot_enantiomers. 
mechanism	Drug Interactions: NSAIDs : Coadministration of <e12> TNF_antagonists </e12> with <e22> aspirin may potentiate the pharmacokinetics of some <e20> aspirin </e20>. 
mechanism	Concomitant administration of <e10> cimetidine </e10>, progestin, and <e20> amiodarone </e20> resulted in elevations of serum coagulantin and antidiabetic_drug_blocking_agents, as well as increased plasma concentrations of <e22> corticosteroids </e22> and <e22> thiazide_antihistamines </e22>. 
mechanism	
mechanism	 <e10> Ciprofloxacin </e10> may enhance the CNS absorption of coadministered <e20> corticosteroids </e20>. 
mechanism	Concomitant administration of <e10> lithium </e10> with <e22> lithium_oxide </e22> is associated with an increased plasma concentration of lithium. 
mechanism	<e10> Prazosine </e10> - Injection of an intravenous solution containing 1 mg carbamazepine, and a solution containing 5 mg carbamazepine, with <e20> benzodiazepines </e20> -e <e20> indinavir </e20> in combination should not be administered. 
mechanism	<e10> Agrelizide </e10>, <e20> Agrelizide_Agrelizide_L-Derivatives </e20>, and ketoconazole may result in enhanced plasma concentrations of <e21> quinidine </e21>. 
mechanism	<e10> Atrifloxacin </e10> may increase the clearance of <e20> phenylbutazone </e20> and may decrease the clearance of # patients <e21> ritonavir </e21>. 
mechanism	It has been shown that <e10> ketoconazole </e10> can potentiate the CNS effects of a certain inhibitor of the CYP3A4_receptor and potentiate the effects of certain antinociceptive drugs. 
mechanism	Antihistamines : Antihistamines - such as <e10> phenytoin </e10>, amiodarone, and barbiturates - may inhibit the metabolism of <e20> norepinephrine </e20>. 
mechanism	Preliminary data from four other studies in patients receiving concomitant <e10> carbamazepine </e10> therapy with proton pump inhibitors such as phenytoin, nelfinavir, fluoxetine, alprazolam, and phenobarbital suggest that concomitant therapy with phenytoin may reduce the clinical effect of these drugs. 
mechanism	In general, <e12> antihypertensive_agents </e12> should be used with caution when <e20> diazepam </e20> is administered with <e22> phenytoin </e22>, <e23> methotrexate </e23>, <e24> temazepam </e24>, or cyclosporine. 
mechanism	A single oral dose of a <e10> oral_contraceptives </e10> ( estrogens and <e20> nevirapine </e20> ) during the same period increased the proportion of <e20> phenobarbital </e20> with tricyclic_antidepressants by 60% and 60% ( respectively, mean, 15% and 21%, respectively), and anticonvulsants by 38% and 41% ( respectively, mean
mechanism	<e10> SSRIs </e10> : Anticoagulants - Drugs including barbiturates, amiodarone, aminoglycosides, anesthetics, corticosteroids, morphine, phenytoin, rifampin, succinylcholine, rifampinoids, succinylcholine_l-leucine, triazolam, <e20> warfarin </e20>, warfarin
mechanism	 
mechanism	Preliminary studies indicate that <e10> dexamethasone </e10> may enhance CNS depressant effects with pharmacological interaction with <e20> levodopa </e20>. 
mechanism	The use of <e10> bicarbonate </e10>, a metabolite of <e20> methanol </e20>, and other nonsteroidal_anti-inflammatory_agents in the same amount as diclofenac, may have been related to an increased renal clearance. 
mechanism	<e10> Spanosadiazine </e10> : A clinical trial of the combination of <e20> phenytoin </e20> and spanosadiazine was initiated with the latter. 
mechanism	Coadministration of <e12> azithromycin </e12> and <e20> diazepam </e20> may be effective in preventing the hypotension of anhydrous acetaminophen, resulting in pharmacodynamic changes of approximately 50% and hypotension of concomitant medication such as antihistamines, phenytoin, and <e20> phenytoin-butylcarbamate </e20>. 
mechanism	Although there are currently no reports of a decrease in the CMA of ethinyl_estradiol in the <e10> nelfinavir </e10> # mg daily regimen, concomitant use of other <e20> phenytoin </e20> and <e22> metoprolol </e22> may result in a greater reduction in catecholamine metabolism. 
mechanism	<e10> Tegretol </e10>, <e22> clonidine </e22>, <e20> clarithromycin, digoxin, halothane, methotrexate, methotrexate, nicotinic acetylcholine, NIMB, and others can result in increased and/or reversible absorption of these medications. 
mechanism	Other drugs that have an anti-oxidant effect may interact with <e10> clonidine </e10>. 
mechanism	 Anticonvulsants : <e10> quinidine </e10> : <e20> tricyclic_antidepressants </e20>, phenytoin, fluoxetine, famotidine, indinavir, phenobarbital, norethindrone, rifadin, rifampin, thiazide_thiazide, thiazide_diuretics, tricyclic_antidepressants_in
mechanism	Patients receiving <e10> propranolol </e10> should not be administered with <e22> azithromycin </e22> or oral contraceptives. 
mechanism	<e12> Tegretol </e12> may increase the chance of developing a serious allergic reaction if given to <e20> tetracyclines </e20>. 
mechanism	 CYP3A4 metabolism has been shown to be reduced in patients receiving <e10> antacids </e10>, divalent_bromide_oxidase_inhibitors, monoamine_oxidase_inhibitors, and some oral <e20> oral contraceptives </e20>. 
mechanism	 Antacids : cimetidine, <e10> fluoxetine </e10>, prednisolone, rifadin, and warfarin. 
mechanism	Niacinamide, acetaminophen, and <e10> cyclosporine </e10> are all capable of causing a concomitant increase in the clearance of <e20> ampicillin </e20>. 
mechanism	 <e10> Anticholinergic_Agents </e10> (such as ibuprofen and warfarin ) are highly potent anti-depressant agents. 
mechanism	<e10> Sporanogide </e10> Interactions with certain strains of fungi that are generally known to increase <e20> anticonvulsants </e20> : <e20> fluvoxamine </e20>, erythromycin and clofibrate. 
mechanism	 CYP2D6 / MAOIs (e,g,, phenothiazines, <e10> rifampin </e10> ) are coadministered with either <e20> cimetidine </e20> or beta-blockers, which can have a pronounced effect on plasma <e22> amiodarone </e22> levels. 
mechanism	Concomitant administration of <e10> phenytoin </e10> and levodopa has been reported to result in a decrease in blood levels of <e20> phenytoin </e20> and levodopa, and decreased serum concentrations of <e22> levodopa </e22>. 
mechanism	 The clinical management of <e10> ketoconazole </e10> should be carefully monitored when concomitant use of ketoconazole and <e20> ketoconazole </e20> is suspected. 
mechanism	Because <e11> thyroid_blocking_agents </e11> may be toxic to thyroid function, the ingestion of these agents may lead to increased risk of thyroid problems, including, but not limited to, type 2 diabetes, renal failure, and renal insufficiency. 
mechanism	
mechanism	<e12> Atropine </e12> is not able to completely block monoamine_oxidase_blocking activity. 
mechanism	In vitro studies with <e12> alpinephrine </e12> (e,g,, <e20> cimetidine </e20> ) have demonstrated that <e20> aminosinotransferase_inhibitors </e20> interact with several bioactive substances in vivo. 
mechanism	Nefazodone - Aripiprazole ( <e10> rifampin </e10> ) does not affect the pharmacokinetics of these drugs. 
mechanism	Phenobarbital - Phenobarbital is considered the most potent benzodiazepine with a frequency and duration similar to the action of <e10> valproic </e10>. 
mechanism	Pharmacokinetic studies suggest that <e10> phenytoin </e10> may potentiate <e20> methotrexate </e20> / methotrexate_related effects. 
mechanism	In a crossover study involving a single dose of beta-blockers (e,g,, <e10> cimetidine </e10>, and placebo ), and concurrent administration of <e20> fibrinogen </e20> and levonorgestrel, <e22> cimetidine </e22> was observed to be effective in patients receiving <e20> cimetidine </e20> alone. 
mechanism	Coadministration of <e12> concomitant oral <e20> corticosteroids </e20> with these drugs did not alter the pharmacokinetics of <e20> methyldopa </e20> or potentiate the pharmacokinetic of these drugs. 
mechanism	<e10> Tylenol </e10> may induce a dose-dependent reduction in catecholamine metabolism. 
mechanism	CYP2A4 / CYP3A4_agonists: <e10> fluoxetine </e10> / MAO-inducers: CYP3A4_agonists: <e22> chlorpromazine </e22>, phenothiazines, phenothiazines_and_diuretics, fluvoxamine, phenothiazines_antagonists, and <e22> salicylates </e22> can interfere with
mechanism	<e10> Protease </e10>, <e22> rifampin </e22>, <e22> phenytoin </e22> and a protease inhibitor of estrogen secretion. 
mechanism	Niacinamide may interact with other <e10> cyclosporine </e10> and/or oral contraceptives. 
mechanism	Preliminary data suggest that <e12> anticonvulsants </e12> are capable of potentiating <e22> mydriatadine </e22> and/or antifungals and possibly reducing the plasma levels of both drugs. 
mechanism	Methotrexate : However, concomitant use of <e10> cimetidine </e10> and corticosteroids, including <e20> phenytoin </e20> and valproate, with <e20> phenytoin </e20> may decrease the absorption of methotrexate. 
mechanism	Coadministration of <e12> ibuprofen </e12> with either of these agents may result in a significantly increased dose of diuretics, including nelfinavir, cyclosporine, digoxin, omeprazole, ampicillin, <e20> tricyclic_antidepressants </e20>, clarithromycin, sympathomimetic_agents, warfarin, warfarin_benzodiazepines
mechanism	<e10> Magnesium </e10> potentiates the metabolism of the <e20> Magnesium_Kappa_inhibitors </e20>. 
mechanism	Acetaminophen ( <e10> Phenobarbital </e10>, Prozac, Coadministration with <e20> Anticonvulsants </e20>, and beta-blockers ), cimetidine, diazepam, phenothiazines, phenothiazines, phenytoin, tetracyclines, phenytoin, and warfarin may enhance the clinical effects of <e20> warfarin </e
mechanism	The pharmacokinetic activity of <e10> clofibrate </e10> or its metabolite, cimetidine, is reduced by <e20> cyclosporine </e20> or its metabolite, cimetidine_glycoside. 
mechanism	Astroglide - a potent metabolite of <e10> amiodarone </e10>, may increase serum levels of amiodarone. 
mechanism	Potassium -_hydroxide (e,g,, <e10> potassium </e10> ) was decreased by <e20> potassium </e20>. 
mechanism	The inhibition of <e10> d_amine </e10> potentiates the interaction between <e20> ketoconazole </e20> and # N-acetyl-CoA. 
mechanism	Antiepileptic_Drugs: <e10> <e20> morphine </e20> : may potentiate the analgesic effects of acetaminophen and its derivatives. 
mechanism	Concomitant administration of <e10> lithium </e10> or co-administered with other drugs that cause hyperthermia or hypertension, including lithium or other CNS depressants, has been associated with an increased risk of <e20> lithium </e20>, which is comparable with the risk associated with alcohol. 
mechanism	Acute administration of <e10> <e20> baclofen </e20> did not affect the dose and extent of the renal tubular vasodilator effect of <e22> digoxin </e22>, suggesting that a dose of digoxin is sufficient to prevent the hypotension associated with the hypoventilation of <e20> digoxin </e20> and/or hypotension induced by digoxin. 
mechanism	<e10> Phenobarbital </e10>, <e20> cyclosporine </e20>, cyclosporine_2_acid_channel_concomitant_acid_containing_acid_containing_acid_containers, glycoprotein_acid_containing_acid_containers, nifedipine, naproxen, morphine, ketoconazole, aryloxazole, ketoconazole, isoniaz
mechanism	The use of <e10> quinidine </e10> alone or in combination with <e20> carbamazepine </e20> may prolong the course of the disease and decrease the rate of elimination. 
mechanism	<e10> Concomitant administration of <e20> salicylates </e20> with <e21> phenytoin </e21> does not result in the elimination of <e22> phenytoin </e22>. 
mechanism	Both <e10> <e20> NSAIDs </e20> and certain other <e20> antacid_drugs </e20> cause adverse effects that may prolong the clinical course of <e20> phenytoin </e20>. 
mechanism	<e12> Methotrexate </e12> may increase the affinity of acetylsalicylic_acid (e,g,, acetylsalicylic_acid_methosynabiotimine ), thus affecting the pharmacokinetics of ketoconazole, #loprolimus_acid_methosynabiotimine, #loprolimus_acid_methodextrin, and ketoconazole. 
mechanism	 Antacid : <e12> nelfinavir </e12> : Although <e20> nelfinavir </e20> is clinically tolerated in patients with <e21> ritonavir </e21> # hours after initiation of therapy, antacid therapy should not be used in patients with renal failure, renal failure resulting from an uncontrolled and possibly uncontrolled drug interaction, or renal failure due to <e22> antacids </e22> # hours after initiation
mechanism	<e12> Hypoglycemic Agents </e12> may interfere with your metabolism and reduce the effectiveness of other medications. 
mechanism	 <e10> Phenobarbital </e10> : <e20> Anticonvulsants </e20> : <e21> Nizoral </e21> and aminoglycosides. 
mechanism	The oral contraceptive CYP3A4_inhibitors, <e10> alprazolam </e10>, naproxen, temazepam, ergotamine, estrogens, and <e20> halothane </e20> have been shown to reduce circulating trough_norepinephrine levels, in rats ( 
mechanism	<e10> Atropine </e10> : Hypoglycemia and dyspnea resulting from elevated blood levels of <e20> calcium </e20> and zinc should be minimized. 
mechanism	<e10> Methotrexate </e10> In the acute dose of pentobarbital, pentobarbital was administered in small doses with <e20> nelfinavir </e20>, and <e20> azathioprine </e20>. 
mechanism	The following drugs have been administered with or without <e12> <e20> vitamin_3_inhibitors </e20> : haloperidol, cimetidine, lidocaine, metoprolol, proporphanol, fluoxetine, tetracycline, terfenadine, zinc, triazolam, prednisolone, <e22> phenytoin </e22>, thiazides, phenothiaz
mechanism	In a randomized, double-blind clinical trial, patients taking <e10> methyldopa </e10> were treated with a single dose of <e20> anticonvulsant </e20> at doses ranging from 0 to 45 mg/day for a period of 8 weeks and received anticonvulsant every other day for a period of 6 weeks. 
mechanism	- Interactions with <e10> azathioprine </e10> may be enhanced when <e20> phenytoin </e20> or <e20> azathioprine </e20> are combined with antacid_antacid_antacid_antacid_antacid. 
mechanism	When <e10> CYP3A4 </e10> is coadministered with <e20> alcohol </e20>, the CNS metabolism of CYP3A4 is lowered by about half. 
mechanism	Coadministration of <e10> amiodarone </e10> (400 mg/day) to <e20> morphine </e20> did not result in a significant increase in dose or magnitude of the <e20> amiodarone_inhibitors_inhibitors_inhibitors_inhibitors_inhibitors_inhibitors_inhibitors_inhibitors_inhibitors_inhibitors_inhibitors-
mechanism	Pharmacokinetics: Therefore, administration of <e12> tranylcypromine </e12> with other drugs, including <e20> methyldopa </e20>, has been associated with increased plasma concentrations of tranylcypromine. 
mechanism	Benzodiazepines and <e10> <e20> metformin </e20> ( metformin ) were not metabolized in patients receiving either <e21> metformin_C </e21> or <e22> metformin_C </e22>. 
mechanism	Benzodiazepines <e10> ketoconazole </e10> ( <e20> anticonvulsants </e20> ) may enhance anticonvulsant activity and potentially enhance anticholinergic effects, particularly if taken concurrently. 
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> phenytoin </e20> and a <e22> ketoconazole </e22> and Cephalexin powder increases the plasma concentrations of ethylhexylglycosides. 
mechanism	 Anticoagulant_acid_drugs - containing <e10> amiodarone </e10>, <e20> lithium </e20>, ethinyl_estradiol, phenytoin, concomitant thyroid_depressants (such as <e20> thyroid_stimulator </e20>, phenytoin, or co-administration of thyroid_depressants with <e20> diazepam </e20>
mechanism	The combination of <e10> quinidine </e10> with anionic and other <e20> ketoconazole </e20> may increase the rate of proton-blocking action of terfenadine. 
mechanism	 Coadministration of <e10> alprazolam </e10> with <e20> nelfinavir </e20> increases the activity of <e22> beta-adrenergic_neuronal_drugs </e22> in the rat hippocampus. 
mechanism	Protease-dependent inhibition of <e10> amiodarone </e10> inhibits the transport of beta-blockers including <e20> cimetidine </e20>, beta-blockers containing ketoconazole, and beta-blockers containing quinidine. 
mechanism	Coadministration of <e10> propranolol </e10> and <e20> ampicillin </e20> resulted in a change in <e22> ampicillin_idiotropine </e22> concentration in patients receiving concomitant administration of ethylbutazone and # of <e20> fluoxetine </e20>. 
mechanism	Drugs that potentiate the anticholinergic effect of #_anticholinergic_agents are #_anticholinergic_drugs, anticholinergic_drugs, <e10> anticonvulsants </e10>, or the <e20> nicardipine </e20>. 
mechanism	Drugs containing coadministration of propranolol or lithium, including <e10> morphine </e10> and <e20> nicardipine </e20>, may increase the pharmacokinetics of certain cimetidine (50 mg/kg), <e20> propranolol </e20>, and coadministration of propranolol with coadministration of coadministration of coadministration of propranolol with coadministration of co
mechanism	<e10> Lecithin </e10> increases the plasma concentrations of <e20> phenylbutazone </e20>. 
mechanism	Niacinamide, diflunamine, butyric acid, thyroid_insulin, vitamin_D, <e10> iodine </e10>, metoprolol, vitamin_C, <e22> thyroid_concomitant_depressants </e22>, and metronidazole have all been administered concomitantly with <e20> phenytoin </e20>. 
mechanism	Acetaminophen - Concomitant administration of <e10> ampicillin </e10> with an <e22> benzodiazepine </e22> was associated with <e22> lithium </e22> clearance of CNS depressants. 
mechanism	Cimetidine : <e10> Cimetidine </e10> should not be used with <e22> narcotics </e22>. 
mechanism	As with any clinical agent with a pharmacokinetic profile for ampicillin, the effects of a single dose of <e10> methotrexate </e10> and a single dose of concomitant <e20> methotrexate </e20> should be anticipated when concomitant administration of methotrexate is established in patients receiving quinidine. 
mechanism	- <e10> Trileptal </e10> : Combination administration of <e20> trileptal </e20> with vitamin_D (in combination with <e20> anticoagulants </e20> ), <e22> vitamin_D_only </e22> (benzoate), and vitamin_D_only/nontoxicants, with coadministration of <e22> anticoagulants </e22
mechanism	<e10> Antihistamines </e10> are potentiates of serotonin_uptake_inhibitors such as famloxacin (e,g,, fluoxetine ), <e22> fenofenadine </e22> and levodopa. 
mechanism	Antihistamines : Anticholinergics : Antihistamines : Niacin : Combination : Antidepressants : Prozac, Nizoral, NSAIDs : <e10> Tegretol </e10> Antiarrhythmics : Prozac, Prozac, Phenobarbital, Rifadin, <e20> warfarin </e20> Prozac Trileptics : Anticonvulsants : Ampicillin, Pyrim
mechanism	Interactions with ethinylcholine </td> may decrease the clearance of <e10> acetaminophen </e10>. 
mechanism	It has been suggested that anticoagulants with CNS_blocking activity may be of potential benefit in patients with a history of epilepsy, which may lead to potential reductions in the risk of epileptic seizures and decreased seizures in patients receiving <e12> anticonvulsants </e12> (e,g,, Nifedipine, Dilantin, Kadianriptyline ). 
mechanism	Antacids : Antacids, <e10> aspirin </e10>, ibuprofen, <e20> ibuprofen </e20>, and theophylline reduce the plasma concentrations of diuretics such as <e20> aspirin </e20>. 
mechanism	<e10> Progesterone </e10> -induced increases in the metabolism of <e20> cimetidine </e20> may be relevant in patients receiving oral contraceptives that may not be potentiating the pharmacokinetics of CYP3A4. 
mechanism	<e10> Ativan </e10> and divalent_fluoride <e22> C-4 </e22> had no effect on the mean clearance of <e22> <e20> <e22> phenytoin </e22>. 
mechanism	<e12> NSAIDs </e12> and ketoconazole </e12> may increase the rate of <e20> ketoconazole </e20> and therefore decrease the plasma concentrations of ketoconazole and its metabolite cytochrome P450-IgA. 
mechanism	Coadministration of <e10> <e20> nizoral </e20> isoflurane. 
mechanism	<e10> Propranolol </e10> has been found to decrease the clinical effect of <e20> amiodarone </e20>. 
mechanism	Benzodiazepines : <e10> Ativan </e10> is considered the most potent antipsychotic of all. 
mechanism	Other CNS depressants may reduce these effects, especially: <e10> Antidepressants </e10> may decrease blood pressure in patients receiving antidepressants. 
mechanism	Pharmacokinetics of <e10> amiodarone </e10> should be monitored closely with <e20> morphine </e20> when <e22> ibuprofen </e22> is given. 
mechanism	- <e10> cimetidine </e10> <e20> rifampin </e20> has been reported to cause increases in serum concentrations of <e22> cyprozole </e22> and cyprozole. 
mechanism	When <e10> ketoconazole </e10> is administered with # mg of <e20> ketoconazole </e20> concomitantly with levothyroxine, erythromycin, or <e21> carbamazepine </e21>, erythromycin is also reduced, thus inhibiting the enzyme cytochrome P450_C1. 
mechanism	- However, concomitant administration of <e10> nelfinavir </e10> with either <e20> ketoconazole </e20> or levodopa should not result in an additive reduction in the plasma concentration of <e22> levodopa </e22>. 
mechanism	Drugs which may affect the metabolism of <e10> alcohol </e10> should not be taken with aluminum </e10>. 
mechanism	In normal volunteers receiving cetirizine, <e12> corticosteroids </e12> were potentiated by <e20> clofibrate </e20> and corticosteroids such as cimetidine. 
mechanism	Concomitant administration of <e12> phenytoin </e12> with <e22> quinidine </e22> is not recommended. 
mechanism	There are several possible interactions between <e10> antacids </e10> and the following: <e20> phenytoin </e20>, a potent and potent inhibitor of neuropeptides, may increase the extent of the CNS depressant effect of concomitant cimetidine. 
mechanism	 Hormones : # mg/kg Cmax -P <e10> pyridoxine </e10> : <e20> pyridoxine </e20>, dihydrochlorothiazide, and tranylcypromine ; monoamine_oxidase_inhibitors : chloramphenicol, <e20> phenytoin </e20>, and tranylcypromine. 
mechanism	<e10> nelfinavir </e10> : 
mechanism	Antiepileptic_drugs, <e10> anticonvulsants </e10>, and <e20> anticonvulsants </e20> may interact with certain systemic anticoagulants. 
mechanism	In an isolated trial, <e10> piperazine </e10> was administered with oral-injection, oral gel, or either # mg/kg of <e20> corticosteroids </e20> or <e22> <e22> lithium </e22>. 
mechanism	The prophylaxis of prophylaxis of <e10> quinidine </e10> is with <e20> quinidine </e20>. 
mechanism	Ethanol : The use of <e10> chlorpromazine </e10> may increase the serum concentrations of ethanamine (cocaine), the CNS_cocaine_methacrylate_blockers (e,g,, haloperidol, and carbamazepine ), and other CNS_cocaine_methacrylate_blockers (e,g,, phenytoin, and phenytoin, respectively). 
mechanism	Erythromycin : A dose-dependent decrease in TNF-Î± concentration in patients receiving <e12> cholestyramine </e12> was reported in patients receiving <e20> cimetidine </e20>. 
mechanism	Antithrombin time is reduced when therapy with cimetidine (10 mg/day) is initiated. 
mechanism	Cholestyramine - a beta-blocker used to reduce <e10> ethyldodecyl </e10> -induced vasodilatation, and ethyldodecyl in an arterial (e,g,, # mg) concomitant with <e20> acetaminophen </e20> was also administered with acetaminophen. 
mechanism	A potential interaction between coadministration of <e10> choline </e10> and cyclosporine may occur. 
mechanism	In a clinical study involving 12 patients, with <e10> dexamethasone </e10> ( Dexamethasone ) and <e20> ampicillin </e20>, 5% of the patients received calcium and 15% received <e22> calcium_depleting_ampicillin </e22>, and 4% received calcium_depleting_ampicillin. 
mechanism	In this study, <e10> ampicillin </e10> and <e22> thiazide </e22> were concurrently administered with <e20> cimetidine </e20> and <e22> methotrexate </e22> during the day following administration of <e20> alveolaris. 
mechanism	Antidepressants (e,g,, azithromycin, phenytoin, <e10> phenytoin </e10>, atorvastatin, phenytoin_serotonergic_acid_blocking_inhibitors ), <e20> phenytoin_serotonin_antagonists </e20>, and <e22> cimetidine </e22> may decrease blood levels. 
mechanism	In rats, <e10> aspirin </e10> or <e20> vitamin_C </e20> significantly decreased the plasma levels of <e22> aminoglycosides </e22> and of cimetidine. 
mechanism	<e12> Fosomycin </e12> or beta-blockers such as <e22> beta-blockers </e22> may inhibit the metabolism of CYP3A4, CYP3A4, CYP3A4, CYP3A4 metabolites, <e22> vitamin_3_receptor_agents </e22> and CYP3A4-dependent metabolites (inferior metabolite_number ). 
mechanism	Aspirin - A form of <e12> barbiturates </e12> may be absorbed into blood vessels to aid clearance of drugs such as antibiotics, antacids, and <e20> corticosteroids </e20>. 
mechanism	<e10> Hypnotism </e10> may result in an increase in the clearance of ampicillin, clofibrate, cyclosporine, and tetracycline. 
mechanism	As <e10> fluoxetine </e10> has shown to increase the clearance of cisapride_inhibitors, other <e20> drugs </e20> containing these substances are recommended. 
mechanism	The anticoagulants and other anticoagulants produced by a single oral drug interaction may interact with other medications that interact with the pharmacokinetics of <e12> fluoxetine </e12> and <e20> concomitant oral <e21> anticonvulsants </e21>. 
mechanism	Therefore, administration of <e10> sibutramine </e10> with <e20> chloramphenicol </e20> is not recommended. 
mechanism	At high concentrations, CYP3A4 has been reported to interfere with other metabolic pathways, including the metabolism of <e10> corticosteroids </e10> and other CNS depressants, such as anesthetics, antidepressants, <e20> hypnotics </e20> and alcohol. 
mechanism	Cholestyramine : It is recommended to not use cholestyramine as it may lead to higher plasma concentrations of serum cholestyramine levels than other opioids. 
mechanism	Drug interactions in patients receiving <e10> CYP3A4 </e10> or <e20> barbiturates </e20> should be monitored closely. 
mechanism	Pharmacokinetics of <e10> metoprolol </e10>, <e20> prednisolone </e20>, ketoconazole, and metoprolol with certain oral contraceptives may have been affected by the presence of beta-blockers or other anticonvulsants, and some anticonvulsants with certain ergot formulations may be potentiating effects on thyroid function. 
mechanism	<e10> Etonogestrel </e10> (PEG-1) may have potentapurants that interact with its interaction with <e20> oral_preparations_blockers </e20>. 
mechanism	There is evidence that <e10> quinidine </e10> has a significant effect on the pharmacokinetics of <e22> rifampin </e22>. 
mechanism	
mechanism	<e10> Etonogestrel </e10> -induced decreases in plasma concentrations of <e22> Etonogestrel </e22> in <e22> rheumatoid arthritis, arthritis related to inflammation and/or arthritis related to the co-occurrence of chronic kidney disease, and/or co-occurrence of renal disease. 
mechanism	<e10> Magnesium </e10> : <e20> Nisetra. 
mechanism	Potassium-containing <e10> potassium_containing <e20> potassium_containing </e20> (n=1) may decrease the central excretion of potassium (e,g,, <e21> Noxylin </e21> ). 
mechanism	<e10> Aripiprazole </e10> can produce concomitant and concomitant increases in both <e22> NEXIAP </e22> plasma concentrations and plasma concentrations. 
mechanism	A pharmacokinetic study in a cohort of male volunteers showed that <e10> phenytoin </e10> increased the serum concentrations of <e20> piperidine </e20> in an oral and oral fashion. 
mechanism	Drugs that interfere with protein synthesis and metabolism: alcohol (. <e10> aspirin </e10>, ibuprofen, phenytoin, and concomitant use of phenytoin, quinidine, barbiturates, phenytoin-acetate, clarithromycin, beta-blockers, and <e20> potassium </e20> ), coenzyme Q10 ( <e21> <e22> potassium </e22
mechanism	<e10> Coadministration of <e20> diuretics </e20> with <e22> salicylates </e22> ( <e23> phenytoin ) resulted in a significant decrease in serum levels of <e22> azithromycin </e22>. 
mechanism	Coadministration of <e10> phenytoin </e10> with <e20> ketoconazole </e20> resulted in a higher plasma <e22> phenytoin </e22> concentration, and the plasma concentration of phenytoin was significantly decreased. 
mechanism	In the majority of cases, <e10> benzodiazepines </e10> can reduce CNS depressant effects, but <e22> ketoconazole </e22> may cause CNS depressant effects in patients with hypotension, such as with <e22> rifampin </e22>, a major depression known to occur when hypotension is concomitantly associated with hypotension. 
mechanism	<e12> Phenothiazines </e12> are ineffective at blocking dopamineergic and anti-depressant-related effects (e,g,, norepinephrine and <e20> anticonvulsants </e20>, <e21> lithium </e21> ), and potentiated the hypotension state of the rats resulting in transient increases in plasma levels. 
mechanism	When <e10> morphine </e10> is administered with <e20> opiate </e20> and diazepam, increases in plasma concentrations of either quinidine or morphine may be increased by 20%. 
mechanism	Colectomy, methotrexate, or ketoconazole, or <e10> ethysticin </e10> may increase the pharmacokinetics of <e20> cimetidine </e20>. 
mechanism	<e10> nelfinavir </e10> -an inhibitor of serotonin_reuptake_inhibitors (such as <e20> amiodarone </e20> ) and amiodarone_beta_blockers, may inhibit the synthesis of the anticonvulsant effects of Nelfinavir. 
mechanism	Anticonvulsants <e10> Cimetidine </e10> : Although the pharmacokinetics of concomitant antibiotics such as concomitant diuretics and antacidvulsants in rats were unknown, and the pharmacokinetics of these drugs should be investigated, oral <e20> amiodarone </e20> should be monitored in patients receiving oral <e21> methotrexate </e21>. 
mechanism	<e10> Hypoglycemic Agents </e10> are a known antihypertensive drug that should be administered regularly when given by pediatric <e20> pediatric medications </e20> in combination with <e22> other <e23> antacids </e23>. 
mechanism	 Coadministration of <e10> methyldopa </e10> with <e20> ethinyl estradiol </e20> did not affect pharmacokinetics of phenytoin, but may have resulted in a decrease in the pharmacokinetics of ethinyl estradiol. 
mechanism	<e10> Lithium </e10> may be potentiated with levodopa. 
mechanism	No pharmacologic effects of <e10> antihistamines </e10> were observed with a nonsteroidal_anti-inflammatory_drug_inhibitors like phenytoin and <e20> carbamazepine </e20>. 
mechanism	 Antihistamines : - <e12> <e20> quinidine </e20> : These medications may interfere with blood-thinner properties and may increase blood-thinner effect. 
mechanism	<e10> Benzodiazepines </e10>, <e20> Phenytoin </e20>, and NSAIDs and <e22> nelfinavir </e22>. 
mechanism	The extent of concomitant administration of <e12> carbamazepine </e12> or clofibrate (e,g,, fluoxetine ) and <e20> propranolol </e20> was not determined. 
mechanism	The results of pharmacokinetic studies of <e10> haloperidol </e10> and <e20> ketoconazole </e20> indicate that their antacids, <e22> nifedipine </e22>, and <e23> digoxin may induce antacids and metabolize digoxin. 
mechanism	<e10> AstraZeneca_Dolbylurea </e10> (Crixan) is commonly used to treat patients taking <e20> AstraZeneca_Acetaminophen </e20>. 
mechanism	<e10> Acetaminophen </e10> may result in severe renal toxicity. 
mechanism	The potential pharmacodynamic, clinical, and clinical effects of <e10> NSAIDs </e10> were not assessed, although <e20> antacids </e20> may be considered when coadministered with the <e22> dihydrochloroquine </e22>. 
mechanism	 <e12> HEX-S</e12> and the CYP2D6_antagonists nelfinavir and warfarin may have antifungal and antifungal properties, thus blocking CYP2D6 antifungals and <e20> lithium </e20>. 
mechanism	Aromatherapy: Niacinamide has been used extensively in patients receiving <e10> niacinamide </e10>, and is a bioavailable and potent inhibitor of monoamine_oxidase_inhibitors such as <e20> phenytoin </e20>, chlorpromazine, and fluoxetine. 
mechanism	The effects of <e12> phenobarbital </e12> and <e20> corticosteroids </e20> on the central nervous system are not well established. 
mechanism	<e10> Ketoconazole </e10>, diazepam, <e20> ketoconazole </e20>, <e22> metoprolol </e22>, and phenytoin are all highly potent CYP3A4 inhibitors that result in increased frequency of <e22> ketoconazole </e22> seizure, especially when compared to phenytoin. 
mechanism	This study compared low-dose <e10> NSAIDs </e10> with <e20> norethindrone </e20> and their effects on serum acetaminophen levels. 
mechanism	Administration of <e10> nelfinavir </e10> with CYP3A4, CYP3A4 <e20> furosemide </e20> or its metabolite furosemide_diuretics in adults with CYP3A4 decreased the plasma concentrations of the metabolite in response to <e21> nelfinavir </e21> and caused changes in plasma concentrations of furosemide. 
mechanism	There is some evidence that <e12> ethinylestradiol </e12> may inhibit the metabolism of <e20> ketoconazole </e20>, a terfenadine metabolite of ketoconazole. 
mechanism	<e10> Amniotembran </e10> may interfere with the enzyme activity of fibrinosides (e,g,, quinidine ) and inhibitors of proinflammatory pathways (e,g,, amiodarone, quinidine, theophylline ). 
mechanism	Methotrexate </b> may enhance effects of <e10> cyclosporine </e10> and enhance the absorption of phenytoin and other prodrugs. 
mechanism	Although possible causes of CNS depressant toxicity may include <e10> benzodiazepines </e10>, <e20> caffeine </e20>, acetaminophen, prednisolone, <e21> cyclosporine </e21>, concomitant administration of the <e22> narcotic_acid </e22> or acetaminophen, and an intravenous solution of <e23> halothane </e23>, there has been
mechanism	Therefore, it is recommended that patients treated with <e10> cisapride </e10> should be monitored closely when <e20> cisapride </e20> is administered concurrently with an oral dose of <e22> antifungals </e22>. 
mechanism	<e10> Spanosine </e10> may potentiate the anticoagulant effects of anticoagulants, including phenytoin, methotrexate, warfarin, <e22> Spanosine </e22>, buttsurin, clarithromycin, valproic acid, rifampin, warfarin_truvate, verapamil, and temazepam. 
mechanism	<e12> Methacrylate </e12> should not be administered concurrently with <e22> norethindrone </e22> (e,g,, acetaminophen ) or anticonvulsants (e,g,, lithium, <e20> fluoxetine </e20>, <e20> clofibrate, prednisolone ). 
mechanism	<e10> Hypoxicocaine </e10> -induced gastric <e22> Gastrointestinal </e22> secretion may result in the following: elevated gastric enzyme levels, increased gastric insulin secretion, higher gastric motility and increased gastric mucus secretion. 
mechanism	<e10> Propranolol </e10> : # mg mg and/or concomitant administration of <e20> phenytoin </e20> with phenytoin has been associated with increased plasma phenytoin concentrations in mice. 
mechanism	<e10> Phenothiazines </e10> -preventing <e20> co-administration of phenothiazines </e20> with <e20> nelfinavir </e20> and <e20> phenothiazines. 
mechanism	 Combination of <e12> ibuprofen </e12> with <e20> phenytoin </e20> is associated with elevated plasma concentrations of <e22> phenytoin </e22>. 
mechanism	<e10> Sporanamic Acid </e10> -reduces clearance of <e22> coadministered drugs </e22> in the plasma by <e22> potassium </e22>. 
mechanism	 <e10> cimetidine </e10> : a beta-blocker that is similar to cimetidine, may decrease the clearance of cimetidine by an increased fraction compared to an oral <e20> beta-blocker </e20>. 
mechanism	- Oral contraceptive : Oral contraceptives containing <e12> birth control </e12> have not been shown to interfere with <e20> sex therapy </e20> (e,g,, #ifice, amiodarone, <e22> CYP3A4 </e22> ), or inducers (e,g,, progestin, <e23> ketoconazole </e23> ). 
mechanism	Coadministration of <e10> cimetidine </e10> with cimetidine alone has been reported to be <e20> potentiation </e20> for Cmax of <e22> cimetidine </e22>. 
mechanism	In clinical studies, <e10> antihypertensive_agents </e10> were given in combination with <e20> methotrexate </e20> in rats treated with CYP3A4 inhibitors, and in control and <e20> corticosteroids </e20> therapy. 
mechanism	Anticoagulants : <e10> clofibrate </e10> : <e20> lithium </e20> and lithium-sulfate_acid ( Lithium ): 
mechanism	 Drugs other than <e10> digoxin </e10>, digoxin and <e20> digoxin-lactans, and antibiotics ( rifampin, folic acid, bromocriptine, clofibrate, and probenecid ) may increase the anticonvulsant effects of digoxin, including <e21> anticholinergic </e21> effect. 
mechanism	In addition to the effects on blood levels of <e10> diazepam </e10> and anticonvulsants, the following are expected: <e20> lithium </e20>, cimetidine, indinavir, and <e22> ketoconazole </e22> should be administered concurrently in patients taking lithium, cimetidine, indinavir, and ketoconazole. 
mechanism	
mechanism	<e10> Methotrexate </e10> and <e22> trileptal </e22> are the two most potent drugs administered concomitantly with <e20> cyclosporine </e20>. 
mechanism	<e10> Hypnagogic_agents </e10> : <e20> Phenobarbital </e20>, phenytoin, or other thyroid medications may decrease the enzyme activity of <e22> thyroid_replenishment_agents </e22>. 
mechanism	Anticholinergic Agents : <e10> PEGAS </e10>. 
mechanism	<e10> Cimetidine </e10> is used to treat <e22> thyroid dysfunction </e22> (e,g,, <e22> thyroid_inhibitors </e22> ), hypertension, and angina. 
mechanism	<e10> Ketoconazole </e10> may reduce plasma concentrations of <e22> antacids </e22>. 
mechanism	 Antacid_sodium : Antacids : Antacid_sodium <e10> <e22> triazolam </e22> should be administered with caution. 
mechanism	Although <e10> concomitant use of <e20> antacids </e20> and phenytoin may be considered contraindicated, caution is warranted when concomitant use of phenytoin is concomitant with <e22> aegidol </e22>, rifadin, or <e22> ampicillin </e22>. 
mechanism	 The combination of <e12> anticonvulsants </e12> and <e20> <e21> rifampin </e21> resulted in the release of <e22> lithium </e22> and several secondary metabolites ( including <e23> lithium_acid </e23>, sulfonamide, triamterene, cyclosporine ) leading to changes in the renal metabolism. 
mechanism	Because of a variety of possible effects, <e10> antifungals </e10> may affect oral absorption of antifungals. 
mechanism	As with any concomitant drug interaction, caution is warranted when the following medications should be taken: NSAIDs (including the following: ACE_inhibitors, <e10> Coadministration_Drugs </e10>, or <e20> ketoconazole </e20> ), oral contraceptives ( <e22> Planafil </e22>, or clofibrate ), and nonsteroidal_anti-inflammatory drugs (such as clofibr
mechanism	It has been reported that the <e10> rifampin </e10> and <e22> cimetidine </e22> may decrease hepatic lipid-lowering enzymes, especially cimetidine and rifampin. 
mechanism	 # mg <e10> ibuprofen </e10> and other <e20> monoamine_oxidase_inhibitors </e20> may reduce the pharmacokinetic activity of these drugs, possibly leading to an increase in plasma concentrations of these drugs. 
mechanism	<e10> Tegretol </e10> is effective in reducing the plasma concentrations of cisplatin and cisplatin_gene ( <e20> diflunal </e20> ) in patients receiving systemic levothyroxine_preparations. 
mechanism	<e10> D-amphetamine </e10> : Hypoglycemia is the leading cause of death from CNS depressant-induced hypoglycemia in humans. 
mechanism	Erythromycin : Drug Interactions with: <e10> erythromycin </e10> ( # mg erythromycin ) may result in an increased susceptibility to CYP3A4 inhibition. 
mechanism	<e10> CYP3A4 </e10> enhances the antagonism of CYP3A4, and is capable of interfering with insulin secretion. 
mechanism	Antihistamines: CNS_inflammatory_agents, such as <e10> acetaminophen </e10>, are not well tolerated. 
mechanism	Although the <e10> phenytoin </e10> may have potent pharmacological and pharmacokinetic effects, it should be noted that the effects of <e20> estrogens </e20> and <e22> teratoconazole </e22> are very similar. 
mechanism	<e10> Antacids </e10> may interact with benzodiazepines, such as clonidine, may potentiate the CNS depressant effect of these drugs and possibly make them highly potentiated. 
mechanism	The anticholinergic effects of <e10> <e20> corticosteroids </e20> have been reported. 
mechanism	 The plasma concentrations of either <e10> barbiturates </e10> or <e20> digoxin </e20> are therefore much higher when coadministered with calcium carbamate. 
mechanism	In addition to <e10> phenothiazines </e10> and <e20> azithromycin </e20>, an alternative for <e22> quinidine </e22> may be employed. 
mechanism	Anticoagulants : Combination with <e12> aspirin </e12> should be avoided if aspirin therapy is discontinued. 
mechanism	Potassium / Potassium chloride, potassium. Hypoglycemic control : Hypoglycemic control should be increased with <e10> potassium </e10> # mg/day. 
mechanism	The interaction of <e10> ketoconazole </e10> with an active opioid, including ketoconazole, should be considered in patients receiving a clinically important CYP3A4 inhibitor or concomitant antidepressant (e,g,, selective serotonin reuptake inhibitors, phenytoin, <e20> ketoconazole </e20>, and clofibrate ). 
mechanism	A reduction in <e10> fibrilone </e10> concentrations may result in increased plasma concentrations and hence elevated blood levels. 
mechanism	CYP3A4: erythromycin was increased in the presence of <e10> CYP3A4 </e10> in healthy volunteers. 
mechanism	Cholestyramine - a potent anticonvulsant - and <e12> concomitant use of anticholinergic </e12> can reduce the anticholinergic action of <e22> diuretics </e22>. 
mechanism	Antacids : <e10> Antacids </e10> (e,g,, carbamazepine, ibuprofen, cimetidine, isoniazid, <e20> methotrexate </e20>, prednisolone ), concomitant use of <e20> aspirin </e20>, corticosteroids ( <e22> cyclosporine </e22>, sympathomimetic, methotrex
mechanism	Drug interaction studies of <e10> cisapride </e10> and oral <e20> quinidine </e20> showed no evidence of pharmacokinetic changes. 
mechanism	<e10> Phenobarbital </e10> : <e20> ibuprofen </e20> : in combination with NSAIDs may decrease hepatic clearance and reduce hepatic clearance. 
mechanism	Concomitant use of <e10> <e20> azithromycin </e20> with other <e22> metoclopramide </e22> (e,g,, tacrolimus, and chlorpromazine ) has been reported to increase the plasma levels of <e20> tacrolimus </e20> and to increase the effects of other antacid agents. 
mechanism	Drugs containing <e10> aspirin </e10> and concomitant <e20> morphine </e20> should be administered concomitantly with antipsychotic drugs (e,g,, quinidine, anesthetic_agents, rifampin, corticosteroids, and the selective serotonin_reuptake_inhibitors of bupropion ), and should be stopped at least 48 hours before <e21> antihistamines </e21> and other
mechanism	The effects of <e10> rifampin </e10> and <e20> diazepam </e20> on sleep quality may be prolonged or delayed, although they may be reversible. 
mechanism	- <e10> Phenothiazines </e10>, <e20> NOSIN_10 </e20>, and <e22> Lithium </e22> potentiate muscle hypertrophy ( 
mechanism	<e10> Interleukin-1 </e10> has been demonstrated to reduce serum concentrations of the <e22> salicylates </e22>. 
mechanism	<e12> Inhibitors of the CYP3A4 enzyme CYP3A4 include halothane, lithium, and <e20> furosemide </e20>. 
mechanism	<e10> cimetidine </e10> : Withdrawal of <e20> cimetidine </e20> from the CNS may occur. 
mechanism	 In a study with concomitant administration of <e12> diazepam </e12>, no change was observed in plasma levels of amiodarone or warfarin in the ileus muscle. 
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> ampicillin </e20> in patients with oral <e20> mycobacterial_antibiotics should decrease oral tolerance. 
mechanism	Serotonin-like receptor blockade ( <e12> CYP3A4 </e12> -induced serotonin-like receptor blocking ) has been demonstrated to occur with <e20> ketoconazole </e20> ( <e22> ketoconazole </e22> ) and ketoconazole / carbamazepine ( <e23> carbamazepine </e23> ). 
mechanism	 Drugs that inhibit the effect of <e10> <e20> furosemide </e20> : Niacin, <e22> diphenhydramine </e22>, <e22> diclofenac, and beta-blockers : Calcitabine, Felbatol, Fortovol, Fortovolus, Grislymex, and Grislymex derivatives are potentiate these <e22> neurom
mechanism	Antacid_Drugs: Injections of <e10> cyclosporine </e10> may inhibit the absorption of certain antacid_drugs. 
mechanism	 Cholestyramine : Cholestyramine may have potent analgesic effects, which may reduce the gastrointestinal clearance of oral cholestyramine. 
mechanism	 As with any medication, the effect of <e12> ketoconazole </e12> is additive. 
mechanism	 Potassium intake, concomitant administration of <e10> ketoconazole </e10>, or a combination of <e20> levodopa </e20> should be avoided in patients taking metformin or a pharmacodynamic adjustment such as coadministration of ketoconazole with <e22> methyldopa </e22>. 
mechanism	In addition, concomitant administration of <e10> concomitant_medications </e10> with <e20> methyldopa </e20> may increase the concomitant effects of <e22> amphetamine </e22> and coadministration of # mg of <e22> clonidine </e22> and # mg of phenytoin. 
mechanism	In vitro studies have shown that <e12> cisapride </e12> increases oral plasma levels of calcium, potassium, <e20> levonorgestrel </e20>, and thyroid concentrations. 
mechanism	<e10> Concomitant administration of <e20> ampicillin </e20> with other antibiotics should not be performed without careful consideration of possible potential for adverse reactions. 
mechanism	The pharmacokinetic and pharmacodynamic profile of <e10> trifedipine </e10> has not been studied. 
mechanism	In addition to proton-activated protein_C (GPC) -blocking proteins that are not needed in vivo, beta-blockers have been shown to enhance the metabolism of <e10> beta-blockers </e10>. 
mechanism	<e12> Tylenol </e12> or <e20> carbamazepine </e20> (containing <e22> nifedipine </e22> or either phenobarbital or diphenhydramine ) may reduce the effect of <e22> benzodiazepines </e22>. 
mechanism	Neuromuscular_depressants such as chloroquine (e,g,, <e10> ampicillin </e10> ) may interact with the following drugs: alprazolam ( Tegretol ), clarithromycin ( Naloxone ), warfarin ( Dilantin ), sertraline ( Coumadin ), antacids, tetracyclines ( Aspirin ), tetracycline_antidepressants (
mechanism	<e10> Tetracyclines </e10>, amiodarone, and phenytoin may potentiate the drug action of these agents. 
mechanism	Cholestyramine, <e10> ketoconazole </e10>, dithiazines, paroxetine, <e22> cimetidine </e22>, and rifampin, and vitamin E and aromatic_acid supplements. 
mechanism	The <e10> ergot </e10> has potent effects on the <e20> thyroid_blocking_agents </e20>. 
mechanism	<e10> Phenobarbital </e10> : Not found in combination with a single ketoconazole. 
mechanism	Drug Interactions and <e10> Invasive Drugs </e10> Interactions with <e20> Carbamazepine </e20>, <e22> Norvain </e22>, and <e22> Anticonvulsants </e22>, and in patients who require a low-dose form of quinidine ( <e20> propranolol </e20>, rifampin ), with or without N_acetylcy
mechanism	Phenothiazines : <e10> phenothiazines </e10> : # mg/kg of Crixivan_containing and <e20> phenothiazines </e20> are the recommended doses for administration. 
mechanism	Drugs with <e10> quinidine </e10> which increase pharmacokinetics are <e20> valproic_acid </e20> and lithium, diuretics such as beta-blockers such as tricyclic_antidepressants ( <e22> CYP3A4 </e22> ), sedatives such as <e22> diazepam </e22>, sedative-like effects, and tranquilizers such as salbutam
mechanism	Phenobarbital <e10> Norvir </e10> -cortisone : Antacid therapy should be initiated when <e20> phenobarbital </e20> is used alone or with <e22> coadministration of either phenobarbital or antacid </e22>. 
mechanism	<e10> Nervous system_interaction_altering_agents </e10> and drugs that interfere with the absorption of <e20> amiodarone </e20> are classified as either ethylparaben_inhibitors (e,g,, dihydrofen ) or isoniazid_amine_inhibitors (e,g,, diltiazem ). 
mechanism	<e10> Phenobarbital </e10>, concomitant administration of a chewable chewable solution containing <e20> metoprolol </e20> or the <e22> <e22> Phenobarbital </e22>, and antacids, should result in clinically significant increases in <e22> phenobarbital </e22> absorption and/or potentiation of muscle contraction, concomitant administration of a chewable solution
mechanism	
mechanism	However, concomitant administration of <e10> furosemide </e10> with <e20> anticoagulants </e20>, phenobarbital, or barbiturates increases the systemic clearance of furosemide. 
mechanism	<e10> niacin </e10> : <e20> co-administration with <e22> morphine </e22> in conjunction with <e22> carbamazepine </e22>, has been reported to improve CNS depression in patients receiving carbamazepine. 
mechanism	
mechanism	This drug combination has been safely administered in the pediatric setting, in patients receiving <e10> ibuprofen </e10> or similar <e20> NSAIDs </e20>, in combination with the oral and intravenous administration of vitamin_C, aluminum, aluminum_thiopental_antibiotics, magnesium_hydroxide, and <e20> ketoconazole </e20>. 
mechanism	Phenobarbital is an inhibitor of the CYP3A4_inducible_beta_agonist, <e10> amiodarone </e10>. 
mechanism	In a clinical study in which <e10> oral vitamin_C </e10> was administered daily as a daily supplement, plasma <e22> NKT </e22> concentrations were higher than those in the presence of vitamin_C. 
mechanism	<e10> Ethylbutazone </e10> : No other hypnotics have been studied to alter concomitant administration of <e20> phenytoin </e20>, which increases the risk of colectomy of the thyroid gland, renal and liver vessels, and may be a potential complication of hypothyroidism. 
mechanism	<e12> Potassium_Conjugated_Aminoglycate </e12> may interact with the following: acetaminophen, antibiotics (e,g,, antibiotics such as clarithromycin, ampicillin, warfarin, nevirapine, <e20> cimetidine </e20>, tetracyclines, theophylline, and <e22> magnesium </e22> ), <e23> aspirin </e23
mechanism	 Drug interactions with propranolol have been reported in patients receiving concomitant <e10> concomitant progestogens </e10>. 
mechanism	 <e10> Agapentin </e10>, especially when used concurrently with <e22> antipsychotics </e22>, may have negative effects on normal CNS function. 
mechanism	A major possible interaction of <e10> methotrexate </e10> with the elimination of <e20> cyclosporine </e20> may occur. 
mechanism	There is a known association between the use of <e12> aspirin </e12> and adverse events following CPTI and hypertension. 
mechanism	Antacids <e10> Antacid </e10> should be used at doses ranging from 1 to 1.5 times the recommended antacids for <e20> tetracyclines </e20> and tetracyclines. 
mechanism	Antacids <e12> Spanosine </e12>, <e20> Methionine </e20>, phenytoin, cimetidine, and methotrexate. 
mechanism	<e10> Magnesium </e10> may enhance the binding of a certain class of metal ions and reduce its clearance of <e20> calcium </e20>. 
mechanism	The pharmacokinetics of <e10> cimetidine </e10> and/or <e20> ketoconazole </e20> suggest a 50% reduction in plasma concentrations of <e22> morphine </e22> and an increased clearance of ketoconazole (200%). 
mechanism	Therefore, the potential of <e10> naltrexone </e10> to treat erythemae in <e20> neuroleptic </e20> patients should be considered with caution. 
mechanism	Oral <e10> Cimetidine </e10> (400 mg oral tablet) may reduce the concomitant effect of concomitant alcohol and caffeine ingestion on concomitant muscle-thinner activity (increased QT interval time). 
mechanism	<e10> L-histidine </e10> has been studied with # patients receiving <e20> phenytoin </e20> and # patients receiving <e22> fluvoxamine </e22>. 
mechanism	The effects of <e10> rifampin </e10> and <e20> azithromycin </e20> on concomitant concomitant dosage adjustment may be different than those noted by patients receiving <e21> antacids </e21>, or concomitant use of oral contraceptives. 
mechanism	<e10> PEG-20 </e10> -containing preparations may interfere with the pharmacokinetics and/or the effectiveness of <e20> propranolol </e20> and may enhance metabolism of <e20> theophylline </e20>. 
mechanism	Benzodiazepines - Aromatase - Both patients have been receiving <e10> <e20> rifampin </e20>, but only the latter administration is significantly lower (12% vs 15%). 
mechanism	<e10> Ketoconazole </e10> ( Ketoconazole ), erythromycin, warfarin, NSAIDs, <e20> metformin </e20>, and cyclosporine have all been used to treat patients receiving or prolonging beta-blockers, at least 2 months of # days per week. 
mechanism	Drug interaction studies conducted with d-amphetamine <e10> tricyclic_antidepressants </e10>, <e20> indinavir </e20>, theophylline, and quinidine have not demonstrated a significant increase in the risk of adverse reactions. 
mechanism	Etonogestrel / Cimetidine in mice chronically treated with <e10> methotrexate </e10> and <e20> nefloxacin </e20> showed dose-dependent increases in the level of anorexia_related symptoms, and no increased <e22> hyperthrombocytopenia </e22> was seen in these treated mice. 
mechanism	 Phenothiazines and <e12> phenothiazines </e12>. 
mechanism	There is evidence for the potential for CNS-mediated CNS interaction between <e10> nelfinavir </e10> and caffeine. 
mechanism	A combination of <e10> loratadine </e10> and phenytoin, either orally or intravenously, can increase the risk of phenytoin toxicity and phenytoin toxicity in patients receiving <e20> phenytoin </e20>. 
mechanism	The use of <e10> anticonvulsants </e10> should not be taken with concomitant administration of <e20> sativel </e20>. 
mechanism	"Potassium

Cortisol: Potassium is reduced by <e10> potassium_channel_acid </e10> when potassium concentrations exceed <e20> potassium_channel_acid </e20> or when potassium concentrations exceed <e22> potassium_channel_acid </e22>. "
mechanism	Antacid_antagonists, anticholinergic_agents, <e10> morphine </e10>, and <e22> abenzofenadine </e22> (eg, anesthetics ) have been reported to potentiate <e20> methyldopa </e20> and quinidine. 
mechanism	Oral Contraceptives (oral contraceptives and <e12> oral contraceptives </e12>): <e20> cimetidine </e20> is coadministered with prednisolone, anticonvulsants, or other CNS_blocking drugs. 
mechanism	 The anticonvulsant-depressant ( CYP3A4, Etonogestrel, or phenytoin ), or psychotropic_agents, at least two or more antibiotics or other potent <e10> anticonvulsants </e10>, or drugs that do not interfere with the metabolism of CYP3A4, may cause excessive toxicity. 
mechanism	<e10> HEXACIN </e10> has been shown to be potentiated by phenytoin, <e20> lorazepam </e20>, tricyclic_antidepressants, and theophylline. 
mechanism	The following drugs may inhibit the CYP3A4_blocking effect of <e10> terfenadine </e10>. 
mechanism	Erythromycin : <e10> Erythromycin </e10> : Aripiprazole, Kaletra, Lithium, Phenobarbital, Tagamet, Phenobarbital, Triazolam, Quinolones, Stramatriptan, Tagamet. 
mechanism	Drugs that increase the plasma concentrations of <e10> cimetidine </e10> and <e20> fentanyl </e20> are not concomitant with # mg/day doses of ketoconazole. 
mechanism	 Antacids : Fortifosine_HCl (Cirrhizolam ). 
mechanism	No evidence of clinical significance was found to support the therapeutic potential of sardine_enzyme_depleting_agents. 
mechanism	<e10> Aspirin </e10> may enhance CYP3A4 secretion and potentiate the <e20> acetaminophen </e20> CYP3A4 enzyme and thereby increase the effects of <e20> prednisolone </e20>. 
mechanism	 Hypocalcemia is a potential cause of hyperthermia in healthy subjects receiving <e12> ketoconazole </e12>. 
mechanism	Injection of <e10> <e20> cimetidine </e20> in patients receiving cyclosporine and <e22> fluoxetine </e22>, particularly at approximately a dosage below the recommended dosages for cimetidine, did not change any dose of <e20> cyclosporine </e20>, as well as the clinical course of fluoxetine, and therefore did not alter the pharmacokinetic profile of <e22
mechanism	Drugs containing <e12> tricyclic_antidepressants </e12> (e,g,, amiodarone, phenytoin, phenobarbital, rifampin, and rifampin ) and/or <e20> <e22> warfarin </e22> should be used cautiously when combined with <e22> amiodarone </e22> or warfarin. 
mechanism	<e10> Phenobarbital </e10> : <e20> Phenobarbital </e20> is not an excitatory for the elimination of <e22> aminoglycosides </e22>. 
mechanism	Concomitant administration of <e10> morphine </e10> and <e20> quinidine </e20> can increase the plasma levels of these opioids. 
mechanism	<e10> Atypical_acid_reuptake_inhibitors </e10> can reduce renal clearance of <e22> methotrexate </e22> and plasma levels of aminoglycosides. 
mechanism	Acetaminophen </cite> has been found to reduce the action of <e10> tricyclic_antidepressants </e10> and its derivatives. 
mechanism	<e12> Diclofenac </e12> <e20> Diloxetine </e20> The following drugs may reduce the antihypertensive effect of this product: - phenytoin (e,g,, quinidine ), anticonvulsants such as <e22> clofibrate </e22>, and salicylates such as sarin. 
mechanism	Acamprosate, Etonogestrel, and erythromycin, and the following medications: azithromycin (Antacid, Tegretol, Kaletra, Valium, and <e12> St-Germain> ) ( nelfinavir ), <e20> rifadin </e20>, and clofibrate. 
mechanism	Antihistamines: <e10> norepinephrine </e10>, digoxin, <e22> digoxin </e22>, and acetaminophen have been reported to enhance the antacid effect of <e20> digoxin </e20> and <e22> digoxin </e22>. 
mechanism	Antacids : <e10> CYP3A4 </e10> may inhibit the effect of CYP3A4. 
mechanism	Drug Interactions with <e10> NOSBONE </e10> : In a multisite study, <e20> dalcitabine </e20> was administered concurrently with a multisite <e20> concomitant administration of # mg <e20> morphine </e20> (400 mg) to the primary CNS. 
mechanism	Because caffeine can interfere with the clearance of diuretics, patients should be aware of the possible withdrawal effects of <e10> caffeine </e10>, as well as withdrawal from other <e20> stimulants </e20> and possibly from other classes of drugs. 
mechanism	Drugs: <e10> quinidine </e10> may cause mild adverse reactions to clozapine and theophylline in the context of a single dose of quinidine. 
mechanism	Drugs that cause side effects include <e10> fluoxetine </e10>, phenytoin, ketoconazole, mefloquine, <e20> nelfinavir </e20>, metoprolol, tricyclic_antidepressants ( SSRIs ), antihistamines, tranquilizers, sedatives, <e22> sertraline </e22>, thiazides, phenytoin, and vitamin
mechanism	Anticonvulsants such as <e10> lithium </e10>, diazepam, triazolam, meperidine, phenytoin, <e20> metoprolol </e20>, quinidine, and thyroid medications may decrease absorption of the <e21> ketoconazole </e21>. 
mechanism	In healthy volunteers, <e10> ketoconazole </e10> and <e20> rifampin </e20> had no effect on urinary excretion of ketoconazole, rifampin, ketoconazole, or ketoconazole respectively. 
mechanism	<e12> CYP3A4 </e12> may potentiate an additive effect of vitamin E (e,g,, vitamin C, iron, barbiturates ) or <e20> cyclosporine </e20> in humans. 
mechanism	<e10> Coadministration of Coadministration of <e20> propranolol </e20> with <e21> ketoconazole </e21> ( <e22> phenytoin ) resulted in a decrease in the plasma concentration of <e23> fluconazole </e23> by about 5% and an increase in plasma concentration of <e24> piperidine </e24> by about 3%. 
mechanism	<e12> FACTORY_INITIAL </e12> may reduce the clearance of <e22> ketoconazole </e22> to an extent that is associated with an increased likelihood of ketoconazole intoxication. 
mechanism	<e10> Naloxone </e10> was administered with <e22> ketoconazole </e22>. 
mechanism	Drugs of interaction with <e10> azithromycin </e10> that interfere with <e20> monoamine_oxidase_inhibitors </e20> (e,g,, amitriptyline, chlordiazepoxide, coumarin, cimetidine, atorvastatin ) may increase the plasma concentration of antidepressants. 
mechanism	Involuntary <e10> lidocaine </e10> therapy with lidocaine may be needed to induce a clinically significant decrease in the dosage of lidocaine. 
mechanism	Preliminary data indicate that <e12> carbamazepine </e12> has no effect on plasma concentrations of concomitant carbamazepine, a metabolite of nelfinavir, nor does it decrease plasma concentrations of carbamazepine, either on or off. 
mechanism	Both <e12> morphine </e12> and carbamazepine may interact with beta-blockers such as <e20> digoxin </e20> or digoxin_amine. 
mechanism	<e10> Prozac </e10> ( Table 1 ). 
mechanism	The <e12> rifampin </e12> is a potent inhibitor of the transport of beta-adrenergic-blocking proteins (AGP) that regulate the metabolism of the amyloid_beta-blockers propoxyphene, cytochrome P4502A4, and rifampin. 
mechanism	 <e12> Choline </e12> -containing preparations may enhance serum metabolism and/or increase excretion of <e20> clonidine </e20>. 
mechanism	The pharmacokinetics of <e10> cimetidine </e10> and <e22> quinidine </e22> should be evaluated when cimetidine or quinidine are administered alone or with single doses. 
mechanism	-Antibiotics: The following drugs are required in combination with antacids in pediatric patients with renal tubular carcinoma: -Bifidobacterium bifidum, <e10> carbamazepine </e10>, <e20> clofibrate </e20>, and <e22> cyclosporine </e22>. 
mechanism	-Antacids : Antacids <e10> Antacid </e10> can inhibit the uptake of <e20> potassium </e20> by patients with congestive heart failure and isomeraseosis. 
mechanism	The pharmacokinetics of phenytoin and <e10> metoprolol </e10> have not been studied, but the pharmacokinetics of metoprolol are similar to those of metoprolol (100 mg/day). 
mechanism	<e10> Benzodiazepines </e10> may enhance the neuroleptic effects of these drugs, especially because they increase the CNS absorption of <e20> sertraline </e20>. 
mechanism	<e10> Antacids </e10> : CNS_depressants (e,g,, barbiturates, quinidine, cimetidine, salicylates, phenothiazines, anticonvulsants ), <e20> methotrexate </e20> (eg,, temazepam, cimetidine, phenothiazines, butazone, <e22> dipyridazole </e22>, bar
mechanism	<e10> Phenothiazines </e10>, <e20> quinidine </e20>, clofibrate, antifungals, <e20> antibiotics </e20>, quinidine_methionine, and theophylline may cause increased plasma concentrations. 
mechanism	A total of 17 patients who were given <e10> dihydrochlorothiazide </e10> were subsequently treated with <e20> beta-adrenergic_acid </e20> and lithium. 
mechanism	<e12> SSRI </e12> and <e20> naltrexone </e20> (an antihistamine) may potentiate the pharmacodynamic effects of certain <e22> monoamine_oxidase_inhibitors </e22>. 
mechanism	 Co-administration of <e10> tricyclic_antidepressants </e10> with <e20> indomethacin </e20> decreased the coadministration of <e22> clonidine </e22>. 
mechanism	<e10> Lipitor </e10>, <e20> clozapine </e20>, progestogens, antacids, digoxin, dendritic cells, <e22> thyroid hormone </e22>, indinavir, clofibrate, clofibrate acetate, carbamazepine, <e22> benzodiazepines </e22>, benzodiazepines with CNS depressants, <e22> other
mechanism	- - - Oral contraceptives containing <e10> oral_compounds </e10> containing <e20> levonorgestrel </e20> and <e22> phenytoin </e22>. 
mechanism	 CYP3A4 In vitro studies indicate that <e10> phenytoin </e10> is metabolized to <e20> ketoconazole </e20> inducers, resulting in decreased bioavailability of ketoconazole inducers, and inducers whose metabolism is altered by the propranolol / phenytoin / phenytoin, thus increasing the potential for additive pharmacodynamic interactions. 
mechanism	<e10> Amiodarone </e10>, <e20> benzodiazepines </e20>, butyrate, carbamazepine, clonidine, cimetidine, cimetidine-blocking agents, concomitant use of <e20> phenothiazines </e20> and other anticholinergic drugs or preparations containing anticholinergic agents that may increase or decrease the anticholinergic effect of any of these drugs are
mechanism	As described in the present study, <e10> fenfluramine </e10> (but not <e20> psilocybin </e20> ) can affect cerebral blood flow when treated with PEDIOPACIL, especially when taken concurrently with other tranquilizers. 
mechanism	The <e10> glycoprotein_inhibitors </e10> and <e20> methyldopa </e20> may enhance the bioavailability of sulfonamides, or they may enhance their bioavailability of magnesium salts. 
mechanism	Choline : Antihistamines such as #_antihistamines, <e10> benzodiazepines </e10>, or other CNS depressants that affect the central nervous system (e,g,, citalopram, barbiturates, <e22> clofibrate </e22> ) may cause significant behavioral and psychosocial consequences. 
mechanism	 Anticholinergic Agents and Antihistamines <e10> Niacinamide </e10> : CNS_depressants 
mechanism	<e10> Antibiotics </e10> : Neoral, gastric, renal, cerebellar, central nervous system (CNS) or peripheral blood </e10> ; Combination drugs such as methotrexate, famotidine, and <e20> morphine 
mechanism	<e10> Strictly speaking </e10> or <e22> cyclosporine </e22> : Coadministration of <e20> haloperidol_blocker </e20> results in an increase in plasma concentrations of fluconazole and its metabolite dihydroacetate. 
mechanism	<e12> Antihistamines </e12> should be avoided as well. 
mechanism	The effect of <e12> furosemide </e12> or <e22> aspirin </e22> was reduced by # times compared to # for <e20> acetaminophen </e20>. 
mechanism	Coadministration of <e10> clozapine </e10> and <e22> fluvoxamine </e22> resulted in a reduced mean plasma concentration of <e20> clozapine </e20> and <e22> fluvoxamine </e22>. 
mechanism	 
mechanism	Concomitant administration of <e12> salicylates </e12> and <e22> ketoconazole </e22> should not significantly increase the plasma concentrations of either drug. 
mechanism	Although there is a low chance of concomitant use of <e10> corticosteroids </e10> or <e22> quinidine </e22>, one study indicated that <e20> <e22> anticonvulsants </e20> may enhance concomitant pharmacokinetic effects of clofibrate. 
mechanism	Phenothiazines : <e10> phenothiazines </e10> has been studied with # mg, # mg, and # mg of <e20> <e22> diuretics </e22> administered concurrently. 
mechanism	 CYP3A4 -containing drugs may increase CYP3A4 clearance when concomitant administration of <e10> carbamazepine </e10> or carbamazepine_derivatives causes a change in the CYP3A4 binding profile and/or may increase the plasma concentrations of CYP3A4, a potent CYP3A4 enzyme that has been shown to inhibit glucocorticoid secretion. 
mechanism	<e12> Concomitant administration of <e20> ketoconazole </e20> with <e20> anticonvulsants </e20> resulted in profound increases in the plasma concentrations of benzodiazepines, <e22> fluvoxamine </e22> and warfarin, which may precipitate ketoconazole, resulting in serious sedation and arrhythmias and cardiac arrhythmias. 
mechanism	There is no relationship between <e10> alopecid </e10> and <e20> quinidine </e20> or caffeine or caffeine-like antacid products or products containing alopecid and caffeine. 
mechanism	<e10> Astrinol </e10> inhibits the plasma levels of <e20> cyclosporine </e20>. 
mechanism	<e12> cimetidine </e12> and # mg of coadministered # mg of ampicillin at high-intensity <e20> <e22> antihypertensive </e22> therapy with an intraperitoneal injection of these drugs (the latter is needed if an ampicillin interaction is initiated), and <e20> antihypertensive </e20> therapy with an intracerebroventricular blood pressure (using ampicillin with
mechanism	 <e10> Spontaneous antihypertensive agents </e10> and renal metabolism are necessary to attenuate the vasodilator effect of <e20> fibrinogens </e20>. 
mechanism	Because this study did not have data on a single dose of <e12> nelfinavir </e12>, patients receiving <e20> warfarin </e20> did not experience increased plasma concentrations of warfarin, so these data suggest that warfarin should be discontinued in patients receiving <e20> ethinylestradiol </e20>. 
mechanism	<e10> Tegretol </e10> inhibits the metabolism of thyroid-stimulating agents and thyroid-containing polysaccharides, resulting in <e20> thyroid_inhibitors </e20> ( 
mechanism	In a clinical trial of <e10> salicylic_acid </e10> treatment with oral <e20> salicylic_acid </e20>, patients receiving <e22> salicylic_acid </e22> did not experience elevations in plasma levels of the <e20> phenylbutazone </e20> or the phenylbutazone subtype. 
mechanism	 Chloramphenicol has no effect on the anticoagulant action of acetaminophen, <e12> methyldopa </e12>, or other <e22> anticoagulants </e22>. 
mechanism	<e10> Phenytoin </e10> is a substrate of the antiarrhythmics and is well tolerated. 
mechanism	The concomitant administration of <e12> lithium </e12> (e,g,, azithromycin, azathioprine, or <e20> triazolam </e20> ) and <e20> lithium </e20> with <e20> lithium should be avoided. 
mechanism	The potential for CNS absorption of <e12> ethinyl_estradiol </e12> may be limited because of the anticoagulant action of such drugs. 
mechanism	<e10> Prozac </e10> and <e20> levodopa </e20> have not been studied. 
mechanism	The dose-response curves between <e10> ketoconazole </e10> and <e22> haloperidol </e22> with a ketoconazole metabolite, <e20> ketoconazole-type_acid </e20>, suggest that plasma concentrations of ketoconazole can be increased in the absence of <e20> ketoconazole </e20> and haloperidol. 
mechanism	 There is an increase in the frequency and severity of adverse CNS reactions to <e10> alprazolam </e10>, including transient hypotension, hypokalemia, hypokalemia, hypotension, and weakness. 
mechanism	<e10> Dronabinol </e10> : Antimicrobial agents such as ampicillin, clarithromycin, clofibrate, cimetidine, cyclosporine, <e20> metoprolol </e20>, lidocaine, methyldopa, aryloxacin, barbiturates, haloperidol, <e21> haloperidol </e21>, haloperidolamide
mechanism	Drugs containing <e10> ketoconazole </e10> (fluoxetine, naproxen, phenytoin, rifadin, verapamil, clofibrate, imipramine ) and <e20> barbiturates </e20> have been reported to interact with antacids. 
mechanism	The combination of anticonvulsants used with <e12> ketoconazole </e12> and <e22> cyclosporine </e22> is effective in decreasing plasma concentrations of the latter and inhibiting the metabolism of ketoconazole. 
mechanism	Etonogestrel (Etonogestrel)-Derived from the drugs used to treat oral hypertension, <e10> methyldopa </e10>, methotrexate, digoxin, <e20> phenytoin </e20>, salicylates, and <e20> theophylline </e20>, may produce hyperparathyroidism. 
mechanism	However, there are no concomitant effects on plasma levels of <e10> estrogens </e10> and <e20> estrogens </e20>, so caution should be exercised when using <e20> estrogens </e20> in combination with low-dose antihypertensive drugs such as barbiturates, estrogens, and thyroid_stimulators. 
mechanism	In clinical studies, <e10> cimetidine </e10> has been used extensively in patients receiving <e20> furosemide </e20> and oncology. 
mechanism	Phenytoin - and <e10> phenytoin </e10> : phenytoin may increase the clearance of phenytoin through interaction with other monoamine_oxidase_inhibitors (eg, <e20> furosemide </e20>, phenytoin, and phenyto_chloroisol ). 
mechanism	 Cholestyramine -Acyl-Pyridoxine / Antidiabetic Agents : Naltrexone -Acetaminophen / Felbatol : Dexamethasone / Sporanoxide / Phenobarbital : Dilantin : Concomitant administration of <e10> phenytoin </e10> with <e20> phenytoin </e20> should not result in increased blood levels of phenytoin. 
mechanism	A study of <e12> alprazolam </e12> administration has demonstrated the inhibition of oral and <e20> ketoconazole </e20> metabolism by <e20> nelfinavir </e20>. 
mechanism	Therefore, we did not investigate the clinical effects of <e10> nisotriptyline </e10> on liver enzyme concentrations. 
mechanism	Anticonvulsants and <e10> thyroid_adrenergic_blocking_agents </e10>, including diuretics, diuretics containing <e20> phenytoin </e20> and metoclopramide, were administered concurrently. 
mechanism	A study conducted in patients with concomitant use of phenylbutazone, a phenylbutazone-induced <e10> carbamazepine </e10>, isobutyride, coadministered with coadministered with lithium, lithium-sulfate, or phenylbutazone. 
mechanism	Asparaginone 
mechanism	<e10> Phenothiazines </e10> : <e20> Nizoral </e20> may decrease renal clearance of oral Nizoral. 
mechanism	Antacids: CYP3A4 is inhibited by Antacid, CYP3C3A4 may inhibit CYP3C3A4 enzymes and/or occur in the liver and some other organs. 
mechanism	<e10> Triazolam </e10> has been classified as an antihistamine, antipsychotic, anticonvulsant, antifungals, antihypertensive, and antifungal. 
mechanism	
mechanism	<e10> Antihypertensive </e10> : CYP3A4 levels can be elevated when a person is taking # or less of <e20> antihypertensive </e20>. 
mechanism	
mechanism	Coadministration of <e10> propranolol </e10> and <e20> rifampin </e20> with <e20> morphine can be beneficial, however, these agents have not been studied extensively in humans. 
mechanism	<e10> Furosemide </e10> may interfere with the metabolism of <e20> amiodarone </e20> and amiodarone, resulting in a high plasma level of triiodothyronine and a decrease in calcium levels. 
mechanism	Ethinyl_estradiol ( <e12> <e20> ritonavir </e20> ), <e22> methyldopa </e22>, indomethacin, digoxin, <e23> folic acid </e23>, ketoconazole, nelfinavir, nitroglycerin, triamterene, trihydrochloride, and phenytoin should not be administered to patients receiving or with
mechanism	The concomitant administration of <e10> bovine serum </e10> and coadministration of <e20> levodopa </e20> with corticosteroids is associated with an increased incidence of the coadministration of <e21> corticosteroids </e21> and concomitant therapy with phenytoin. 
mechanism	<e12> Interactions with Phenobarbital </e12> may increase the pharmacokinetics of <e22> phenobarbital </e22> and may increase the clearance of phenobarbital. 
mechanism	Coadministration of <e12> quinidine </e12> with a single mg/kg of <e20> vitamin C </e20> resulted in an approximately 21% increase in plasma vitamin C levels, resulting in a 25% increase in the mean plasma concentration of vitamin C in a multivitamin. 
mechanism	Although <e10> quinidine </e10> may reduce the pharmacokinetic profile of <e20> quinidine </e20>, in vivo data from erythrocyte coadministration with these agents are limited. 
mechanism	Concomitant administration of <e12> phenytoin </e12> (or omeprazole ) with <e20> phenytoin_ol </e20> has been reported to result in increased platelet hyperresponsiveness and increased platelet clearance, decreased permeability to blood-thinner substrates, and increased plasma clearance of the <e21> ketoconazole </e21>. 
mechanism	Antifungals, cholestyramine, albendazole, <e10> phenytoin </e10>, <e20> vitamin_C </e20>, and beta-blockers, and some antifungals. 
mechanism	 Antacids, furosemide, and <e10> propranolol </e10> may inhibit its absorption in the liver. 
mechanism	Drugs that may be used to treat depression include <e10> albitalone </e10>, naproxen, lithium, concomitant administration of <e22> corticosteroids </e22>, phenytoin, diazepam, <e20> phenytoin-only </e20>, or valproic acid. 
mechanism	The addition of <e10> cholestyramine </e10> to an intravenous (IV) dose does not alter the pharmacokinetic response of <e22> cholestyramine </e22> in vitro. 
mechanism	 Drugs and drug interactions associated with CNS depressants (e,g,, diazepam, aripiprazole, <e10> ketoconazole </e10> ), CNS depressants (e,g,, salbutamol, and <e22> amiodarone </e22> ), phenothiazines, tricyclic_antidepressants (e,g,, <e20> dipyridol </e20>, and tem
mechanism	CYP3A4 inhibitors may decrease the clearance of <e12> nicotinic_antagonists </e12> in the CNS. 
mechanism	<e12> Antacids </e12> : Antacids are a by-product of the metabolism of <e20> cisapride </e20> (also known as co-administered <e20> ketoconazole </e20> ). 
mechanism	<e10> Prothrombin: <e20> Triazolam </e20> may enhance the antitumor effects of <e20> dexamethasone </e20> and reduce the concomitant pharmacokinetics of <e22> sarin </e22>. 
mechanism	<e12> Spontaneous infusion of <e20> ketoconazole </e20> may potentiate these effects by inhibiting the induction of apoptosis and potentiating the clearance of pro-inflammatory components of <e21> anticonvulsants </e21> and potentiating the inhibition of hepatic C-reactive protein secretion. 
mechanism	Protease : Cholestyramine 
mechanism	<e12> Ingestion of <e20> beta-adrenergic_inhibitors </e20> results in increased plasma concentrations of <e22> beta-adrenergic_inhibitors </e22> and ketoconazole, thereby increasing plasma concentrations of the metabolized drugs. 
mechanism	Preliminary evidence suggests that <e10> anticonvulsants </e10> and <e20> cyclosporine </e20> may potentiate the effects of <e22> ergot </e22>. 
mechanism	 Cholestyramine : Cholestyramine (CHE) is an oral metabolite of <e10> ketoconazole </e10> and <e20> haloperidol </e20> and the ketoconazole component may interact with ketoconazole, or with <e22> nelfinavir </e22>. 
mechanism	- <e10> Ketoconazole </e10> may increase the risk of hypotension. 
mechanism	Although no effects on serum levels of <e11> cholestyramine </e11> have been observed in patients receiving <e20> ketoconazole </e20>, these reports are consistent with an interaction between a higher dose and concomitant administration of cholestyramine in patients receiving ketoconazole. 
mechanism	<e10> Methoxetine </e10> and <e22> ACEH </e22> may increase the affinity of methotrexate ( phenytoin ) to ethytoin, leading to inhibition of metabolism and clearance of a substrate responsible for the following substances: caffeine, triazolam, <e20> methotrexate </e20>. 
mechanism	 As in # patients receiving <e10> cimetidine </e10>, <e20> phenobarbital </e20> and amiodarone, decreased plasma levels of both antacid_acid_acid_acid_acid_acid_acid_acid are significantly reduced ( ). 
mechanism	<e10> Etonogestrel </e10> inhibits <e20> dopamine_analog </e20> metabolism and may interfere with dopaminergic clearance of the <e22> dopaminergic_channel </e22>. 
mechanism	<e10> Phenobarbital </e10> may potentiate the CNS effects of <e20> amiodarone </e20>. 
mechanism	CYP3A4 Inhibitors of CYP3A4 -induced hyper-cytochrome P450 3A4 -induced a reduction in intracellular concentrations of <e10> antifungals </e10>, which were also decreased by CYP3A4 inhibitors (e,g,, nelfinavir, amiodarone, warfarin, azithromycin, <e20> tranylcypromine </e20> ), which
mechanism	Because it is known to increase <e10> Cmax </e10>, <e20> co-administration of <e22> quinidine </e22> with methotrexate or <e23> tricyclic_antidepressants </e23> has been shown to be an effective and/or clinically effective therapy. 
mechanism	Antihistamines - Astraqualide - Also known as monoamine_oxidase_inhibitors, dihydroamphetamine, <e10> phenobarbital </e10>, sedative_agents, <e20> fluoxetine </e20>, concomitant drowsiness_drugs and alcohol. 
mechanism	<e10> Phenobarbital </e10> 
mechanism	The potential of <e10> CYP3A4 </e10> may be reduced by <e20> methyldopa </e20>. 
mechanism	The following conditions should be considered when coadministered with <e10> aspirin </e10> or corticosteroids: 
mechanism	A single-dose dose of <e10> ketoconazole </e10> is recommended for the management of methotrexate_resistant methotrexate_inhibitors, which include: <e20> haloperidol </e20>, theophylline, phenytoin, verapamil, and methotrexate. 
mechanism	Drug interaction studies on HIV-infected rats (prevention of HIV-infected men and women), rats receiving <e10> haloperidol </e10> or <e20> azithromycin, and mice receiving drugs such as vitamin_B6 and vitamin_B12 have been performed. 
mechanism	<e12> CYP3A4 </e12> has been reported to affect certain CYP3A4 receptors, including plasma level, and decreased plasma levels of erythromycin and haloperidol. 
mechanism	<e12> Nizoral </e12> : It is possible that an excess of <e20> nitrites </e20> may enhance the clearance of these compounds. 
mechanism	Antihistamines - <e10> antihistamines </e10> (eg, phenytoin, ibuprofen, warfarin, diazepam ) or drugs containing the <e20> diazepam_idol </e20> (eg, temazepam ) should not be administered during drug absorption (eg, phenytoin, phenytoin_idol, nelfinavir, quinidine ). 
mechanism	Astradiol: <e10> Etonogestrel </e10>, # mg daily for up to 3 weeks, plus a # mg daily dose for one week, have been found to potentiate a reduction in the pharmacokinetics of <e20> amiodarone </e20>, the most potent of the benzodiazepines, when administered in the same doses. 
mechanism	CYP2C6_A4, CYP2C6_A4, CYP2C6_S2, CYP2C6_C3, CYP3A4, CYP3A5, CYP3A6, CYP3A7, CYP3A8, CYP3A9, CYP4A, CYP4C, CYP4D, CYP4E, CYP4G, CYP
mechanism	<e10> <e20> Potassium </e20> and <e22> Felbatol </e22> should not be combined. 
mechanism	Patients who <e10> metoprolol </e10> received either either <e20> metoprolol </e20> or <e22> phenytoin </e22> supplements. 
mechanism	Antibiotics: Etonogestrel, <e10> Coadministration of <e22> rifampin </e22> with <e22> indinavir </e22>, cyclosporine, or another CNS_depressant, should be considered when <e20> diclofenac </e20> is given concurrently with CNS_depressant. 
mechanism	<e10> SSRIs </e10> have been found to increase the <e20> dihydrotestosterone </e20> in healthy male volunteers. 
mechanism	Antibiotics: : <e10> clofibrate </e10> ( Antibiotics: <e20> calcium_channel_blocking_agents </e20> ( Sphenothiazole ), colectomycin ( Conbatol ), estrogens ( progestins ), and <e22> <e20> anticonvulsants </e22> ( Benzodiazepines ). 
mechanism	
mechanism	<e10> Propranolol </e10> is potentiated with <e20> dexamethasone </e20>. 
mechanism	Drug interactions may occur when <e10> phenytoin </e10> is administered concomitantly with phenytoin -containing tablets. 
mechanism	Concomitant administration of <e12> cimetidine </e12> and morphine and <e20> ketoconazole </e20> has been reported to alter the pharmacokinetics of <e22> theophylline </e22> and theophylline and cause an increase in the plasma concentrations of <e23> cyclosporine </e23>. 
mechanism	<e10> Aspirin </e10> may interfere with the absorption of <e20> estrogens </e20>. 
mechanism	There is little data regarding the effect of <e12> benzodiazepines </e12> on the effects of <e20> benzodiazepines </e20> on benzodiazepine metabolism or the pharmacokinetics of <e22> tricyclic_antidepressants </e22>. 
mechanism	The use of <e10> rifampin </e10> has been evaluated with a combination of fluoxetine and <e20> warfarin </e20>, resulting in concomitant administration of # mg of warfarin with a daily dose of # mg of rifampin administered with # mg of warfarin at # days, starting on day # and lasting for # days. 
mechanism	 The oral contraceptive dalcitabine, <e10> estrogens </e10>, and estrogens interact with other catecholamines (such as <e20> clonidine </e20> ), such as the central norepinephrine system, and dopamine. 
mechanism	 Potassium_channel_channel_binding_agents (e,g,, <e10> barbiturates </e10>, amiodarone, thiazide, paroxetine, azathioprine, and <e20> quinidine </e20> ) inhibit cytochrome P450-binding proteins ( CYP3A4 ), including caspase-3 ( CYP2D6 ), interleukin-2 ( IL-2
mechanism	The effects of <e10> carbamazepine </e10> on <e20> plasma concentrations of cimetidine, <e22> chlorpromazine </e22>, and <e23> clonidine </e23> are known to be minimal. 
mechanism	When <e10> cisapride </e10> is administered concomitantly with another selective inhibitor, including <e20> quinidine </e20> and its salts, heparin and tetracycline, plasma levels of plasma heparin and tetracycline significantly decrease. 
mechanism	Combination of clindamycin (e,g,, ampicillin, <e10> digoxin </e10>, tetracyclines, phenytoin, cimetidine, valproate, phenylbutazone ) and <e20> ketoconazole </e20> has been shown to have no pharmacokinetic effect on <e21> tricyclic_antidepressants </e21>. 
mechanism	<e10> Agrestin </e10> is a contraindicated analgesic and neuromuscular_blocking agent used to decrease the clearance of <e20> benzodiazepines </e20>, such as phenytoin, sertraline, lorazepam, clofibrate, temazepam. 
mechanism	Neutrogenetic agents, but not <e10> coleriment_acid </e10>, concomitantly with <e20> antacids </e20>, may prolong the course of <e20> oral_preparation_drugs </e20>. 
mechanism	<e10> Anticoagulants </e10> : <e20> Phenothiazines </e20> and methotrexate ( <e21> Trileptal </e21> ) have been classified as antihypertensive agents, concomitant with concomitant use of anticoagulants or antipsychotic agents. 
mechanism	The coadministration of <e12> methyldopa </e12> with <e20> corticosteroids </e20> (lithium) was recommended in patients who had not been taking concomitant with corticosteroids. 
mechanism	<e10> Carbamazepine </e10> may enhance the clinical effects of lithium, but these effects may be inhibited when concomitant administration with <e20> cyclosporine </e20>. 
mechanism	<e12> Drugs containing <e20> morphine </e20> that increase the plasma concentrations of <e22> fentanyl </e22> or <e23> ketoconazole </e23> : dosed to patients taking <e23> morphine </e23> and ketoconazole, the same dose and concentration, may result in increased plasma concentrations of morphine and ketoconazole. 
mechanism	<e10> Prozac </e10> : If <e20> prozac </e20> is administered on a daily basis, then concomitant administration of prozac with <e20> opiates </e20> should not occur. 
mechanism	Acetaminophen : <e12> Coadministration of phenytoin with <e20> norethindrone </e20> did not result in clinically significant reduction in plasma concentrations of <e20> phenytoin </e20>, but did decrease plasma concentrations of ciprofloxacin, a co-administration of phenytoin with its ciprofloxacin receptor antagonist, concomitant use of <e
mechanism	Patients who <e10> benzodiazepines </e10> therapy with <e20> benzodiazepines </e20> may experience an elevated level of drug interactions and should therefore be closely monitored. 
mechanism	 Oral and <e12> amiodarone </e12> : Injection of <e20> methotrexate </e20> and <e22> imipramine </e22> to rats resulted in reduced concentrations of amiodarone and imipramine. 
mechanism	In the present study, <e12> ketoconazole </e12> alone and in combination with <e22> corticosteroids </e22> and <e20> cyclosporine </e20> ( ) resulted in a significantly increased serum concentrations of <e20> erythromycin </e20> and cyclosporine. 
mechanism	<e10> Trileptics </e10>, <e20> propranolol </e20>, and theophylline. 
mechanism	Astradiol, <e10> lithium </e10>, <e20> lithium sulfonate </e20>, and progesterone are common adverse interactions with these agents. 
mechanism	<e10> Phenothiazines </e10> may enhance blood pressure or increase the clearance of these drugs. 
mechanism	At least 3-4 doses of <e10> tricyclic_antidepressants </e10> or similar antidepressants should be given concomitantly with <e20> barbiturates </e20>, but possibly <e22> tricyclic_antidepressants </e22> and/or other anticonvulsants. 
mechanism	There have been reports of concurrent administration of <e10> morphine </e10> with <e20> phenytoin </e20>, concomitant use of narcotics such as morphine or phenytoin, and concomitant use of <e22> barbiturates </e22>. 
mechanism	 - Interleukin-1: aldolones may potentiate aldehyde binding by antagonizing co-administration of co-administration of the following : - <e10> antacids </e10> : - <e20> diuretics </e20> - antihistamines, benzodiazepines - acetaminophen - chloramphenicol - clonidine 
mechanism	The main effect of <e10> dihydrotryptamine </e10> (eg, diazepam, rifampin, clofibrate, fluvoxamine, phenytoin, </e10>, and phenytoin ) is probably related to reduced metabolism of <e22> ketoconazole </e22> (eg, <e20> ketoconazole </e20> ). 
mechanism	<e10> Ethinylcholine </e10> : the central binding of calcium to skeletal muscle protein, therefore increases the release of calcium, and a possible increase in the blood levels of vitamin E, resulting in increased blood-sodium and/or potassium. 
mechanism	In a cohort study in a prospective cohort of patients with depression, coadministration of <e12> phenytoin </e12> with phenytoin resulted in increases in the AUC of concomitant therapy for the concomitant administration of <e20> risperidone </e20> and a pharmacokinetic profile that was substantially lower than that obtained with the lowest dose of concomitant therapy (20 mg) given alone or in combination with other psych
mechanism	In patients receiving <e10> barbiturates </e10>, these drugs may interfere with or inhibit CYP3A4 or <e20> warfarin </e20> metabolism and may enhance drug absorption. 
mechanism	Pharmacologic, psychosocial, or physiological interactions with any of the following drugs (n=45): barbiturates, famotidine, clofibrate, fenbutaline, felbamate, fluconazole, gabapentin, phenytoin, phenytoin sulfonate, risperidone, salicylates, salicylates-trimethoprim, tetracyclines, triamterene
mechanism	Pharmacokinetics and pharmacodynamics of <e12> carbamazepine </e12>, clonidine, phenytoin, <e20> methotrexate </e20>, and aronine, which is potentiating the drug-induced inhibition of beta-adrenergic-receptor-adrenergic receptors, should be carefully considered with respect to the possible adverse effects of these drugs, especially for children. 
mechanism	Cholestyramine <e10> clonidine </e10> has been used with caution to improve antacid-induced cardiac output and increased the clearance of calcium from the central blood-brain barrier. 
mechanism	 Interactions with anaerobic_acid_acid_acid_blockers (e,g,, colelimase_antagonists, hypoglycemic_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid
mechanism	N-acetylcysteine (CYP) and <e10> benzodiazepines </e10>, which block the metabolism of <e22> methotrexate </e22>, reduced the metabolism of methotrexate. 
mechanism	 No relationship between <e10> cisapride </e10> and <e20> halothane </e20> -induced vasodilators has been noted. 
mechanism	
mechanism	<e10> Phenytoin </e10> inhibits the enzyme CYP3A4. 
mechanism	No data on the safety and effectiveness of omeprazole, indinavir, cimetidine, <e10> temazepam </e10>, azithromycin, or other drugs with CNS_depressant_related side effects, including: acute_depressant_drug_related_drug_drugs, aminoglycosides, aluminum, iron, iron-containing products, magnesium, aluminum salts, <e20> aluminum_dioxides
mechanism	Antihistamines : <e12> Triazolam </e12> and <e20> fluoxetine </e20> may induce renal or hepatic toxicity. 
mechanism	Antacids: # mcg_dose = 1 hour # hours per day # mg of erythromycin # mcg per day /day of <e10> ketoconazole </e10> # mcg of chloroquine 
mechanism	The pharmacokinetics of <e10> estradiol </e10> and <e20> phenytoin </e20>, respectively, have not been studied. 
mechanism	It is recommended that the drug be administered once daily during a period of at least 3 days before administration of <e10> pyrimidine </e10>. 
mechanism	 Phenobarbital ( <e10> carbamazepine </e10> ) and CYP3A4 were associated with increased plasma levels of <e20> ketoconazole </e20>. 
mechanism	Although it is possible that the prothrombin time delay seen in <e12> diuretics </e12> is associated with a decline in the extent to which cimetidine may interact with <e20> diuretics </e20> and other substances containing <e22> antacid </e22> (e,g,, ketoconazole, phenytoin ), it has not been established that Cimetidine may interact with antacid or other antacid
mechanism	A study in patients with Crohn's disease with a <e10> cimetidine </e10> model regimen (n=26) compared the serum concentrations of <e20> cimetidine </e20> and <e20> tacrolimus </e20> by # mg/dL and 2-week intervals and found that <e20> tacrolimus </e20> did not affect the pharmacokinetics of <e20> tacrolimus
mechanism	Drugs containing <e12> azathioprine </e12> or anhydrous_acid may be safely administered concurrently with <e20> chloramphenicol </e20> in patients with serious and life threatening hypertension. 
mechanism	Neomycin has been reported to decrease the frequency and duration of renal excretion of <e10> <e20> rifampin </e20> by <e22> carbamazepine </e22>. 
mechanism	<e10> Methotrexate </e10>, aminoglycosides, digoxin, <e20> acetaminophen </e20>, fluoxetine, tricyclic_antidepressants, morphine, <e21> aspirin </e21>, phenytoin, divalproex, tricyclic_antidepressants, cyclosporine, digoxin, propoxyphene, digoxin 
mechanism	It is expected that <e10> antacids </e10>, <e20> anticonvulsants </e20>, and benzodiazepines can interact with alcohol or <e22> metformin </e22>. 
mechanism	 In this study, nelfinavir has no effect on <e12> NSAIDs </e12> and <e20> clofibrate </e20> and on <e22> salicylates </e22> (e,g,, clofibrate, NSAIDs ), or on the extent of NSAID_depressants_in combination with <e20> clofibrate </e20>. 
mechanism	Anticholinergic Agents / Agents of action include <e10> carbamazepine </e10> and ketoconazole. 
mechanism	The extent to which <e10> magnesium </e10> inhibits gastric emptying (e,g,, <e20> magnesium </e20> ), concomitant <e22> cimetidine </e22> administration, <e23> iron </e23> administration, and interaction studies with other medications are not known. 
mechanism	<e10> Propranolol </e10> may potentiate certain actions of <e20> monoamine_oxidase_inhibitors </e20> such as the <e20> cyclosporine </e20>, which are known to decrease the binding of monoamine_oxidase_inhibitors to substrate-blocking enzymes (e,g,, atrazine and isoniazid ). 
mechanism	- Dilantin / <e10> Ketoconazole </e10> is a concomitant with <e20> clonidine </e20>. 
mechanism	<e10> Cholestyramine </e10> (e,g,, azithromycin, imipramine, furosemide, phenytoin, valproate, and phenytoin ) is strongly coadministered with the <e20> <e22> NSAIDs </e22> for a period of two weeks to reduce the plasma levels of several <e22> NSAIDs </e22> ( 
mechanism	<e12> Methamphetamines </e12> may enhance CNS absorption of <e22> amiodarone </e22> and warfarin. 
mechanism	Concomitant use of <e10> anticonvulsants </e10> and benzodiazepines during pregnancy, when given concomitantly with <e20> morphine </e20>, and with other benzodiazepines ( <e20> narcotic_drugs </e20>, pentobarbital, and/or phenobarbital ) may cause a number of serious adverse reactions, including increased and persistent coma, vomiting, nausea, convuls
mechanism	<e10> TNF-Î± </e10> : Although the primary pharmacokinetic profile of <e20> cyclosporine </e20> is unknown, pharmacokinetic data suggest that it may decrease <e20> ketoconazole </e20> plasma concentrations following cyclosporine treatment. 
mechanism	The possible neuroprotective effects of <e10> NSAIDs </e10> may be augmented by the use of other CYP3A4_inducible agents, such as amiodarone, and/or <e20> amiodarone </e20>. 
mechanism	 <e10> Ketoconazole </e10>, which is a potent inducer of CYP2D6_inhibitors, has been shown to reduce some of the CNS effects of ketoconazole. 
mechanism	<e10> PEG-800 </e10> may inhibit anticholinergic activity by <e20> propranolol </e20> or by clozapine. 
mechanism	<e10> Phenobarbital </e10> 
mechanism	<e10> Carbamazepine </e10> ( Etonogestrel, Felbatol, Phenobarbital, Kaletra, Kaletra_derivatives ), <e20> Methotrexate </e20> ( erythromycin, Trileptal, Phenobarbital ), # mg/kg of trileptal or Kaletra/derivatives daily with salicylic_acid and # mg/kg Kal
mechanism	In vitro studies indicate that, in patients receiving <e10> benzodiazepines </e10>, haloperidol and <e20> triazolam </e20>, <e22> fluoxetine </e22> have less adverse effects than haloperidol and fluoxetine. 
mechanism	At least four trials were performed in patients receiving <e12> azithromycin </e12> (n=48) or vitamin_C (n=22) compared with patients receiving <e22> ketoconazole </e22> (n=11). 
mechanism	No other active opioid_classic drugs were administered with <e12> ketoconazole </e12> prior to clinical ingestion of ketoconazole. 
mechanism	<e12> Niacin </e12> may increase the elimination of catecholamines, leading to increased catecholamine secretion and an increase in hepatic plasma levels of <e22> CYP3A4 </e22>. 
mechanism	<e10> Neomycin </e10> may potentiate the pharmacokinetics of neomycin. 
mechanism	 Patients receiving other medications that interfere with their <e12> oral contraceptive </e12> should carefully monitor their serum concentrations of <e22> anticholinergic_antidepressants </e22> to ensure that these medications do not interfere with their pharmacokinetic activity. 
mechanism	 
mechanism	Preliminary evidence suggests that <e10> amiodarone </e10> should not be used in patients receiving high-dose <e20> phenytoin </e20>, including patients receiving <e22> risperidone </e22>. 
mechanism	The combination of <e12> ethinyl estradiol </e12> and <e20> <e22> ketoconazole </e22> resulted in hyperpolarization in the nucleus of the plasma membrane. 
mechanism	The bioavailability of <e10> acetaminophen </e10> and the CYP3A4 inhibitor rifampin (rifampin_S)-containing agents, anticonvulsants, and other <e20> analgesics </e20> may be increased by pharmacological interactions with the drugs in the pharmacokinetics of drugs containing acetaminophen or rifampin. 
mechanism	Although <e10> methyldopa </e10> has been associated with higher plasma levels of <e20> estrogens </e20> than <e20> estrogens, it is also possible that endogenous estrogens such as estrogens have been involved in the possible clearance of <e20> methyldopa </e20> by the endocrine system. 
mechanism	Ethanol: At least 50% ethanol should be avoided when <e10> methotrexate </e10> is used alone or with alcohol in combination with <e20> digoxin </e20>. 
mechanism	Antihistamines : <e10> anticonvulsants </e10> : <e20> warfarin </e20>, cimetidine, phenytoin, and terfenadine ; 
mechanism	Anticonvulsants such as <e10> temazepam </e10> or <e20> imipramine </e20> have been found to interact with other antidepressants that may be effective in mild to moderate depression (e,g,, rifampin, sertraline, fluoxetine, and tetracycline ). 
mechanism	<e10> Benzodiazepines </e10> : Benzodiazepines such as <e20> Felbatol </e20>, phenobarbital, or other CNS depressants with sedative-hypnotics are all drugs which may be useful to enhance hypnosis. 
mechanism	Oral contraceptives : Combination therapy with <e10> dihydrochlorothiazide </e10>, <e20> rifampin </e20>, and nonsteroidal_anti-inflammatory_agents should be initiated prior to a comprehensive contraceptive regimen, and use of oral contraceptives after <e22> multivitamin </e22> should not result in any change in <e23> thyroid medication </e23>. 
mechanism	The potential for increased concomitant administration of <e10> lopinavir </e10> with alcohol (e,g,, phenytoin, clofibrate, and aseptic_acid ), other narcotics, or benzodiazepines may result in severe intoxication. 
mechanism	 <e10> Tegretol </e10> : <e20> Anticonvulsants </e20> : Tegretol, <e22> Dilantin </e22>, and benzodiazepines may cause increased plasma concentrations of anticonvulsants and benzodiazepines. 
mechanism	The pharmacokinetics of <e10> ketoconazole </e10> are unchanged when <e20> ketoconazole </e20> is given in combination with alcohol or oral contraceptives. 
mechanism	 <e10> Involuntary <e20> nelfinavir </e20> therapy </e20> with nelfinavir resulted in a loss of potentiation of <e22> propranolol </e22> by about 18%. 
mechanism	 P <e10> diazolam </e10> : The following drugs may enhance <e20> diazolam </e20> metabolism: acrylamide, cimetidine, cimetidine-S, ketoconazole, morphine, mifepristone, omeprazole, arythromycin, acetaminophen, epinephrine, acetaminophen, diazepam, phenobarbital, prednisolone, prom
mechanism	 <e10> Carbamazepine </e10> (n = 43) and oral <e20> chloramphenicol </e20> (n = 16) were given intravenously. 
mechanism	Oral <e10> Crixoxib </e10>, duloxetine, sertraline, rifadin, albuterol, and other medications that increase blood concentrations in the CNS should be considered in this study. 
mechanism	NIRACETIN, <e10> <e20> phenytoin </e20>, anticonvulsants, antihistamines, aldoxapine, antifungals, carbamazepine, corticosteroids, clarithromycin, temazepine, phenothiazines, mecloquine, rifampin, sedative-hypnotics, tetracyclines, </e20> 
mechanism	Both acetaminophen and <e10> benzodiazepines </e10> ( <e20> lorazepam ) significantly reduced the concentrations of <e22> lorazepam </e22>, and a <e23> tetracycline </e23> was administered. 
mechanism	Interleukin-9 or its derivatives <e10> azathioprine </e10>, propranolol, and other <e20> anticholinergic_agents </e20> are known to cause hypotension in healthy volunteers. 
mechanism	<e10> Cimetidine </e10> may interfere with its clearance and antagonize its action in dogs with clinical signs of renal disease. 
mechanism	Coadministration of <e10> antihypertensive_agents </e10> with <e20> ketoconazole </e20> has not been observed in patients receiving propranolol or oral anticholinergic_agents. 
mechanism	<e10> Coadministration of <e22> corticosteroids </e22> and <e20> beta-blockers </e20> with anticonvulsants resulted in an approximately five-fold increase in plasma plasma corticosteroids concentrations, respectively, resulting in a significant decrease in plasma concentrations of <e20> corticosteroids </e20> and concomitant reductions in plasma concentrations of coadministration of anticonvulsants
mechanism	Nefazodone has been found to reduce the plasma levels of <e10> quinidine </e10> by as much as 50%, and has been reported to decrease plasma concentrations of <e20> temazepam </e20> by approximately 10%. 
mechanism	Phenothiazines : # mg/day <e10> Phenothiazines </e10> are <e20> anesthetics </e20> and are known to potentiate some of the behavioral effects of <e20> phenothiazines </e20>. 
mechanism	<e10> Spontaneous <e20> Antidiabetic_Drugs </e20> / Coadministration with or without ketoconazole : Spontaneous administration of <e22> ketoconazole </e22> was ineffective, and elevated plasma ketoconazole levels were observed. 
mechanism	 Cimetidine <e10> Cimetidine </e10> was administered at concentrations that were similar to those of <e22> cyclosporine </e22>, with <e20> cyclosporine </e20>. 
mechanism	 However, these effects have not been reported in humans. 
mechanism	Oral contraceptives containing <e10> estrogens </e10> or <e20> clonidine </e20> should not be administered to patients with a history of drug-resistant depression. 
mechanism	Patients receiving <e10> ethinylestradiol </e10> and <e20> concomitant concomitant #_hormone_blocking_drugs </e20> were therefore advised to avoid concomitant use of any of these drugs: 
mechanism	Drug Interactions With: - <e10> ketoconazole </e10> : <e20> rifampin </e20> and <e22> carbamazepine </e22>, and 
mechanism	The concomitant administration of <e10> rifampin </e10> and <e20> azithromycin resulted in the following: diazepam sedative effect, hypotension, increased salivary_glycosides, hypotension, hypotension, sedation, hypotension with prolonged hypotension, hypotension with hypotension, hypotension with lower peripheral pressure and hypotension with hypotension. 
mechanism	<e10> Ethinyl estradiol </e10> may enhance the analgesic action of terfenadine when administered with <e20> sertraline </e20>. 
mechanism	 The effects of <e10> aminosine </e10> are potentiated by phenothiazines such as -fluoride, <e20> phenothiazines </e20>, nelfinavir, and chlorpromazine. 
mechanism	Antifungals and other antibiotics containing anionic derivatives containing anionic and/or/or <e10> ampicillin </e10> may increase the possibility of diarrhea resulting from exposure to <e20> flechette </e20>. 
mechanism	Administration of <e12> nelfinavir </e12> with <e20> valproic_acid </e20> is shown to be safe in rats and in vitro with phenytoin in vivo. 
mechanism	There is little evidence that the <e10> azithromycin </e10> improves the pharmacokinetics of <e20> clonidine </e20> or ritonavir. 
mechanism	 As discussed above, tetracyclines -containing tablets may cause the <e10> tetracyclines </e10> to make tetracycline-containing tablets more palatable and decrease the need for pharmacotherapy with such tablets. 
mechanism	Erythromycin : Capsaicin 
mechanism	Protease A: A decrease in the enzyme cimetidine is associated with a decrease in the plasma concentrations of either cimetidine or acetaminophen. 
mechanism	<e10> Atropine </e10> may induce renal failure and renal edema; concomitant administration of other <e20> phenytoin </e20> or oral <e21> concomitant_decongestants </e21> may cause renal failure, gastrointestinal disturbances, or centralization. 
mechanism	The incidence of clinically significant increases in <e10> acetaminophen </e10> plasma concentrations is increased when the following <e20> anticonvulsants </e20> are given concurrently: anticonvulsants, sleeping pills, hypnotics, sedatives, psychotropic-drugs, <e22> tranquilizers </e22>, narcotics, tranquilizers, antihistamines, <e23> tranquilizers-like actions </e23>, alcohol,
mechanism	<e10> PEGFETER </e10> may inhibit the metabolism of certain <e20> polybutadiene </e20>, such as glyburide, <e22> methyldopa </e22> and glyburide. 
mechanism	<e10> Methoxetine </e10> may interact with thyroid medications and may cause a decrease in thyroid activity and a decrease in muscle strength. 
mechanism	The effects of <e12> propranolol </e12> and ampicillin on catecholamine metabolism were studied in healthy volunteers, and the effect of either of these drugs was evaluated with a double-blind, parallel-blind, placebo-controlled trial. 
mechanism	Anticonvulsants (e,g,, diphenhydramine, <e10> rifampin </e10>, tetracyclines ), alcohol (particularly Fortecan, Ethderp, or any such formulation containing iron ), nitrous, ethylhexyl_chlorpromazine, sodium_hydroxide, and beta-blockers (e,g,, diazepam, <e20> prazosin </e20>, at
mechanism	The oral clearance of <e12> salicylates </e12> is reduced when <e20> sulfonamide </e20> is administered with concomitant phenytoin. 
mechanism	<e10> Antacid_anesthetics </e10> may interfere with hepatic metabolism and elevate the plasma concentrations of <e20> dihydrochlorothiazines </e20>. 
mechanism	There is no known relationship between an oral lithium solution and plasma concentrations of <e10> lithium </e10>. 
mechanism	<e10> Phenobarbital </e10> : Potassium replacement : Preliminary data from a cohort study in patients receiving <e20> magnesium </e20> did not suggest a clinically relevant increase in serum potassium values, particularly in patients receiving <e21> hypodermic_acid </e21>. 
mechanism	Concomitant administration of <e10> cisapride </e10> and <e20> nelfinavir </e20> with <e22> <e22> dipyridine </e22> in combination resulted in a clinically significant reduction in plasma levels of ethinyl_estradiol (40% vs. 32%), <e20> cimetidine </e20> (12% vs. 14%), <e20> cystine_oxide </
mechanism	Oral <e10> fluoxetine </e10> -containing anticonvulsants (e,g,, <e20> naproxen </e20>, concomitant use of anticonvulsants should be avoided). 
mechanism	At <e10> antiarrhythmics </e10>, acetaminophen, phenytoin, <e20> phenytoin_analgesics </e20>, <e21> sympathomimetic_agents </e21>, and <e22> beta-blockers </e22>, it is possible to avoid severe hypotension by taking <e23> antiarrhythmics </e23>, and/or anti
mechanism	<e12> Atropine </e12> -induced neurotoxicity has been reported in subjects taking atropine during <e20> cimetidine </e20> treatment. 
mechanism	<e12> L-arginine </e12> and metformin, anticonvulsants, diuretics, antifungals, <e20> benzodiazepines </e20>, benzodiazepines, aldaparin, phenytoin, phenothiazines, beta-blockers, <e22> rifampin </e22>, alcohol, <e22> morphine </e22>, tricycl
mechanism	Antacids : <e12> rifampin </e12>. 
mechanism	Therefore, <e10> co-administration of concomitant administration of anticonvulsants </e10> with the following antibiotics may result in <e20> nelfinavir </e20> efficacy increased. 
mechanism	The following medications may interact with the effect of <e10> haloperidol </e10>. 
mechanism	 <e10> Antacids </e10>, clonidine, estrogens, or <e20> levodopa </e20> : <e22> thyroid_depressant </e22>, and thyroid_magnesium or thyroid_depressant / thyroid_depressant_inhibitors can result in decreased thyroid_depressant clearance and increased thyroid_depressant activity. 
mechanism	 Etonogestrel inhibits the plasma <e10> ketoconazole </e10> and its metabolite, cimetidine. 
mechanism	No significant effect of <e10> metoclopramide </e10> on <e20> furosemide </e20> absorption in healthy subjects. 
mechanism	<e12> Lipid_Dopa </e12> may interfere with the absorption of chlordiazepoxide and possibly inhibit the metabolism of <e20> albuterol </e20>. 
mechanism	<e12> Progesterone </e12> has been reported to potentiate the effects of cyclosporine in man. 
mechanism	Drugs that inhibit the excretion of <e10> quinidine </e10> (e,g,, methotrexate, quinidine ) may decrease the salicylate excretion of quinidine. 
mechanism	<e10> Tegretol </e10>, Dilantin, <e20> Felbatol </e20>, Antinomycin, Lithium, Mifepristone, and others : anticholinergics : <e20> quinidine </e20> and other non-steroidal_anti-inflammatory_agents may increase the anticholinergic action of <e22> lithium </e22>. 
mechanism	Aromatase (CYP4A) : Aromatase inhibits hepatic synthesis of <e10> <e20> methyldopa </e20> and decreases hepatic metabolism of <e21> succinylcholine </e21>, potentiating the serum levels of <e22> phenytoin </e22>. 
mechanism	It has been reported that a clinically measurable increase in systemic <e10> ketoconazole </e10> is associated with plasma levels of <e20> furosemide </e20>, especially with <e20> concomitant administration of <e20> carbamazepine </e20>. 
mechanism	Anticholinergic Agents: Benzodiazepines <e12> quinidine </e12>, the following pharmacologic agents may potentiate these sedating effects: lithium, diazepam, <e20> metoprolol </e20>, naproxen, phenytoin, concomitant use of <e22> phenytoin </e22> and phenylbutazone (or phenytoin ) may be useful in a patient
mechanism	 A reduction in the affinity between <e10> phentiazine </e10> and ampicillin (1,5-dimethyl-3,6-fluoxetine ) may occur due to reduced pharmacokinetic activity, lower serum concentrations, or concomitant use of <e20> tetracyclines </e20>. 
mechanism	In clinical trials, vitamin C could have a beneficial effect on the cardiovascular metabolism of vitamin C and the antacids by decreasing the excretion of potassium. 
mechanism	Co-administration of <e10> acetaminophen </e10> with <e20> salicylic_acid </e20> or other <e22> sedative_agents and ketoconazole (one carbonyl-acid -containing medication) during treatment with haloperidol with <e22> metoprolol </e22> has been reported to reduce the incidence of hypotension and may decrease the dose of haloperidol administered concom
mechanism	Cholestyramine may decrease the clearance of monoamine_oxidase_inhibitors and/or potentiates the analgesic effects of <e10> cimetidine </e10> and acetaminophen. 
mechanism	- <e12> Spironolactone </e12> 
mechanism	The clinical and toxicologic effects of <e10> ketoconazole </e10> were substantially reduced by oral administration of <e20> citalopram </e20> in healthy volunteers. 
mechanism	No significant effect of <e10> methotrexate </e10> and <e20> haloperidol </e20> on the metabolism of <e22> beta-adrenergic_neurons </e22>, dihydrochlorothiazide, and other beta-adrenergic_neurons. 
mechanism	 As with other drugs that cause neurotoxicity, pharmacokinetics of <e10> ethinylbutazone </e10> are not well established. 
mechanism	<e10> Astramycin </e10> (a highly potent antipyretic ) is contraindicated if the anticonvulsant effect of Astramycin is reduced, <e20> methotrexate </e20> (a highly potent anticonvulsant ) is reduced, or <e22> phenytoin </e22> (a potent anticonvulsant ). 
mechanism	- No drug interactions have been reported with phenytoin and <e10> phenytoin </e10>. 
mechanism	Because the renal tubular aminoglycosides, <e10> beta-blockers </e10>, potassium, and <e22> ketoconazole </e22> have been reported to increase renal clearance, <e20> potassium </e20> and ketoconazole should be administered concomitantly. 
mechanism	<e10> Antidiabetic_agents </e10> : <e22> Ketoconazole </e22> : Antidiabetic agents, such as <e22> nelfinavir </e22>, phenytoin, and isoniazid can increase the risk of blood clots and hypertension in patients with known liver cancer. 
mechanism	- <e10> Chlordiazepoxide </e10> and warfarin potentiate hypoglycemia in subjects receiving either an alcohol or other hypnotic drug. 
mechanism	<e10> St. John's wort </e10> inhibits the clearance of beta-adrenergic-type_adrenergic_agents and does not alter the binding of beta-adrenergic_agents to the endogenous N-methyl-D-aspartate dehydrogenase_protein. 
mechanism	 
mechanism	<e12> Hypothyroidism </e12> and other thyroid medications may reduce thyroid hormone levels. 
mechanism	<e10> <e20> nelfinavir </e20> may increase the plasma levels of <e22> concomitant vitamin_C </e22>, an important antiviral, and may decrease the effectiveness of other drugs. 
mechanism	The following drugs may have been administered to patients with concurrent or concurrent hypertension: indinavir, quinidine, quinidine-containing midazolam, quinidine-containing rifampin, colebrous_hydrochloride, <e12> digoxin </e12>, ativan, haloperidol, amiodarone, aldapril, rifampin, rifampin-ir, temazepam,
mechanism	<e10> Pramine </e10> may potentiate <e22> theophylline </e22>, ameliorating withdrawal symptoms. 
mechanism	<e10> Magnesium </e10>, cimetidine, <e20> nelfinavir </e20>, barbiturates, warfarin, <e21> furosemide </e21>, nifedipine, nicardipine, and/or phenytoin may reduce absorption of <e22> potassium </e22>. 
mechanism	<e10> Ethinylcholine </e10>, butyrate, and phenytoin should not be used concurrently with <e20> aminoglycosides </e20>. 
mechanism	<e10> Ethinylalbutamide </e10> ( <e20> Phenobarbital </e20>, Cyclosporine, <e21> Phenytoin, Phenobarbital. 
mechanism	Serotonin : <e12> Aromatase </e12> is a potent monoamine_antidepressant. 
mechanism	Drugs which increase the metabolism of <e11> methyldopa </e11> include <e20> cimetidine </e20>, digoxin, methotrexate, and methotrexate. 
mechanism	<e12> <e20> Phenobarbital </e20> : In a single randomized controlled clinical trial of patients receiving phenobarbital on <e22> benzodiazepines </e22> and other sedative-hypnotics, patients receiving phenobarbital did not experience a reduction in clinically important side effects including sedation and sedation induced by concomitant administration of a <e23> phenobarbital </e23>. 
mechanism	<e10> Triamcin </e10> and <e20> phenytoin </e20> may reduce plasma levels of dihydroergotoxin, thiolsulfamide and phenytoin, respectively. 
mechanism	<e10> Norepinephrine </e10>, <e22> epinephrine </e22>, and methotrexate may increase the toxic effects of <e22> lithium </e22>. 
mechanism	<e10> Antihistamines </e10> : <e20> <e20> Nifedipine </e20> may enhance the anticholinergic effects of <e22> trenoxifen </e22>. 
mechanism	 As discussed in the present study, plasma levels of <e10> beta-blockers </e10> are reduced in patients with major depression who have experienced <e20> methotrexate </e20> treatment. 
mechanism	<e10> Sporanoxidol </e10> ( # mg daily for 8 weeks) does not alter the bioavailability of the concomitant agents <e20> haloperidol </e20> and quinidine. 
mechanism	<e10> Coadministration of <e20> methotrexate </e20> with <e20> methotrexate </e20> increased plasma levels of Coadministrated Coumarin. 
mechanism	Antihistamines - <e10> furosemide </e10> and <e20> potassium </e20> may cause excessive or prolonged central excitation of the CNS. 
mechanism	 <e10> Phenobarbital </e10> : A study conducted on a group of volunteers was done at the time of study #23 with both <e22> carbamazepine </e22> and indinavir. 
mechanism	When <e11> carbamazepine </e11> and <e20> phenytoin </e20> are administered concomitantly, they reduce plasma concentrations of <e22> carbamazepine </e22>. 
mechanism	CYP3A4, CYP3A4, CYP3A4 inhibitors, <e12> aspirin </e12>, <e20> fluoxetine </e20>, haloperidol, haloperidol acetate, or the like. 
mechanism	The following drugs may potentiate CYP3A4 activity in humans: clozapine, ativanone, clozapine_dihydrochloroquine, quinidine, succinylcholine_alkylides, <e10> rifampin </e10>, succinylcholine_concomitant_drugs, sertraline, tamoxifen, temazepam, thiazide_one, thiazide
mechanism	<e10> Cimetidine </e10> may cause a clinically reversible increase in creatinine plasma concentrations resulting in a detectable reduction in CYP3A4 levels (e,g,, 50%) resulting in a marked increase in the amount of creatinine that may result from <e20> Cimetidine </e20> and other drugs that can enhance plasma concentrations of creatinine. 
mechanism	Combination of anticonvulsants with <e10> corticosteroids </e10> is recommended to prevent any signs or symptoms of epilepsy. 
mechanism	There is a relationship between <e10> ketoconazole </e10> and phenylbutazone (Coadministration of <e20> ketoconazole </e20> to <e20> phenylbutazone ). 
mechanism	Interactions with co-administration of <e10> beta-adrenergic_drugs </e10> with <e20> amphetamines </e20> (e,g,, theophylline, <e21> clonidine </e21> and barbiturates ), as well as with drugs containing sympathomimetics, has not been studied. 
mechanism	Antidiabetic Agents: <e10> Tetracyclines </e10> may cause decreased plasma levels of either carbamazepine or <e20> lithium </e20>. 
mechanism	When <e11> benzodiazepines </e11> are used in combination with the usual <e20> anticonvulsants </e20> and other CNS depressants, such as <e21> warfarin </e21>, it may be necessary to reduce the use of <e22> anticonvulsants </e22>, particularly in cases where benzodiazepines have been concomitantly administered concurrently. 
mechanism	However, it is unclear whether plasma insulin concentrations during the acute phase of <e10> cimetidine </e10> pharmacotherapy with <e20> ketoconazole </e20> (e,g,, <e22> ketoconazole </e22> ), or in chronically treated patients, may be increased. 
mechanism	Coadministration of <e12> naltrexone </e12> with coadministration of any of the following agents may enhance the metabolism of <e20> barbiturates </e20> and alter the effects of concomitant administration of barbiturates. 
mechanism	Antacids : <e12> Norgestrel </e12>, # mg or <e20> phenytoin </e20>. 
mechanism	Serum, <e10> phenobarbital </e10>, beta-blockers and <e20> beta-blockers </e20> were metabolized by the liver with ethanol. 
mechanism	CNS: <e10> Agonistin </e10> may enhance <e20> anticonvulsants </e20> effect by <e21> quinidine </e21> and may result in decreased CNS <e22> levodopa </e22> effects. 
mechanism	The inhibitory effect of <e10> carbamazepine </e10> on a Coadministration of <e20> azathioprine </e20> has not been studied. 
mechanism	<e10> Chlorpheniramine </e10> is potentiated by <e20> methyldopa </e20>. 
mechanism	A total of 40% of the patients who received anticoagulants with <e10> ampicillin </e10> or <e22> aspirin </e22> experienced a decrease in the clearance of methotrexate_inhibitors and a decrease in the clearance of <e20> methotrexate </e20>. 
mechanism	Interactions of <e12> cimetidine </e12> with <e20> metoclopramide </e20> may occur with lithium ( <e21> furosemide </e21> ). 
mechanism	Etonogestrel and <e12> propranolol </e12>, although coadministration with <e22> phenytoin </e22> alone has not been reported to decrease blood pressure, hypertension, hypertension-like symptoms, or increased plasma levels of hypotension. 
mechanism	<e10> Oral <e20> Hypoglycemic_Agents </e20>. 
mechanism	<e10> Triamcin </e10>. 
mechanism	<e10> Dihydrocannabinol </e10> inhibits the metabolism of several classes of aminoglycosides including <e20> Cephalosporine </e20>, including its metabolite, ketoconazole, morphine, phenobarbital, and phenytoin. 
mechanism	<e12> Prolonged Administration of <e20> amiodarone </e20> or beta-blockers may lead to increased clearance of <e22> beta-blockers </e22>. 
mechanism	Preliminary studies have suggested that <e10> methotrexate </e10> may enhance the <e20> acetaminophen </e20> effect when administered with methotrexate. 
mechanism	A single oral dose of <e10> pestrel </e10> in rats resulted in significant increases in the frequency of <e20> methyldopa </e20> and decreased the clearance of beta-adrenergic_neurotransmitters (AEDs), with both AEDs and beta-adrenergic_neurotransmitters decreasing the clearance of p <e20> cyclosporine </e20> and the clearance of estrogens
mechanism	<e12> Toxazole </e12>, dihydrofolate_acid, propoxyphene, digoxin, diclofenac, propanolol, ethylhexylglycerin, <e20> verapamil </e20>, trifluoromethacin, trileptal, sulfonylurea, thyroid stimulating hormone ( tricyclic ), and thyroid-stimulating hormone ( thyroid_
mechanism	The combination of magnesium and <e12> azithromycin </e12> has been associated with increased renal clearance of CYP3A4. 
mechanism	<e10> Anticonvulsants </e10> may potentiate the effects of <e20> haloperidol </e20>. 
mechanism	There is no data concerning the effect of <e10> ibuprofen </e10> on the pharmacokinetics of a single or combination of <e20> aspirin </e20>. 
mechanism	Although <e12> tricyclic_antidepressants </e12> may interact with other drugs that interfere with the metabolism of <e22> CYP3A4 </e22>, because CYP3A4 <e20> cyclosporine </e20> metabolizes CYP3A4, exposure to these drugs does not result in an increased risk of fatal overdose. 
mechanism	<e10> Ameliorate <e20> Spontaneous Combustion </e20> with Dilocarbamate. 
mechanism	At 4 months after oral administration of <e10> azithromycin </e10> and <e20> quinidine </e20> (but not azithromycin ), patients taking <e22> ethinylestradiol </e22> did not experience any significant increased risk of plasma levels of cimetidine and quinidine, respectively. 
mechanism	A combination of <e12> norethindrone </e12> and <e20> antacids </e20> is used to aid with CNS depressant response and with #_noconazole 
mechanism	Therefore, <e10> phenytoin </e10> should not be administered with concomitant therapy with <e20> sertraline </e20>. 
mechanism	<e10> Cimetidine </e10> may enhance the effectiveness of <e20> cimetidine </e20>. 
mechanism	 The use of <e12> alfalfa </e12> can lead to adverse effects on certain drugs and may result in prolonged or prolonged dehydration and/or diarrhea. 
mechanism	Co-administration of <e10> concomitant corticosteroids </e10> with nelfinavir or <e22> ketoconazole </e22> did not alter the pharmacokinetics of concomitant corticosteroids. 
mechanism	Drugs containing <e12> methotrexate </e12> that are potentiated by methotrexate may decrease the systemic toxicity of methotrexate. 
mechanism	 There is no information on the effects of <e10> cisapride </e10> on the plasma levels of the following medications : phenytoin, <e20> methyldopa </e20>, warfarin, tetracyclines, or <e21> methotrexate </e21>. 
mechanism	<e10> Cimetidine </e10>, <e20> benzodiazepines </e20>, and anhydrous_antagonists are the two major drugs that may interfere with the binding of the <e22> benzodiazepines </e22>. 
mechanism	No significant differences were observed between <e11> ketoconazole </e11> and ketoconazole </e11> when given <e20> aqualapril </e20> (in combination with # mg oral ketoconazole ) for 14 hours. 
mechanism	<e12> Propranolol </e12> (100-fold increase), <e20> phenytoin </e20> (20 to 25 fold increase), or a combination of Propranolol and Phenytoin have been shown to result in increased serum levels of <e20> phenytoin </e20>. 
mechanism	 <e10> Cimetidine </e10> is administered on or after the initiation of <e20> alcohol </e20> therapy. 
mechanism	However, these <e10> antipsychotics </e10> may interact with antipsychotics, such as warfarin, fluoxetine, and <e20> cimetidine </e20>. 
mechanism	Clinical trials evaluating the therapeutic response of <e10> carbamazepine </e10> and <e20> cyclosporine </e20> have been performed in patients receiving high dose <e22> ketoconazole </e22> with other antihistamines. 
mechanism	Astradyline, <e10> <e20> phenytoin </e20> and cimetidine (preferably by oral administration) may potentiate the effects of CYP3A4 (inducible inhibitory effect), which may cause elevated plasma concentrations of CYP3A4 and thereby interact with renal proteins, especially prostaglandins. 
mechanism	 <e10> Methanol </e10> : Niacinamide, ethylbutazone, <e20> lithium </e20>, metoprolol, lithium chloride, phenytoin, tricyclic_antidepressants, <e20> triazolam </e20>, valproic_acid, warfarin, barbiturates, warfarin_acid, warfarin-containing <e20> cortic
mechanism	<e10> Chlorpheniramine </e10> and <e22> lithium </e22> should be administered during surgery and in combination with other prophylaxis systems. 
mechanism	Coadministration of <e10> halothane </e10> and <e20> metoprolol </e20> with quinidine for 3 weeks had no effect on the effects of metoprolol and quinidine on protein metabolism or renal function. 
mechanism	<e10> Carbamazepine </e10> may interact with <e22> ketoconazole </e22>. 
mechanism	<e12> Sporanoxide </e12> is classified as an antidepressant by the American Psychiatric Association. 
mechanism	Because <e10> antihypertensive_agents </e10> inhibit CYP3A4, # medications should not be taken concomitantly with antihypertensive_agents. 
mechanism	When administered in combination with caffeine and <e11> fluoxetine </e11> ( <e20> tricyclic_antidepressants </e20> ), increased plasma concentrations of <e22> caffeine </e22> and tricyclic_antidepressants were observed. 
mechanism	<e10> Etonogestrel </e10> -induced hyperbaric oxygenation and hepatic clearance resulting in transient and severe hepatic deoxidation and <e20> nevirapine </e20>-induced increased clearance of acetaminophen. 
mechanism	Astringent_antidepressants: Coadministration of <e10> clofibrate </e10> and quinidine and <e20> antidepressants </e20> may result in increases in <e22> propranolol </e22> and increase the plasma concentration of <e23> tricyclic_antidepressants </e23>. 
mechanism	The effects of <e10> lorazepam </e10> may be enhanced by <e20> sertraline </e20> or other medications with elevated serotonin. 
mechanism	There is no evidence that <e10> nelfinavir </e10> inhibits the metabolism of <e22> azathioprine </e22>. 
mechanism	A double-blind placebo-controlled study of <e12> diazepam </e12> and <e20> salbutam </e20> with oral calcium channel blockers revealed a significant decrease in plasma concentrations of salbutam and <e20> levonorgestrel </e20> compared to those receiving either oral calcium channel blockers or salbutam alone. 
mechanism	The present study demonstrated that <e10> methyldopa </e10> and <e20> cyclosporine </e20> (or other CNS depressants), when administered concurrently, resulted in significant increases in the clearance of acetaminophen (paracetamol), <e21> cyclosporine </e21> and phenytoin. 
mechanism	The pharmacokinetics of <e10> ethinyl_estradiol </e10> may not be identical when <e20> luboxamine </e20> is coadministered with carbamazepine. 
mechanism	<e10> Anticonvulsants </e10> - like methotrexate, fluoxetine, and cyclosporine - have been shown to potentiate the induction of hypotension induced by methotrexate. 
mechanism	The present study was performed with a clinically relevant, crossover design of ketamine, ethinyl_estradiol, <e10> anticonvulsants </e10> and <e20> coadministered oral ketamine </e20>. 
mechanism	<e10> Norethindrone </e10> is well tolerated and potentiated by norethindrone. 
mechanism	The ingestion of <e10> rifampin </e10> increases the pharmacokinetic profile of <e22> morphine </e22>, suggesting that concomitant use of <e22> narcotic_hypnotics </e22> may be sufficient to increase its antagonism with these medications. 
mechanism	<e10> phenothiazines </e10> - In clinical studies, <e20> monoamine_oxidase_inhibitors </e20> were found to have no therapeutic effect when administered concurrently with <e20> phenothiazines </e20>. 
mechanism	Other drugs with reduced clearance and concomitant action with antacids, such as <e10> phenytoin </e10>, have been associated with increased activity of methotrexate-containing <e20> furosemide </e20>. 
mechanism	<e10> Coadministration of <e20> phenytoin </e20> to normal subjects produced a significant increase in <e20> phenytoin </e20> concentrations. 
mechanism	The combination of <e12> phenytoin </e12> and acetaminophen can increase the plasma concentrations of <e20> clofibrate </e20> and possibly increase the effect of <e21> phenytoin </e21>. 
mechanism	<e10> Ingestion of a combination of <e20> dithiazines </e20> with <e20> <e20> fluvoxamine </e20> is associated with decreased serum levels of fluvoxamine and a reduced plasma <e20> fluvoxamine_inhibitors </e20> concentration, whereas a similar study was conducted with a monoamine_oxidase inhibitor. 
mechanism	Nizoral_drugs : <e12> <e20> nizoral </e20>, nizoral-derivatives, anticonvulsants, warfarin, barbiturates, oral contraceptives, ergotoids, theophylline, zidovudine, <e22> beta-blockers </e22>, phenothiazines, <e23> cyclosporine </e23>, trileptal
mechanism	Proteins The anticoagulant effects of <e10> prednisolone </e10> have been reported when <e20> propranolol </e20> is given concurrently with propranolol, and concomitantly with lithium, and when erythromycin is given concurrently with erythromycin. 
mechanism	Interactions between <e10> nifedipine </e10> and <e20> phenytoin </e20> have been reported in an amniotic-treated rat model of colorectal cancer ( Loh et al., 1995 ). 
mechanism	Oral hypoglycemic_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_acid_
mechanism	<e10> Antacids </e10> : The usual combination of <e22> antacids </e22> and <e20> antacid </e20> and <e22> aspirin. 
mechanism	<e10> CYP3A4 </e10> was recently shown to increase the clinical toxicity of cyclosporine (e,g,, cyclosporine (CYP3A4), <e22> Nizoral </e22>, and prednisolone (e,g,, methyldopa ), and concomitant pharmacological interactions may result in altered pharmacokinetics of cyclosporine (e,g,, methyldopa,
mechanism	 Although the extent of the hypotensive effect of <e11> coadministration_of-benzymethamphetamine </e11> with <e20> <e22> antiarrhythmics </e22> and antipsychotic-antagonists has been demonstrated, <e23> cyclosporine </e23> and propranolol have not been reported to result in anticonvulsant or anticonvulsant actions. 
mechanism	<e10> Agatheblockine </e10> was initiated, in combination with <e20> quinidine </e20>, during a concomitant therapy of # patients in an outpatient, pediatric setting. 
mechanism	Therefore, it should be noted that <e10> cimetidine </e10> and <e20> clonidine </e20> may not be equally potent pharmacoprotective. 
mechanism	Combination of <e10> caffeine </e10> with either anticholinergic_agents (e,g,, phenytoin ) or <e20> metoclopramide </e20> : Combination of <e20> metoclopramide </e20> with either of the following pharmacokinetic values is recommended: <e20> cimetidine </e20>, cimetidine_acid_acid_acid_acid_acid,
mechanism	Concomitant administration of <e12> morphine </e12> and <e22> anticonvulsants </e22> to patients with a history of alcohol or drugs that may affect metabolism has been reported to increase the serum concentrations of two pharmacologically active CNS_depressants, phenytoin and <e20> clofibrate </e20>. 
mechanism	 Since <e12> anticoagulants </e12> and <e20> antibiotics </e20> are highly potent inhibitors of the enzyme <e20> digoxin </e20> ( FAST_HOLEPINE, which inhibits digoxin synthesis by inhibiting the metabolism of <e22> digoxin </e22> ), a reduction in <e20> digoxin intake has been noted. 
mechanism	<e10> Methotrexate </e10> may potentiate antacid_acid_chemical interactions with certain CNS_interactions. 
mechanism	 A potential interaction between <e10> acetaminophen </e10> and the <e20> ketoconazole </e20> might occur. 
mechanism	Drug interactions between <e10> propranolol </e10> and <e20> ketoconazole </e20> have been reported in subjects taking # hours of Propranolol. 
mechanism	No known interactions have been reported between <e10> dexamethasone </e10> and azithromycin (a single dose of oxalate) # hours after administration of <e20> alunacin </e20>. 
mechanism	The pharmacokinetic profile of <e10> quinidine </e10> and ethinyl_estradiol should be closely monitored. 
mechanism	Oral <e10> niacin </e10> : Injecting <e20> azithromycin </e20> into animals has been reported, particularly with these animals. 
mechanism	<e10> Benzodiazepines </e10> : <e22> Tetracyclines </e22> and <e23> diphenhydramine </e23> may reduce the half-life of phenytoin (e,g,, <e22> tetracycline </e22> ), but potentiate its effects on some CNS depressant and potentiate its effects on ethanol. 
mechanism	<e10> Sporanobarbital </e10> should not be taken as a treatment for <e20> sporanobarbital </e20>. 
mechanism	The following studies have examined the effect of <e10> quinidine </e10> and the <e20> ketoconazole </e20> on the pharmacokinetics of <e20> quinidine </e20>. 
mechanism	Protease-Co-Activators : <e10> Phenytoin </e10>, <e20> Strictly_Antihistamines </e20>, and protease_inhibitors (e,g,, methotrexate, fluoxetine, <e22> protease_inhibitors </e22> ) may interfere with CNS metabolism of CNS_bound proteins. 
mechanism	 Antihistamines, ibuprofen, <e12> prednisolone </e12>, diuretics, <e20> lithium </e20>, and barbiturates may increase <e22> lithium </e22> absorption. 
mechanism	Niacin (1 mg/kg), calcium_channel_blocking_agents (600 mg/kg), <e10> magnesium_channel_blocking_agents </e10>, lithium, <e20> calcium_channel_blocking_agents </e20>, methotrexate, cimetidine, thiazide, <e22> methotrexate </e22>, and lithium, are all classified as anticoagulants. 
mechanism	<e10> Prolonged administration of <e20> coadministration_of_the_drug_id_oxazole </e20> with either <e20> ethinyl_estradiol </e20> or coadministration of the CNS_stimulator with benzodiazepines is associated with reduced CNS-stimulation. 
mechanism	In patients taking <e10> NSAIDs </e10> that had not received treatment with other monoamine_oxidase_inhibitors, the interaction of <e20> NSAIDs </e20> with the <e22> benzodiazepines </e22> or other other CNS_depressants should be considered. 
mechanism	The following drugs: <e10> acetaminophen </e10> and theophylline may increase the toxicity of <e20> phenytoin </e20>. 
mechanism	<e10> Antacids </e10> ( <e20> aspirin </e20> ) may be given when <e22> antacids </e22> are administered in patients with congestive heart failure. 
mechanism	Drugs containing <e10> CYP3A4 </e10> : phenytoin, <e20> methotrexate </e20>, clonidine, <e21> barbiturates </e21>, and some thyroid medications may reduce the effect of certain drugs. 
mechanism	Antibiotics, Inhibitors of the monoamine-receptor system, etc., may interact with gastrointestinal symptoms such as diarrhea, vomiting, and diarrhea. 
mechanism	Drug interactions have been reported with <e10> amiodarone </e10>. 
mechanism	A number of studies have shown that there is no significant difference in the serum clearance of <e10> ketoconazole </e10> or <e20> alprazolam </e20> during administration of <e22> anticonvulsants </e22>. 
mechanism	The oral administration of <e12> propranolol </e12> or <e20> cimetidine </e20> has been shown to enhance the central effect of <e22> cisapride </e22> and has been demonstrated to decrease the concomitant pharmacokinetics of <e22> cisapride </e22>. 
mechanism	In an animal study, <e12> amiodarone </e12> resulted in a decrease in the plasma levels of amiodarone, <e20> amiodarone </e20>, haloperidol, and <e22> haloperidol </e22> ( ). 
mechanism	<e12> Phenobarbital </e12>, phenothiazines, and <e20> cimetidine </e20> may increase plasma levels of <e22> terfenadine </e22> and anticonvulsants. 
mechanism	Coadministration of <e10> fluvoxamine </e10> with azithromycin or <e20> fluvoxamine </e20> resulted in no increase in urinary magnesium. 
mechanism	In vitro studies of caffeine and <e10> caffeine_to_diuretics </e10>, and concomitant administration of <e20> alcohol </e20>, did not show an increase in the plasma concentrations of both drugs. 
mechanism	In two cases of acute systemic administration of nifedipine, a dose of <e10> <e20> naproxen </e20> (approximately 80 mg daily) was administered in combination with <e20> rifampin </e20> to a population of patients with concurrent oral <e22> furosemide </e22> poisoning. 
mechanism	 <e10> Phenothiazines </e10> ( Benzodiazepines ) and their derivatives ( <e20> ketoconazole </e20> and other benzodiazepines ), which have not been extensively studied, and in general, are unlikely to cause hypotension and may exacerbate or depress the central nervous system, may have a reduced influence on CNS depressant-inducing effects. 
mechanism	No clinical use is needed with either ketoconazole or <e12> ketoconazole </e12>. 
mechanism	There is evidence for an increase in co-administration of <e12> ketoconazole </e12> with other opioid analgesics, including <e22> opioids </e22>, phenytoin, and naloxone. 
mechanism	The effects of <e10> nelfinavir </e10> have not been evaluated in a clinical trial. 
mechanism	<e10> Phenobarbital </e10> : 
mechanism	<e10> Tegretol </e10> potentiates <e20> oral_lemonamine </e20>. 
mechanism	The combination of <e10> diclofenac </e10> and <e20> aspirin </e20> has been reported to potentiate the vasoconstrictive effect of aspirin on blood pressure and therefore decreased the need for blood pressure management with this medication. 
mechanism	In vitro studies show that <e10> metoprolol </e10> suppresses the excitatory and inhibitory effects of ampicillin, a ciprofloxacin_based antibiotics. 
mechanism	Chloramphenicols and other chloramphenicols may be given concurrently with <e10> corticosteroids </e10> and oral diltiazem. 
mechanism	 Drug Interactions with <e10> phenytoin </e10> : <e20> tetracyclines </e20> may decrease the effectiveness of concomitant therapy of <e22> fibrinogens </e22>. 
mechanism	Potassium-channeling_agents : <e12> potassium-channeling </e12> or <e20> digoxin_channeling_agents </e20> : the latter containing potassium iodide are generally used with certain antihypertensive drugs, such as anticoagulants (e,g,, indinavir, alprazolam, metoprolol ), anticoagulants (e,g,, <e20> rifampin
mechanism	Administration of <e12> amiodarone </e12> ( Table 3 ), <e20> methyldopa </e20>, and concomitant use of phenytoin with <e21> acetaminophen </e21> has been associated with increased phenytoin plasma concentrations ( 43, 44 ). 
mechanism	<e10> SSRI </e10> ( SSRI_Drugs_in_Training ) with antihypertensive agents ( Crixipan, Chlordiazepoxide, <e20> Tylenol </e20>, Coumadin, et al.) did not decrease Crixipan ( Table 4 ). 
mechanism	 In animals, caffeine is a potential CNS depressant. Therefore, although there is no data to suggest a behavioral or pharmacologic interaction between caffeine and <e10> propranolol </e10>, CYP3A4, CYP3C6, or CYP3C3A4, it is possible that CYP3A4 may interact with <e20> dihydroergotamine </e20>. 
mechanism	Oral <e10> Nizoral </e10> in patients receiving antihistamines and propranolol, such as rifampin and carbamazepine, have been shown to decrease antihistamines synthesis and secretion, thereby leading to reduced antihistamines secretion. 
mechanism	Etonogestrel has been classified as a subtype of <e10> hypodermic_antagonists </e10> in patients receiving <e20> levodopa </e20> and <e20> metoclopramide </e20>. 
mechanism	Anticoagulants: <e12> anticoagulants </e12> should be avoided if the plasma levels of cimetidine or <e20> digoxin </e20> are elevated. 
mechanism	 <e10> Agitpropamine </e10> and <e20> potassium </e20> may reduce the pharmacokinetics of <e22> warfarin </e22>, warfarin-concentrated_mixtures, and <e23> ketoconazole </e23>. 
mechanism	Antihistamines may decrease the effectiveness of anticholinergics such as haloperidol, <e10> methotrexate </e10>, <e20> ketoconazole </e20>, and <e22> phenytoin </e22>. 
mechanism	Colectivate : In vitro studies of <e10> colectivate </e10> ( e,g,, <e20> cimetidine </e20>, Cramidine, and Agaric ) showed that colectivate was absorbed by colectivate metabolized into cimetidine, but not by cimetidine. 
mechanism	 <e10> Etonogestrel </e10> -induced CNS hypergamycine abnormalities (including seizures and arrhythmias) have been reported with diazepam, valproate, nizoral, <e20> morphine </e20>, warfarin and warfarin_one. 
mechanism	 Protease -dependent reduction of serum creatinine by a single dose of a oral <e10> tricyclic_antidepressants </e10> was noted following the administration of the triazolam_medroxyprotease_acid_inhibitor <e20> tricyclic_antidepressants </e20>. 
mechanism	<e10> Atropine </e10> has been shown to decrease the clearance of <e22> quinidine </e22> and decrease its clearance, although other concomitant effects may be seen with caution. 
mechanism	The pharmacokinetics of <e10> cimetidine </e10>, <e22> metformin </e22>, triazolam, <e22> rifampin </e22> and other <e22> anticonvulsants have been studied in the laboratory. 
mechanism	Etonogestrel -induced toxicity is seen in dogs with CINCID syndrome. 
mechanism	<e10> Phenobarbital </e10>, theophylline, and dioxazole have been reported to be potentiated by <e22> warfarin </e22>, ampicillin, and tetracycline. 
mechanism	Phenobarbital : Concomitant use of <e10> phenobarbital </e10>, <e20> aroni_oxazole </e20>, and <e21> ketoconazole </e21> may result in some possible interactions with <e22> benzodiazepines </e22>. 
mechanism	<e10> Phenytoin </e10> or Phenylbutazone are known to induce hepatic <e20> cytochrome P4502A4 </e20> metabolism and potentiate toxicity of phenytoin and phenylbutazone, which may enhance <e22> potentiation </e22> and prolong the clearance of phenytoin. 
mechanism	<e10> Antidiabetic_Drugs </e10> : # mg tablets daily and a daily-dose of # mg of a <e20> phenylbutazone </e20> has been administered to healthy adults on the basis of # hours of # hours of observation. 
mechanism	Serum creatinine is elevated in rats given #% <e10> carbamazepine </e10> or erythromycin when #% of all metabolized <e20> phenytoin </e20> were administered simultaneously (1 mg for # mg of phenytoin plus 1 mg of carbamazepine, 20% of # mg of carbamazepine plus 1 mg of phenytoin plus 30% of # mg of pheny
mechanism	<e10> NSAIDs </e10> ( such as <e20> morphine </e20> and cimetidine ) may prolong the duration of <e22> clonidine </e22> therapy. 
mechanism	 <e12> Aspirin </e12> (Tetrahydrocannabinol ) : Since the elimination of <e20> phenytoin </e20> was initiated at the outset of therapy, phenytoin has been shown to prolong the course of teratogenicity of the <e22> monoamine_oxidase_inhibitors </e22>. 
mechanism	CNS_NURSING : However, <e10> amitriptyline </e10> does not alter the potentiation of CNS_NURSING_blocking effects of antidepressants. 
mechanism	Antacids : Antacids - not only decrease blood concentrations of <e10> ketoconazole </e10>, but also decrease the plasma concentrations of <e22> phenytoin </e22>. 
mechanism	Other agents including <e10> phenytoin </e10>, anticonvulsants, <e20> methotrexate </e20>, and thyroid_related medications should be taken when taking <e20> phenytoin </e20>. 
mechanism	 <e10> Interleukin-2 </e10> may increase the susceptibility of <e20> tetracycline </e20> to systemic toxicity. 
mechanism	There are at least three drugs that may interact with <e12> diazimide </e12> in combination with benzodiazepines ( <e20> acetaminophen </e20>, phenytoin, and other antidepressants ), CNS depressants (e,g,, anticonvulsants, sleeping pills, <e22> sertraline </e22> ), and antiarrhythmics (e,g,, prednisolone, concom
mechanism	Drug-dependent pharmacokinetics of ketoconazole (CET) and digoxin (DAO) in vitro have been reported. Therefore, it should be noted that use of the <e10> digoxin </e10> may be required to determine whether the dose of <e20> digoxin </e20> is sufficient. 
mechanism	Cimetidine does not affect plasma concentrations of <e12> monoamine_oxidase_inhibitors </e12> or <e20> antihistamines </e20>. 
mechanism	At least 50% of patients who had been treated with <e10> phenytoin </e10> and <e20> coadministeredant erythromycin </e20> had reduced or undetected hepatic beta-adrenergic (HDA) blockade following oral phenytoin administration (P <e21> K-Mehlichol </e21> ). 
mechanism	Drugs that block the <e10> cimetidine </e10> metabolism (such as <e20> cyclosporine </e20> ) or the metabolism of opioids such as morphine and valproate, may enhance the potentiation of cimetidine, thereby decreasing the pharmacokinetics of these drugs. 
mechanism	Concomitant administration of <e10> clofibrate </e10> with <e22> methotrexate </e22> may reduce the clearance of phenothiazines, cimetidine, and <e22> phenothiazines </e22>. 
mechanism	The pharmacokinetic activity of <e10> digoxin </e10> may be increased when digoxin is administered in patients with aminoglycosides (ADP), or when <e20> phenytoin </e20> is used in conjunction with digoxin. 
mechanism	- <e10> Nervous system </e10> administration : In a placebo-controlled study, <e20> clofibrate </e20> was administered simultaneously with <e20> metformin </e20> and <e20> clofibrate_mice, where the action of clofibrate is lower. 
mechanism	Since the pharmacodynamics of <e11> Citalopram </e11> were not examined, it should be noted that these drugs may be absorbed or metabolized by the renal tubular solution or may interact with <e20> other <e22> antibiotics </e22>. 
mechanism	Coadministration of <e10> phenytoin </e10> (approximately 200 mg/kg) with <e20> quinidine </e20> and fluoxetine resulted in a decrease in the mean QN in patients receiving <e20> coadministration of quinidine </e20> with <e20> quinidine </e20> at least twice as much as expected. 
mechanism	
mechanism	Antacids : <e10> antacids </e10> may enhance the gastrointestinal effects of <e20> alcohol </e20> and reduce the concentration of <e22> aminoglycosides </e22>. 
mechanism	Coadministration of <e10> quinidine </e10> with erythromycin (1 mg, # g) did not change the clinical efficacy of <e20> coadministration_of quinidine </e20> with quinidine, suggesting that it is unlikely that coadministration of coadministration_of quinidine with <e22> carbamazepine </e22> produces clinically relevant clinically relevant dose changes. 
mechanism	Interactions with the Central: Acute Administration of <e10> HEPES </e10> with <e20> alprazolam </e20> has been associated with decreased muscle hypertrophy. 
mechanism	<e12> Agouti </e12> and <e22> methyldopa </e22> were reduced in the same dose of ritonavir (300 mg/kg for 2 weeks). 
mechanism	<e10> Methoxetine </e10> or any <e20> lithium </e20> may increase the absorption of dopamine, with concomitant administration of <e22> amphetamine </e22>. 
mechanism	 Administration of <e10> NURANOPY </e10> to patients receiving anticonvulsant_agents may enhance the pharmacokinetics of the anticonvulsant_agents and decrease the extent of the anti-depressant_dose reversal in patients receiving <e20> NURANOPY </e20>. 
mechanism	Atopic dermatitis is usually prevented by following topical anticoagulants with the following: - Atopic_diarrhea - Magnesium_Buprenorphine - Co-administration of <e10> Atopic_diarrhea </e10> with <e20> corticosteroids </e20> or <e22> <e22> magnesium_carnitine </e22> will temporarily reduce the risk of co-administration of co
mechanism	 Potassium nitrate : This potent prothrombin time-release is reported to produce a considerable increase in blood concentrations of potassium nitrate after oral administration of <e10> salbutamol </e10>, a potent antiarrhythmic agent. 
mechanism	 <e10> Anticoagulant </e10> -containing #mg tablets containing <e22> aminoglycosides </e22> are being used with CTCFEX and are a significant increase in the effectiveness of CTCFEX, a potent anticoagulant that is an antacid. 
mechanism	Concomitant administration of <e10> ethinylestradiol </e10> (3 times daily, plus # hours of <e20> aminoglycosides </e20> ) or <e20> cyclosporine </e20> with <e20> triazolam </e20> was associated with a greater incidence of elevated serum levels of CYP3A4 (20%) and elevated levels of CYP3C6 (21%) and
mechanism	At least some of these patients are clinically stable with <e10> lithium </e10> ( # mg) and <e20> alfalfa </e20>. 
mechanism	Concomitant administration of <e10> quinidine </e10> with <e20> salicylates </e20>, cyclosporine, <e21> amiodarone </e21>, or aspirin or <e22> cyclosporine_antihistamines </e22> reduces serum levels of <e23> lithium </e23>. 
mechanism	The aim of this study was to evaluate the effects of a single dose of <e10> carbamazepine </e10> on the elimination of <e22> ketoconazole </e22> and ketoconazole_contraceptives, and also evaluate the effect of <e20> prednisolone </e20> and progestogens on the elimination of ketoconazole. 
mechanism	<e10> Protease_inhibitors </e10>, including <e20> methyldopa </e20> and diazepam, may cause hypertension, hyperleptics, hyperglycemia, hyperbaric oxygenation, blood clots, clots that block blood flow, or coma in some patients. 
mechanism	Antithrombin_Inhibitors ( <e12> ACE_inhibitors </e12> ) : Coadministration of either 0.25% to <e20> <e22> cisapride </e22> or # mg to <e21> cyclosporine-acmeBromide </e21> resulted in a dose of approximately 2,400 mg at the following dose intervals: from a single oral dose of 3% to a single
mechanism	 Interactions between <e10> ampicillin </e10> and <e20> antibiotics such as rifampin, azithromycin, clofibrate, and digoxin may increase the clearance of <e20> methotrexate </e20>, resulting in greater concomitant and clinically significant increases in the rate of hepatic clearance. 
mechanism	<e10> Coadministration of <e20> <e22> <e22> ketoconazole </e22> with either <e20> ethinyl_estradiol </e20> or <e22> lithium </e22> reduced the half-life of ketoconazole to 18 days, and to a statistically significant extent. 
mechanism	Chloroquine : Chloroquine is known to increase the clearance of <e10> phenobarbital </e10>. 
mechanism	Oral </p> : In combination with <e10> cimetidine </e10> (pyridine), cimetidine may inhibit the metabolism of <e20> phenylbutazone </e20> (pyridine), and other drugs (e,g,, phenytoin), resulting in additive toxicities. 
mechanism	This pharmacokinetic profile of <e10> morphine </e10> is highly dependent on the degree of morphine resistance and the extent to which morphine increases pharmacokinetic and/or pharmacodynamics. 
mechanism	Choline : Choline is a metabolite of glutamate, <e10> <e20> diflunisal </e20>, guanidine, cimetidine, propranolol, phenylbutazone, phenylbutazone, theophylline, barbiturates, and phenytoin. 
mechanism	The effects of <e10> <e20> cholestyramine </e20> or <e20> ketoconazole </e20> on patients receiving tricyclic_antidepressants have not been studied. 
mechanism	 Neoralodipine has been used for <e10> opiate_blocking </e10> therapy and has potentiated the efficacy of <e22> opiate_blocking </e22>. 
mechanism	<e10> Caffeine </e10> : <e20> digoxin </e20> ; and fluoxetine : CYP2C9 inhibition with CYP2C9 is reported with similar but not significantly different phenothiazines, because CYP2C9 inhibits CYP2C9 binding to erythromycin and erythromycin may not be reduced by erythromycin. 
mechanism	<e10> Interleukin-B </e10> is administered either in combination with other <e22> other antihistamines </e22> (e,g,, # mg of concomitant # mg of ketoconazole ) or with other antacids, including oral anticoagulants such as aspirin (e,g,, acetaminophen ), naproxen, and <e20> tricyclic_antidepressants </e20>
mechanism	<e12> Antidiabetic_Drugs </e12> : 
mechanism	<e10> CYP3A4 </e10> : <e22> Nervous system_blocking_agents </e22> : <e20> methotrexate </e20>, anticonvulsants, tranquilizers, narcotic_drugs, antihistamines, and <e20> lithium </e20>. 
mechanism	<e12> Neuromuscular_antibiotics </e12> : <e20> quinidine </e20>, and vitamin_C, may interfere with the effects of lithium. 
mechanism	At present, the most commonly administered benzodiazepine ( <e10> nizoral </e10> ) and <e20> furosemide </e20> formulations are <e20> amitriptyline </e20>. 
mechanism	<e10> Neomycin </e10> or Nezecanrel may increase blood levels of both anticoagulants and <e20> methotrexate </e20>. 
mechanism	It is possible that <e10> Etonogestrel </e10> and <e20> ketoconazole </e20> may be administered concurrently with other <e22> opiates </e22> or other anticonvulsants. 
mechanism	In addition, <e10> nifedipine </e10> should be used with caution and should not be combined with any other drugs that may interfere with metabolism of ketoconazole. 
mechanism	<e12> Interleukin-A </e12> may reduce the bioavailability of anesthetics that may potentiate the action of interleukin-A. 
mechanism	<e10> L_Carnitine </e10> has been used as a sedative in patients with drug hypersensitivity reactions to <e22> nelfinavir </e22>. 
mechanism	Patients receiving <e10> lorazepam </e10>, <e20> methotrexate </e20>, a class of antihypertensive_agents, or concomitantly with <e22> nelfinavir </e22> should be monitored closely. 
mechanism	 Drugs which are generally used to treat <e12> CNS_depressants </e12> or to prevent the metabolism of <e22> dopamine </e22> may interact with CNS_depressants, or may interfere with CYP3A4 activity. 
mechanism	 Involuntary <e10> anticonvulsants </e10> therapy is a recommended treatment for chronic renal failure. 
mechanism	<e10> Antacids </e10> : In patients receiving <e20> methotrexate </e20> therapy, plasma levels of tetracycline may increase when the tetracycline does not decrease with <e22> methotrexate </e22> therapy. 
mechanism	Antacids, such as <e10> antacids </e10>, propranolol, corticosteroids, <e20> cimetidine </e20>, and others, may impair antacids metabolism and therefore may result in decreased plasma levels of <e20> antacids </e20>. 
mechanism	In a rat model of vitamin E deficiency, a decreased metabolism of vitamin E was observed in vitro (e,g,, 5-hydroxyvitamin_E_treated rats: <e10> concomitant administration of <e22> tetracycline </e22> with <e20> warfarin </e20> and coadministration of magnesium-containing or zinc-containing tablets with vitamin E-treated patients). 
mechanism	<e10> <e20> Lipitor </e20>, oral contraceptive, anticoagulants, antidepressants, antipsychotics, and/or <e20> narcotics </e20> are the most frequently prescribed or used antibiotics, particularly of <e20> warfarin </e20>. 
mechanism	Antidepressants <e12> Phenobarbital </e12> or <e20> Rifampin </e20> have been studied in patients who were classified as exhibiting SSRI <e20> warfarin </e20> or warfarin-containing tablets. 
mechanism	Nihonbamate - Interactions: <e12> Nihonbamate </e12> -inhibitors with CYP3A4, <e20> anticholinergic </e20>, and anticonvulsants, and <e20> magnesium salts. 
mechanism	When <e10> rifampin </e10> is administered alone or with two of the following agents: <e20> amiodarone </e20> (Antacid) and <e20> ketoconazole </e20> (Clinical). 
mechanism	Administration of <e12> Cimetidine </e12> with a monoamine oxidase inhibitor, norepinephrine_inhibitors, or the selective antiarrhythmics #2_and_5 ( #7_fluorouracil ) did not result in reduced serum levels of either the <e20> morphine </e20> or an antiarrhythmics #4_and_5. 
mechanism	 <e10> Ethinyl-CoA </e10> : <e20> acetaminophen </e20> -induced increased plasma acetaminophen concentrations in rats. 
mechanism	<e10> HEPOXACIN </e10> may decrease the efficacy of <e20> indomethacin </e20>. 
mechanism	The <e10> cimetidine </e10> may potentiate the renal effects of <e20> benzodiazepines </e20> and lithium, causing vomiting and other hypotension. 
mechanism	<e12> Coadministration of <e20> cimetidine </e20> with <e22> ethinyl_estradiol </e22> resulted in decreased plasma levels of cimetidine. 
mechanism	Colectomy by <e10> aspirin </e10> resulted in a decrease in serum levels of ethinyl_estradiol and ethinyl_estradiol_containing pills, decreased plasma levels of catecholamines, and decreased the plasma concentrations of <e20> benzodiazepines </e20> and anticonvulsants. 
mechanism	<e10> Protease_inhibitors </e10> may reduce the bioavailability of methotrexate, but not the plasma concentrations of methotrexate, as these are lower than in healthy volunteers. 
mechanism	<e10> Benzodiazepines </e10> have not been concomitantly studied in patients with Type 2 diabetes or severe hypertension. 
mechanism	 A dose of <e10> ketoconazole </e10> was recommended for patients who had recently received other antacid agents (e,g,, rifampin, quinidine, <e20> diphenhydramine </e20>, clofibrate, dinitrophenone, temazepam, valproic acid, nelfinavir, <e21> NSAIDs </e21>, barbiturates, phenoth
mechanism	 Interactions with the endogenous aminosidase inhibitor cisapride have been reported in patients receiving <e12> beta-adrenergic_antagonists </e12>, and the effect of beta-adrenergic_antagonists on <e20> co-administration of <e22> aorticosteroids </e22> with other <e22> CNS_stimulators </e22> may be increased. 
mechanism	A total of 29 patients (14%) had received <e10> ketoconazole </e10> or <e20> cyclosporine </e20> and one patient received a multivitamin, while the other patient received a fluconazole (n=10). 
mechanism	Oral administration of <e12> ketoconazole </e12>, buttermilk, albuterol, <e20> sucralfate </e20> and a beta-blocker of <e21> albuterol </e21> may lead to reduced renal clearance of these compounds. 
mechanism	 Norgestrel, <e10> sizosterine </e10>, epinephrine, and benzodiazepines ; 
mechanism	<e10> Tegretol </e10> : <e20> NSAIDs </e20> : 
mechanism	Erythromycin: The anticoagulant effect of ethytoin on the excretion of <e10> azithromycin </e10> should be avoided when taking azithromycin. 
mechanism	Patients receiving <e10> CEPHILPTIN </e10> have been known to experience an increased rate of depression following cephalosporine infusion in response to a dose of <e20> ampicillin </e20>. 
mechanism	The use of phenylbutazone ( <e10> ketoconazole </e10> ), as well as <e20> lorazepam </e20>, is recommended. 
mechanism	There is a decreased risk of CNS absorption of <e10> fluconazole </e10> due to the potential of concomitant administration of <e20> temazepam </e20> with these preparations. 
mechanism	Benzodiazepines : <e10> anticonvulsants </e10> ( Cimetidine, <e22> warfarin </e22> ) may enhance the effects of <e20> barbiturates </e20>. 
mechanism	<e10> Acetaminophen </e10> may interact with the following medications: aspirin, carbamazepine, diazepam, phenytoin, <e20> naproxen </e20>, fluoxetine, fluvoxamine, and metoclopramide. 
mechanism	<e10> Ketoconazole </e10> -induced vasodilatation, and an increase in the plasma level of <e22> fibrate </e22> and a decrease in blood pressure in healthy volunteers. 
mechanism	Coadministration of <e10> lithium </e10> with <e20> lithium_beta_antagonists </e20> in rat, mouse, and rat brains may produce potent antipsychotic-like effects. 
mechanism	Neoralfloxacin In patients receiving <e12> <e20> nelfinavir </e20> with an oral dose of <e22> cisapride </e22> and <e23> clofibrate, coadministration of cisapride did not alter <e23> gastric emptying or emptying. 
mechanism	<e10> Spironolactone </e10> or other <e22> agents may interact with <e23> aspirin </e22>, leading to changes in renal function. 
mechanism	<e10> HCT-A </e10> should not be administered in patients receiving CYP3A4. 
mechanism	Drug interactions with <e10> CYP3A4 </e10> were not studied. 
mechanism	Anticholinergic : Preliminary data suggest that <e12> corticosteroids </e12> may potentiate the actions of acetaminophen ( acetaminophen ), and it is important to monitor and monitor acetaminophen pharmacokinetics. 
mechanism	<e10> Phenobarbital </e10>. 
mechanism	Ascorbic Acid ( <e10> erythromycin </e10> ) and methotrexate ( <e20> rifampin </e20> ) produce potent potent antihypertensive effects, caution should be exercised in patients receiving this regimen when taking oral lithium. 
mechanism	Preliminary data from the clinical trial of furosemide in patients with clinically significant epilepsy indicate that furosemide may potentiate the behavioral and gastrointestinal effects of cimetidine. 
mechanism	Cholestyramine, <e10> diphenhydramine </e10> and <e20> fluoxetine </e20>. 
mechanism	- Oral administration of <e10> chloramphenicol </e10> may inhibit oral CYP3A4 (e,g,, <e20> cimetidine </e20> ) binding. 
mechanism	<e10> Tylenol </e10> potentiates the action of <e20> phenytoin </e20> on <e22> methotrexate </e22>. 
mechanism	Oral <e12> Oral </e12> Drug: Antacids/preparations for # mg dose-dependently at # weeks of # weeks and # days of # weeks # days of # weeks, with or without a <e20> vitamin </e20> supplement, and in combination with <e22> lithium </e22> or any other form of lithium. 
mechanism	The proton pump inhibitor <e12> albuterol </e12> ( Spanosapril ) has been shown to inhibit the absorption of cytochrome P4503A4 ( CYP3A4 ), suggesting that inhibition of CYP3A4 metabolism may not be necessary. 
mechanism	It is not known whether caffeine_acid_reduction_or_diuretics ( caffeine_acid_reduction_agents ) increase the risk of hypotension. 
mechanism	<e10> NSAIDs </e10> may decrease the effects of <e20> beta-adrenergic_drugs </e20>. 
mechanism	Patients receiving monoamine_oxidase_inhibitors should be considered with caution in patients receiving multiple <e12> MAOIs </e12> when administering <e20> carbamazepine </e20>. 
mechanism	In patients receiving <e10> vitamin_C </e10>, fluoxetine, and propranolol, it is recommended that erythromycin be administered prior to and during <e20> therapy #. 
mechanism	<e10> Anti-inflammatory agents </e10> : anti-inflammatory agents, cyclosporine, anti-oxidants ( <e20> ACE-3 </e20>, <e21> Triazolam ), and protease inhibitors ( <e22> Cimetidine ). 
mechanism	 Etonogestrel has no effect on blood pressure, <e10> thyroid_stimulant </e10> absorption, blood pressure-lowering effects or gastrointestinal effects in patients receiving <e20> hypoglycemic_antagonists </e20> or insulin-lowering drugs such as famotidine and zolpidem. 
mechanism	A low dose of <e10> propranolol </e10> can be expected to result in potentiation of the effect of propranolol when given in conjunction with beta-blockers. 
mechanism	Antacids ( <e10> tranylcypromine </e10> ) and <e20> fluconazole </e20> 
mechanism	 Interactions between <e10> acetaminophen </e10> and <e22> colefloxacin </e22> should be considered when taking colefloxacin alone. 
mechanism	<e10> nelfinavir </e10> reduces the blood levels of co-administered, <e20> lithium </e20>, propranolol, and <e22> diclofenac </e22>. 
mechanism	The interaction between <e10> phenytoin </e10> and concomitant therapy of <e20> morphine </e20> has not been studied. 
mechanism	Neutrogenetics : A careful review of the data demonstrated that <e10> neutrogenetics </e10> resulted in less than half the reduction in protein excretion of non-selective_receptor_beta_agonists in patients receiving <e20> carbamazepine </e20>. 
mechanism	The following drugs may decrease or substantially inhibit the pharmacokinetics of CYP3A4: phenytoin, <e10> phenytoin_citrulline </e10>, <e20> cyclosporine </e20>, and <e22> digoxin </e22>. 
mechanism	Coadministration of <e10> erythromycin </e10> with a <e22> norethindrone </e22> or another anticonvulsant regimen (e,g,, oral <e20> thiazide </e20> and oral <e22> warfarin ) resulted in a significantly reduced fluorescence intensity and a decrease in fluorescence activity. 
mechanism	In a study of three healthy volunteers, <e10> vitamin_C </e10> intake was increased by 3%, <e22> vitamin_D </e22> intake was decreased by 15%, and <e22> folic acid </e22> intake by 12%. 
mechanism	 Prenatal administration of <e12> prednisolone </e12> and dalcithin may increase the pharmacokinetics of <e20> phenobarbital </e20>. 
mechanism	Etonogestrel - Aromatic Agents : <e12> Coadministration of <e20> nelfinavir </e20> with <e20> nefinavir </e20> resulted in an increase in plasma concentrations of Aromatic Agents that may prolong the exposure to <e22> quinidine </e22>. 
mechanism	Drugs with antitumor_drug_availability similar to that in <e10> azithromycin </e10> ( erythromycin ) have been reported to reduce the clearance of some (e,g,, ketoconazole, zidovudine ) and prevent the onset of ketoconazole. 
mechanism	Since <e10> Anticonvulsants </e10> have been recommended to prevent <e20> diazem </e20> toxicity, diazem preparations should not be used in patients with HIV disease who are already taking <e22> antihistamines </e22>. 
mechanism	Cimetidine_containing tablets containing <e12> ibuprofen </e12>, cimetidine, digoxin, and <e20> cyclosporine </e20> were added to <e22> intravenous_injection ipsumipine </e22>. 
mechanism	Etonogestrel, indinavir, <e10> phenothiazines </e10>, <e20> acetaminophen </e20>, rifampin, quinidine, and <e21> rifampin </e21> ( 
mechanism	However, patients receiving <e10> morphine </e10> had no apparent effect on the toxicity of <e20> opiate_inhibitors </e20>, <e20> acetaminophen </e20>, nor do they affect their effects on anticoagulant_drugs. 
mechanism	Antifungals: <e10> divalproex </e10> -concentrated salicylic_acid </e10> is sometimes prescribed for <e20> azithromycin </e20>, azithromycin_spontaneous_acid_diuretics, and other antifungals. 
mechanism	CYP3A4, norepinephrine, <e10> nicotinic_acid </e10>, and <e22> digoxin </e22> may be potentiating these effects. 
mechanism	<e10> Ciprofloxacin </e10> may enhance the clearance of <e20> morphine </e20>. 
mechanism	 In a clinical trial with patients taking <e10> antihypertensive_drug_agents </e10>, it was found that <e20> clonidine </e20> was able to completely reverse intracellular inhibition of furosemide-induced hyperparathyroidism. 
mechanism	The following drugs may interact with the metabolite metabolism of <e10> amiodarone </e10> : <e20> benzodiazepines </e20>, methotrexate, myristic_thrombin_acid, lithium, morphine, quinidine, thyroid-depressants, thyroid_depressants, thyroid_stimulation_inhibitors, sedatives, somatropines, thyroid_suppressants, and <e20
mechanism	The pharmacokinetics of <e10> lorazepam </e10> or <e20> rifampin </e20> are similarly related to the pharmacokinetics of <e20> propranolol </e20>, a metabolite of propionic_acid. 
mechanism	<e10> Cholestyramine </e10> may interact with the CYP3A4 enzyme, although the extent of interaction is not known. 
mechanism	<e10> Methadone </e10> may enhance the effect of the <e20> Phenobarbital </e20>. 
mechanism	The potential interaction between the following drugs: corticosteroids, <e10> anticonvulsants </e10>, antipsychotics, somatotropin-releasing_system (TNS) or <e22> dopamine_blocking_agents </e22>, <e20> metformin </e20>, and antidepressants can be mitigated by taking <e22> anticonvulsants </e22> and <e20> metform
mechanism	Because it has not been investigated as a thyroid_lowering agent (e,g,, <e12> albino-hydrochloride </e12>, thyroid_lowering_agents ), <e20> carbamazepine </e20> may not be tolerated by patients taking <e22> albino-hydrochloride </e22>. 
mechanism	Antacids : No treatment for <e10> antacids </e10>, either in plasma or in urine, has been demonstrated to prevent their absorption or sensitization in patients receiving <e20> antacids </e20>, and did not occur with #2 (rhodamine ), #3 (methoxamine ), #4 (methoxybenzoquinone ), #5 (dihydrochlorothiazide ), #6 (
mechanism	<e10> Magnesium </e10> may decrease the efficacy of <e20> iron </e20>. 
mechanism	 Drug Interactions : <e10> diflurane </e10> : Drugs that cause hypertension or hypoglycemia (i.e., the metabolite of <e20> nitrous_oxide </e20> ) may interact with the coadministration of the <e22> quinidine </e22>. 
mechanism	The following is a list of possible pharmacologic interactions between <e10> NSAIDs </e10> and <e20> digoxin </e20>. 
mechanism	Antacids : <e10> Phenobarbital </e10>, <e20> quinidine </e20>, and beta-blockers, as well as antidepressants (e,g,, tetracyclines, ampicillin, phenytoin, prednisolone ), are known to decrease the bioavailability of CYP3A4_inhibitors, as did quinidine. 
mechanism	Drugs other than theophylline that interact with theophylline or theophylline_beta-hydroxide and <e10> phenytoin </e10> (e,g,, fluoxetine, isoniazid, naproxen ) have been associated with changes in plasma concentrations and toxicity. 
mechanism	<e10> L-tryptophan </e10> has been shown to have therapeutic effects on the plasma levels of concomitant phenothiazines. 
mechanism	Propranolol <e12> <e20> antihypertensive_drug </e20> </e20> and <e22> amiodarone </e22> may interfere with the metabolism of a clinically important metabolite of choline. 
mechanism	The administration of <e12> benzodiazepines </e12> with benzodiazepines such as valproic acid, <e20> indinavir </e20>, phenytoin, and warfarin has been associated with decreased CNS inhibition and CNS conduction inhibition resulting in a clinically significant decrease in the half-life of <e21> benzodiazepines </e21>. 
mechanism	 CYP3A4 : <e10> Coadministration of CYP3A4 in the presence of <e20> digoxin </e20> with digoxin and <e22> digoxin-based contraceptives, where digoxin is <e22> a digoxin-based contraceptive </e22>, may result in increased oral contraceptive doses. 
mechanism	There is little information available about the extent to which <e12> phenothiazines </e12> may interact with phenothiazines (e,g,, <e20> benzodiazepines </e20> ), and the extent to which phenothiazines interact with <e20> sedative_antidepressants </e20>. 
mechanism	<e10> Ethanol </e10> is given on doses of <e20> phenobarbital </e20> and other CNS_depressants, which result in reduced plasma levels of both phenobarbital and phenobarbital. 
mechanism	Antacids, <e12> Tetracyclines </e12>, <e20> <e21> Benzodiazepines </e21>, Benzodiazepines, phenytoin, fluoxetine, and phenytoin may affect CNS absorption. 
mechanism	<e10> Inhalation of <e22> <e23> sodiumbenzylhydrate </e22> in rats resulted in a significant reduction in serum concentrations of the aminoglycosides sulfonylureanide and niacinamide, and decreased the secretion of <e22> anticonvulsants </e22>. 
mechanism	The coadministration of <e10> d-myroxine </e10> with any other anticonvulsants other than these, including the <e20> azithromycin </e20> and <e21> fluoxetine </e21>, has not been studied, although an ongoing study is necessary to evaluate the effects of the dihydrochloride-containing formulations on the clinical reactions of these individuals. 
mechanism	At least one study with <e10> phenytoin </e10> has shown a clinically significant increase in mean plasma <e20> phenytoin </e20> concentrations following oral administration of <e22> methotrexate </e22>. 
mechanism	There is no significant interaction between <e10> anticonvulsants </e10> and <e20> <e20> chloroquine </e20>. 
mechanism	The pharmacokinetics of <e10> phenytoin </e10> in patients receiving concomitant oral phenytoin, <e20> phenytoin </e20>, furosemide, <e22> digoxin </e22>, and digoxin are not well characterized. 
mechanism	<e10> Propranolol </e10> : Antacid 
mechanism	Cholestyramine ( <e12> cholestyramine </e12> ) is a potent inhibitor of plasma concentrations of <e20> phenytoin </e20>. 
mechanism	A double-blind, placebo-controlled study of erythromycin and a pharmacokinetic study of <e10> rifampin </e10> with a known additive of <e20> methyldopa </e20> was conducted in two adults (1 male and 1 female) receiving the <e20> methyldopa </e20> or azithromycin. 
mechanism	<e10> Furosemide </e10> increases the plasma concentrations of #3 inducers of calcium, <e20> potassium </e20>, and calcium_chloride. 
mechanism	<e10> cimetidine </e10> can potentiate the action of cyclosporine on anticholinergic receptors (eg, <e20> warfarin </e20> ), such that potentiating these anticholinergic effects may result in anticholinergic reactions to CNS depressants like alcohol. 
mechanism	 <e10> Atropine </e10> and <e20> Phenobarbital </e20> have been reported to decrease the absorption of <e20> fluoxetine </e20> and carbamazepine. 
mechanism	<e10> Phenobarbital </e10> has not been studied with patients receiving treatment with <e22> morphine </e22>, erythromycin, <e23> haloperidol </e23>, cyclosporine, or salicylates. 
mechanism	The concomitant administration of <e10> bacitracin </e10> and carbamazepine may increase the risk of severe CNS depression (eg, amiodarone, acetaminophen ), hypotension (eg, alprazolam ), renal failure (eg, <e20> metoprolol </e20> ), hypotension, renal failure (eg, metoprolol ), and potassium loss. 
mechanism	Antacid : In vitro studies suggest that, when <e10> coadministration of <e20> indinavir </e20> with NSAIDs or <e22> thiazide </e22> (e,g,, # mg for # days), <e20> NSAIDs </e20> may increase the pharmacokinetics of thyroid hormone, which may enhance the pharmacokinetics of antihistamines. 
mechanism	<e10> Methadone </e10> therapy; concomitant use of <e20> morphine </e20> should be considered in patients receiving <e22> phenytoin </e22>. 
mechanism	- <e12> Norepinephrine </e12> ( <e20> Norepinephrine_Clinical_Drugs_in-an-Etobic_Cardiovascular_Nervous_System ) should be avoided when initiating a concomitant combination of <e20> antihistamines </e20> and antacids. 
mechanism	Since acetaminophen has no adverse effects on the plasma levels of <e10> amiodarone </e10>, <e20> phenytoin </e20>, and ketoconazole, acetaminophen should not be taken at any time prior to initiation of <e22> coadministration of either <e22> carbamazepine </e22> or cimetidine </e22>. 
mechanism	<e10> Neutrogena </e10> isoenzymes in the conduction zone of #_agents_inhibitors. 
mechanism	Antihistamines: cimetidine, and <e10> diphenhydramine </e10> are safe for patients taking these drugs. 
mechanism	N-acetyl-Hexamine_inhibitors such as <e10> acetaminophen </e10> (Cimetidine ) and concomitant administration of quinidine may increase the clearance of drugs such as <e20> phenobarbital </e20> and quinidine, thereby increasing the chance of adverse events. 
mechanism	<e10> Carbamazepine </e10> : Preliminary evidence suggests that a concomitant use of <e22> phenytoin </e22> or the other drugs phenytoin and <e22> phenytoin_benzodiazepines </e22>, may cause severe CNS depressant effects. 
mechanism	Acids : <e10> Phenothiazines </e10> (fluoxetine, phenytoin, phenytoin_sodium ) and other <e20> anticonvulsants </e20> are known to decrease serum levels of diazepam. 
mechanism	The inhibitory effect of <e10> phenytoin </e10> and <e20> prednisolone </e20> on dopamine (dopa) metabolism is controlled by the following: <e20> antihypertensive_drugs </e20>, anticonvulsants, and benzodiazepines. 
mechanism	The most potent therapy for <e10> antihypertensive_agents </e10> and <e20> tranquilizers </e20>, CYP3A4, cyclosporine, and thiazides, should be administered with caution when used with concomitant therapy with # or <e22> lithium </e22>. 
mechanism	The administration of <e10> sertraline </e10> in combination with <e22> sertraline </e22> may increase the adverse effects of these drugs. 
mechanism	 However, erythromycin_blocking_agents (eg, <e10> ibuprofen </e10> ) have been reported to inhibit the binding of <e20> metformin </e20>. 
mechanism	CNS_inhibitors (such as theophylline, butyrophenones, theophylline, <e12> alfazodone </e12>, phenytoin, and other CNS_analgesic_agents ), CNS_releasing_agents (such as alcohol, phenytoin, <e20> tranylcypromine </e20>, methotrexate, methotrexate, <e20> dig
mechanism	Clinical study in patients with diabetes, with the use of <e10> beta-blockers </e10> or <e20> beta-blockers </e20>, was limited. 
mechanism	Antacid : Antacid use should be avoided because of the potential for toxicity of <e10> digoxin </e10> and <e20> digoxin </e20> with the following: <e22> methyldopa </e22>, clarithromycin, ampicillin, beta-blockers, <e22> trileptaminates </e22> and antibiotics that are not concomitantly with digoxin and may increase the risk of
mechanism	When <e10> acetaminophen </e10> is administered with an intravenous dose, it should be noted that <e20> acetaminophen </e20> should be given within the general anesthesia protocol and concomitantly with <e22> acetaminophen </e22>. 
mechanism	<e10> Citalopram </e10> reduces the elimination of oral <e22> anticonvulsants </e22> and increases the half-life of oral anticonvulsants by approximately 15 minutes (10-20%) and 15 minutes (20-45%) respectively (21,22). 
mechanism	Drug Interactions: <e10> CYP3A4 </e10> -preparation of <e20> aminoglycosides </e20> resulted in increased serum plasma concentrations of these drugs. 
mechanism	Concomitant use of <e12> morphine </e12> and <e22> dihydrochloride </e22> should be stopped for patients receiving concomitant use of either of these drugs. 
mechanism	The following drugs may decrease the elimination of CYP3A4 (e,g,, <e10> ketoconazole </e10>, anticonvulsants, warfarin, <e22> anticonvulsants </e22>, and some antidiabetic_drugs ): methotrexate, warfarin, phenytoin, salicylic_acid_inhibitors, fluoxetine, <e20> methot
mechanism	<e10> SSRIs </e10> : <e20> clonidine </e20>, concomitant administration of aspirin, concomitant administration of a <e21> potassium </e21>, or anhydride, may increase the plasma concentrations of <e22> SSRIs </e22>. 
mechanism	<e10> Agapeptide </e10> and its metabolites, like ketoconazole and cimetidine, are highly potent antagonists of methotrexate, thus, concomitantly, concomitant administration of <e22> anticonvulsants </e22> and anticonvulsants with Agapeptide can reduce their pharmacokinetic action by over 30%. 
mechanism	The plasma concentrations of <e12> dexamethasone </e12> and <e20> methyldopa </e20> are not affected by concurrent administration of <e22> dexamethasone </e22> or the use of phenytoin. 
mechanism	In a study, d_nephenone, <e10> phenytoin </e10>, <e20> <e20> terfenadine </e20>, or <e22> acetaminophen_antagonists </e22> were used to modify and thereby reduce <e22> d_nephenone </e22> action. 
mechanism	The clinical presentation of hepatic-stemfiltration-induced renal failure is comparable to those experienced with other <e10> hepatic-stemfiltration-induced renal failure </e10> in patients receiving <e20> oral </e20> therapy. 
mechanism	<e10> Methoxazole </e10> may enhance the plasma concentrations of <e20> cyclosporine </e20> and may increase the plasma concentrations of morphine. 
mechanism	Atopyramide - an oral contraceptive containing <e10> coadministered progestogens </e10> and <e20> ketoconazole </e20> - has been used safely and with small doses in the study of <e22> tricyclic_antidepressants </e22> and atrazine. 
mechanism	 Therefore, it is recommended that <e10> diazepam </e10> and benzodiazepines with high therapeutic potential be avoided in patients with severe central nervous system (CNS) hypoglycemia who require a pharmacological response of <e20> anticonvulsants </e20> and their administration to control CNS hypoglycemia. 
mechanism	The concomitant administration of <e10> methotrexate </e10> and/or <e22> haloperidol </e22> was not associated with an increased incidence of gastric emptying in patients receiving other <e22> ketoconazole </e22>. 
mechanism	Etonogestrel Injections of <e10> Etonogestrel </e10>, <e20> cyclosporine </e20>, methotrexate, or other benzodiazepines may potentiate the sedation-induced hypoglycemia effects of <e22> phenytoin </e22>. 
mechanism	<e12> Fentanyl </e12> (piperazine) was not effective against the oral route of cephalosporine_2, but the pharmacokinetics of furosemide, phenytoin, and tetracycline were substantially increased. 
mechanism	In a clinical trial with erythromycin and amiodarone, patients receiving the latter were not required to <e10> erythromycin </e10> concomitantly. 
mechanism	Concomitant administration of <e10> benzodiazepines </e10> and <e22> phenytoin </e22>, with <e23> cyclosporine </e23> or a combination of those two drugs, may reduce the pharmacokinetics and/or potentiate the potentiation of benzodiazepines. 
mechanism	The use of <e10> aspirin </e10> in conjunction with nonsteroidal_anti-inflammatory_agents is recommended. 
mechanism	 The presence of <e10> cimetidine </e10> may increase the effects of <e20> salicylic_acid </e20>, thus decreasing the dose of dizantile and the dose of estrogens. 
mechanism	It has been shown that <e10> dihydrosuropyridine </e10> may reduce its bioavailability. 
mechanism	<e10> amiodarone </e10> is not metabolized by CYP3A4, CYP3A4 or CYP3A4 enzyme systems, nor does it occur in patients with an active metabolite of amiodarone. 
mechanism	- <e10> NSAIDs </e10> may induce liver toxicity and may decrease renal clearance of <e22> prednisolone </e22>. 
mechanism	Preliminary clinical evidence suggests that coadministration of <e10> anticonvulsants </e10> with <e22> naproxen </e22> should be avoided during pregnancy or during first trimester. 
mechanism	<e12> Antihistamines </e12> -like drugs that can cause hyperlipidemia and/or hypoglycemia, may potentiate the metabolism of methotrexate, ketoconazole, and concomitant medications containing ethinyl_estradiol, or are of similar class to methotrexate. 
mechanism	-Injection of <e12> nelfinavir </e12> in patients with type 2 diabetes is concomitant with its administration by <e22> intravenous_injection_drugs </e22>. 
mechanism	Ascorbic acid, concomitant administration of <e10> phenytoin </e10> and dinitrophenone, and concomitant administration of phenytoin with </e10>, which is metabolized in vitro, may result in increased plasma levels of <e22> phenytoin </e22> and may result in a decrease in plasma levels of <e22> dihydroquinone </e22>. 
mechanism	<e12> Benzodiazepines </e12> or <e20> digoxin </e20> may increase the anticonvulsant effect of certain other <e22> tranquilizers </e22>. 
mechanism	In animal studies, <e10> phenothiazines </e10> were administered concurrently with <e20> clonidine </e20> and/or succinylcholine. 
mechanism	It is possible that <e10> oral <e20> coadministration </e20> with <e22> anesthetics </e22> may increase <e20> CNS permeability to benzodiazepines and/or similar substances. 
mechanism	<e10> Triethanolamine </e10> should be administered with caution when coadministered with antibiotics such as lorazepam, an antacid, <e20> probenecid </e20> and phenytoin. 
mechanism	
mechanism	Therefore, there is no known dose-dependent difference in the incidence of <e10> vitamin_C </e10> and <e20> vitamin_A </e20> in the serum levels of coadministered <e20> vitamin_C </e20> and vitamin_A. 
mechanism	<e10> amiodarone </e10> induces the production of <e20> warfarin </e20> (CYP3A4) in the liver (CYP3A4)-bound beta-adrenergic neurons. 
mechanism	When <e11> H2-blocking_agents </e11> are used together with <e20> acetaminophen </e20>, <e21> antihistamines </e21> and vitamin_2_blocking_agents, they may produce higher concentrations of both drugs. 
mechanism	A similar proportion of <e11> Cinabix </e11> and <e20> carbamazepine </e20> was observed in patients receiving the pharmacologic_antiarrhythmics (S-M, <e20> valproic_acid </e20> and/or its inactivated constituent, <e20> phenytoin ). 
mechanism	CNS interaction with <e10> corticosteroids </e10> may increase the CNS excitability of those with elevated CNS concentrations of <e20> corticosteroids </e20> and, in the latter case, may potentiate the CNS release of certain drugs. 
mechanism	 The potential toxicity of a <e10> tricyclic_antidepressants </e10> in the management of neuropsychiatric disorders should be considered with caution. 
mechanism	In two clinical studies, bicarbonate and oral anticoagulants were administered concurrently, concomitantly, <e10> oral anticoagulants </e10> and <e20> diclofenac </e20>. 
mechanism	Interactions between <e10> anticholinergic_agents </e10> and <e20> methotrexate </e20> may occur. 
mechanism	Although <e10> anticholinergic_agents </e10> may be beneficial, their effectiveness and general concomitant effects should be evaluated carefully when pharmacokinetic studies are initiated in patients with multiple sclerosis ( MS ). 
mechanism	 The following drugs may interact with <e10> quinidine </e10> in a patient who has not been treated with quinidine : <e20> ethinylcholine </e20> and digoxin, anticonvulsants, anticonvulsants with <e22> anticonvulsants </e22> or <e23> lidocaine. 
mechanism	No clinical trials have been performed to evaluate the pharmacokinetics or bioavailability of <e10> phenytoin </e10> with other <e20> tranquilizers </e20>. 
mechanism	<e10> cimetidine </e10> and cimetidine, or <e20> lithium </e20>, should be avoided. 
mechanism	The effects of <e10> levodopa </e10> and ethinylcholine_blockers on the clearance of <e20> ketoconazole </e20> and acetylcholine_blockers, renal damage, renal protein replacement, renal metabolism, hepatic metabolism, hepatic insulin resistance and renal toxicity have been studied. 
mechanism	Concomitant administration of <e10> metoclopramide </e10> with <e20> levodopa </e20> did not result in increased concentrations of <e22> beta-blockers </e22> or ampicillin, the latter being of concomitant use. 
mechanism	 <e10> Calcium_channel_depleting_acid </e10> is commonly administered to patients receiving <e20> magnesium_channel_depleting_acid </e20>, antacids and concomitant administration of <e21> magnesium_channel_depleting_acid </e21>, antihistamines. 
mechanism	<e12> Sporine </e12> is a potent form of <e20> carbamazepine </e20>, but may interact with certain <e22> amphetamines </e22>. 
mechanism	<e10> Concomitant administration of <e20> monoamine_oxidase_inhibitors </e20> may result in a increased plasma concentration of the active metabolite <e22> phenytoin </e22>, resulting in increased plasma levels of phenytoin. 
mechanism	Although patients who have <e10> ketoconazole </e10> and <e20> phenytoin </e20> have reported an elevated ketoconazole concentration, pharmacokinetic studies indicate that the ketoconazole metabolite of <e22> erythromycin </e22> is unaffected by the drug's ketoconazole component. 
mechanism	Concomitant administration of <e12> ketoconazole </e12> with <e20> indinavir </e20> in patients with congestive heart failure or with a combination of concomitant use of metformin and nelfinavir has not been concomitantly associated with decreased blood levels of concomitant metformin. 
mechanism	Anticonvulsants : No study has been conducted to determine the efficacy of <e10> oral <e20> rifampin </e20> in the management of anemia and rickets in a group of patients. 
mechanism	<e10> Caffeine </e10> is also administered in conjunction with other drugs that may cause hypotension, such as <e20> clofibrate </e20>, phenytoin, valproic acid, magnesium salts, and thioridazine. 
mechanism	 Oral <e10> NSAIDs </e10> may interfere with the clearance of oral <e20> anticoagulants </e20>, increasing the chance of drug-induced coma. 
mechanism	In the clinical setting of patients receiving <e10> monoamine_oxidase_inhibitors </e10> or CYP3A4 inhibitors, <e20> dexamethasone </e20> should be used, since other antipsychotics that enhance the safety profile of clonidine may potentiate the interaction of clonidine with a pharmacologic effect. 
mechanism	<e10> Tegretol </e10> is a potent anticonvulsant, diuretics and <e20> rifampin </e20>. 
mechanism	<e12> Fructose </e12> -like potentiating agents (e,g,, glucose_lactate, phenytoin, phenytoin-containing glycerol, <e20> corticosteroids </e20>, warfarin, or glyburide ) may increase the absorption of digoxin, which increases its toxicity. 
mechanism	Concomitant administration of <e10> anticonvulsants </e10> and lidocaine may result in reduced plasma levels of these drugs, but <e20> ketoconazole </e20> may not. 
mechanism	The combination of <e12> clindamycin </e12> with # mg of <e22> carbamazepine </e22> produces an additive effect that is potentiated by <e23> # mg_inflocetamine </e23>. 
mechanism	In vivo studies have shown that ethinylestradiol is able to reduce the induction of <e10> cyclosporine </e10> and is therefore more potent than <e20> valproic_acid </e20>. 
mechanism	 <e10> N-acetylcysteine </e10> : <e20> NSAIDs </e20> and anticholinergics, and antipyretics such as methotrexate, phenothiazines, erythromycin, and <e20> ketoconazole </e20> have been found to decrease plasma concentrations of ampicillin, sertraline, clarithromycin, atorvastatin, and co
mechanism	In a dose-dependent manner, <e10> cisapride </e10> may increase the concentrations of <e20> phenobarbital </e20> and prolong the clinical course of <e21> haloperidol </e21>. 
mechanism	 <e10> Etonogestrel </e10> : <e20> phenytoin </e20> inducers and antagonists may have been potentiated by clonidine, phenytoin, quinidine, methotrexate, <e20> phenytoin_acid </e20> and phenytoin_acid_blockers. 
mechanism	The interaction between <e10> concomitant use of antihistamines </e10> and phenothiazines in patients with renal disease is known, however, and its potential impact on the renal clearance of <e20> concomitant use of anticonvulsants </e20> may be reduced by concomitant administration of these medications in patients with a concomitant need for <e22> concomitant use of anticonvulsants </e22>
mechanism	Serotonin -inducible_acid_amino_acid_channel (ALTAC ) inhibitors may enhance the potential of monoamine_oxidase_inhibitors ( MAOIs ), or their <e12> CYP3A4_activator_inhibitors </e12> ( CYP3A4_amino_acid_channel ). 
mechanism	 Oral Administration of <e10> phenytoin </e10> is not recommended. 
mechanism	- <e10> Antacids </e10> : <e20> ketoconazole </e20> or quinidine-containing tablets have been shown to decrease plasma concentrations of antacids, which may have adverse effects on thyroid function and metabolism. 
mechanism	Theophylline is metabolized to <e12> chlordiazepoxide </e12>, and its binding sites may be changed by it when concomitantly with other nonsteroidal_anti-inflammatory_agents (e,g,, # mg) and at higher doses. 
mechanism	 
mechanism	
mechanism	 Preliminary evidence indicates that <e10> fluoxetine </e10> may induce a clearance of catecholamine-induced amyloid-beta, as well as a proton-oxidase response to <e20> valproic_acid </e20>. 
mechanism	<e12> Hernia </e12> inhibits the metabolism of <e20> chloramphenicol </e20> and its metabolite, carbapenemide, and increases the rate of calcium-dependent hypoglycemia. 
mechanism	- Dilatoxin- Inhibitors: At least # of clinically established patients (5-9) with <e11> DIO-A </e11> exhibited significant signs of tolerance to <e22> dioxygen </e22> -related events. 
mechanism	<e10> Etonogestrel </e10> reduces plasma levels of <e20> indomethacin </e20> and theophylline. 
mechanism	Drugs such as <e10> benzodiazepines </e10>, barbiturates, and acetaminophen may increase CNS depressant effects. 
mechanism	<e10> Inhibitors of the metabolism of dioxygenase_one and the protease_ones that bind it such as <e22> ketoconazole </e22> ( E_butanol ) and <e22> ketoconazole </e22> and similar antagonists have been reported in vitro and animal experiments. 
mechanism	Because phenytoin inhibits the secretion of <e10> cimetidine </e10> and itrelizone, dihydrochloroquine and/or concomitant administration of <e22> phenytoin </e22> to patients taking <e20> phenytoin </e20> is recommended. 
mechanism	Coadministration of the <e12> Triazolam </e12> with <e20> azathioprine </e20> resulted in a plasma decrease of <e22> ritonavir </e22> plasma concentrations and a significant increase in the plasma concentrations of <e22> clonidine </e22> and azathioprine. 
mechanism	<e10> Propranolol </e10>, <e20> acetaminophen </e20>, and certain other CNS_depressants: acetaminophen, ibuprofen, temazepam, barbiturates, warfarin, and other CNS_depressants like diuretics and tranquilizers like lithium, and other CNS_depressants like tranquilizers like clofibrate, sedatives, and others. 
mechanism	Ethinyl_estradiol and <e10> cyclosporine </e10> may increase the absorption of <e20> methyldopa </e20> by ampicillin. 
mechanism	Antifungals: In a clinical study with <e10> aspirin </e10>, aspirin prevented the antifungal effects of <e20> temazepam </e20> and a control group of <e20> spironolactone </e20>. 
mechanism	Aspartate : The use of <e10> propranolol </e10> has been associated with reduced oral absorption of the amiodarone. 
mechanism	Chlorpheniramine_inhibitors <e10> Etonogestrel </e10> ; or anticonvulsants with the elimination of <e22> diclofenac </e22>, and certain derivatives. 
mechanism	 Methothiazide : Theophylline <e10> phenytoin </e10> (phenytoin) and its metabolite <e20> phenytoin_II </e20>, potentiate the effects of <e22> benzodiazepines </e22> and other benzodiazepines, and thus make certain maintenance of <e23> alcohol_inhibitors </e23> as ineffective. 
mechanism	In a study with patients receiving zestyrenol, a significant difference in the bioavailability of <e12> nelfinavir </e12> was noted in patients receiving <e20> clozapine </e20>. 
mechanism	The combination of <e12> ketoconazole </e12> with ketoconazole has been demonstrated in the treatment of <e20> morphine </e20>. 
mechanism	- <e10> Benzodiazepines </e10> : Increased antacids levels may occur when <e20> ketoconazole </e20> is administered intravenously or <e20> quinidine </e20> (with or without propranolol ). 
mechanism	<e10> Carbamazepine </e10> -induced potentiation of the inhibitory effect of acetylsalicylic_acid (AA). 
mechanism	Anticholinergic/Antacid Interactions : <e10> Afloxacin </e10> -like effects may occur when oral afloxacin may be administered concurrently with <e20> phenytoin </e20>. 
mechanism	A number of studies have shown that <e12> anticonvulsants </e12> may enhance the effect of <e22> spermatogestrel </e22>. 
mechanism	Drug Interactions: Administration of <e10> cyclosporine </e10> or other inhibitors ( <e20> amiodarone </e20>, phenytoin, phenytoin derivatives, beta-blockers, carbamazepine, or aspirin ) or <e21> acetaminophen </e21> with aluminum and/or nitrofurantoin, and/or with any other additive that is additive with aluminum has been shown to increase
mechanism	Patients receiving <e10> Phenobarbital </e10>, <e20> carbamazepine </e20>, levodopa, tricyclic_antidepressants, phenytoin, <e22> phenytoin_of-hydrochloride </e22>, and carbamazepine will be expected to experience a concomitant reduction in plasma concentrations of <e23> phenytoin_of-hydrochlor
mechanism	Interleukin-9 therapy with <e10> interleukin </e10> should be administered during therapy with <e20> cisplatin </e20> for a period of at least 3 months to monitor and lower the incidence of side effects. 
mechanism	Therefore, it should be noted that <e12> anticonvulsants </e12> and <e22> alcohol </e22> may have potent anticonvulsant-like effects. 
mechanism	A study in pediatric patients showed that <e12> aspirin </e12> did not affect the pharmacokinetics of aspirin. 
mechanism	Because <e10> ethinyl_estradiol </e10> inhibits CYP3A4 enzymes in vitro, caution is warranted in patients receiving <e20> levonorgestrel </e20> therapy. 
mechanism	<e10> St. Jude </e10> : <e22> St. Jude ______________________________________. 
mechanism	 
mechanism	 Therefore, caution should be exercised when receiving <e10> phenobarbital </e10> when either <e20> <e20> phenobarbital </e20> or a <e22> beta-blocker </e22> is given. 
mechanism	Phenothiazines : In healthy volunteers, <e10> amiodarone </e10> has been classified as an <e20> indinavir </e20>, or <e20> indinavir_derivatives. 
mechanism	<e10> Involuntary discontinuation of <e20> cyclosporine </e20> or oral potassium </e20> is not recommended. 
mechanism	Etonogestrel has been reported to decrease hepatic cholesterol in patients receiving <e10> beta-blockers </e10>, <e20> cisapride </e20>, or <e22> salicylates </e22>. 
mechanism	<e10> Antihistamines </e10> may decrease the CNS binding of <e20> clonidine </e20>, including cimetidine and its analogues. 
mechanism	Inhibition of the enzyme CYP3A4 ( CYP3C4 ) protein and CYP3D4 ( CYP3D4 ) in rats resulted in an elevation in erythromycin tolerance. 
mechanism	 Concomitant administration of <e10> quinidine </e10> with <e22> antihypertensive_agents </e22> may result in reduced clearance of <e22> phenytoin </e22>. 
mechanism	Astropathomas were more common in patients receiving phenobarbital with <e10> azithromycin </e10> than patients receiving phenobarbital alone or in combination with <e20> phenobarbital </e20>. 
mechanism	 Drugs such as amiodarone, cimetidine, <e10> ketoconazole </e10>, diazepam, <e22> phenytoin </e22>, <e22> clonidine </e22>, rifampin, sedative_agents, thyroid_stimulators, caffeine, terfenadine, warfarin, warfarin-depleting_agents, morphine, <e20> methotrex
mechanism	Therefore, it is recommended that pharmacologic therapy be instituted in patients receiving <e10> aspirin </e10> for the management of hypertension, <e20> methotrexate </e20>, hypotension, <e22> methotrexate </e22> concomitant with <e20> methotrexate </e20>. 
mechanism	Cholestyramine has been reported to decrease serum ferritin levels and reduce the clearance of <e10> cholestyramine </e10> by the central nervous system (CNS). 
mechanism	Interactions between <e10> anticonvulsants </e10> and benzodiazepines were noted with respect to <e20> benzodiazepines </e20>. 
mechanism	Administration of <e10> salicylates </e10> to dogs without <e20> oral contraceptives </e20> resulted in elevated serum levels of salicylates. 
mechanism	A single oral dose of theophylline has been shown to reduce the clearance of <e10> sertraline </e10>. 
mechanism	There is no data to suggest that <e10> tricyclic_antidepressants </e10> reduce the pharmacokinetic profile of antihypertensive agents (such as aspirin, diuretics, <e20> sedatives </e20>, and tranquilizers ). 
mechanism	Interleukin-6 (IL-6) : Immunosuppression by intracellular intracellular_epinephrine may potentiate the effects of <e10> methyldopa </e10>, but some of these effects may be attenuated by <e20> ketoconazole </e20>. 
mechanism	The prothrombin time may be reduced with <e10> rifampin </e10> in some patients receiving <e20> tranylcypromine </e20>. 
mechanism	<e10> Atromid-Nafionine </e10> may cause changes in the body fluids and absorption of <e22> quinidine </e22>. 
mechanism	<e12> Acute administration of <e20> methyldopa </e20> with concomitant administration of ethinyl_estradiol, diazepam, <e22> temazepam </e22>, and dizantiin in combination with <e20> naproxen </e20> resulted in the complete elimination of <e20> methyldopa </e20>. 
mechanism	Oral <e10> Anticonvulsants </e10> have been shown to interact with the CNS and may increase the metabolism of these drugs. 
mechanism	Antacids: 
mechanism	In clinical studies, concurrent administration of <e12> ketoconazole </e12> or <e20> naproxen </e20> resulted in a 75% increase in plasma concentrations of ketoconazole and naproxen, respectively. 
mechanism	Antacids : <e10> Anticholinergic </e10> Interactions with <e20> phenytoin </e20> : Drug interactions with other <e20> pharmacologically active antacids : <e22> aspirin </e22> -containing tablets -with <e22> sertraline </e22> -containing tablets -with tablets containing phenytoin or anticholinergic tablets -with tablets containing anticholinergic tablets
mechanism	<e10> Concomitant administration of <e20> naltrexone </e20> or <e22> potassium </e22> to patients taking <e22> phenytoin </e22> should be avoided. 
mechanism	<e12> Anticoagulants </e12> such as diuretics, prednisolone, and <e22> cyclosporine </e22> should be avoided. 
mechanism	Prolonged or prolonged use of <e12> morphine </e12> (hypoglycemia), alcohol (abrupt action on the sympathomimetic pathway), morphine (hypoglycemic action on the renal tubular vessels), methotrexate (hypoglycemic action on the renal blood supply), or nonsteroidal_anti-inflammatory_agents (diuretics that block the effect of <e20> ACE_inhibitors </e20> ) or other systemic
mechanism	Since there is evidence that <e10> rifampin </e10> is capable of <e20> tetracycline </e20> toxicity, caution is needed when considering potential interactions. 
mechanism	Drugs that increase <e10> cimetidine </e10> or <e20> amiodarone </e20> may have additive effects on the renal clearance of sodium-channel-blocking diuretics and may also affect renal clearance of potassium, blood pressure and/or blood sugar control. 
mechanism	Potassium_channel_hydrochloride_containing <e10> Naegleron </e10> can interfere with thyroid_stimulation and thyroid hormones. 
mechanism	Concomitant administration of <e12> beta-blockers </e12> with <e20> methyldopa </e20> resulted in a decreased binding of <e22> dihydrobromocaine </e22> to the enantiomeric, non-enzymatic, anticonvulsant and non-steroidal_antibiotics. 
mechanism	CNS_drug_blockers : <e10> phenytoin </e10> is an endogenous CNS_drug that is classified as a CNS_drug_blocker and has been extensively studied with human ethinyl estradiol ( estradiol ) in animal studies, including studies with male and female rats. 
mechanism	<e10> N_butanone </e10> has not been studied with caution due to the potential for the interaction of a <e20> nelfinavir </e20> with phenothiazines (e,g,, atrazine, ampicillin, butyrophenone ) in the development of migraine. 
mechanism	 <e10> Trileptal </e10>, quinidine, estrogens, <e20> rifampin </e20> and estrogen replacement therapy ( <e22> thyroid </e22> ) has been shown to be a potentially useful and <e22> anticonvulsant </e22> effect on the serum levels of <e22> amiodarone </e22>. 
mechanism	Anticonvulsants : Coadministration of <e10> prednisolone </e10> and <e20> cyclosporine </e20> to 50-90% of patients taking diuretics and <e22> prednisolone </e22> as part of a single dose regimen did not decrease diuretic concentrations, and in the case of anticonvulsant efficacy, a dose-dependent reduction of <e22> diure
mechanism	Serum potassium is reduced by <e11> NaCl </e11> when <e20> potassium </e20> is given concurrently with intravenous <e22> KOH-6 </e22>. 
mechanism	Combination of <e10> benzodiazepines </e10> with <e20> amiodarone </e20> and <e21> methyldopa </e21> resulted in decreased potentiation of morphine. 
mechanism	Because of its clinical and laboratory toxicity, caution should be exercised when administration of <e10> nelfinavir </e10> is administered concomitantly with <e22> alveolar_acid </e22> ( nelfinavir ). 
mechanism	A concurrent administration of <e10> vitamin_C </e10> with <e20> vitamin_C </e20> in rats resulted in a marked decrease in serum ferritin levels, and serum ferritin levels did not change following administration of <e20> phenytoin </e20> alone. 
mechanism	Other Antibiotics: Lipid_lowering_agents ( <e10> tacrolimus </e10>, methotrexate, methotrexate, lidocaine, <e22> co-administration of <e22> ACE_inhibitors </e22> with either lidocaine or methotrexate and concurrently co-administered with # mg/day of # mg of methotrexate were not observed; 
mechanism	Interactions with corticosteroids, <e12> <e20> niacin </e20>, and <e22> concomitant administration of corticosteroids with <e20> antiarrhythmics </e22> and <e22> sedatives has not been reported. 
mechanism	<e12> Prozac </e12> : The <e22> sedative concomitant with lithium </e22> may have a significant effect on these pharmacokinetic parameters. 
mechanism	 <e12> Furosemide </e12> or <e20> phenobarbital </e20> may induce a potent antidepressant effect in the primary CNS. 
mechanism	<e10> Benzodiazepines </e10> : <e22> tranquilizers </e22> : 
mechanism	 As an endogenous potentiation of the CYP3A4 system, a pharmacokinetic profile may be enhanced when oral <e10> cimetidine </e10> is used with cimetidine, especially in the presence of <e20> clindamycin </e20>, cimetidine-like peptide chains, or with oral CYP3A4 inhibitors such as <e21> prednisolone </e21>, or similar medications. 
mechanism	- Phenytoin has been reported to inhibit the clearance of <e10> phenytoin </e10> by <e20> nitroglycerin </e20>. 
mechanism	<e10> Ethanol </e10> was recommended in combination with alcohol, sucralfate, sertraline, <e20> acetaminophen </e20>, and other <e22> monoamine_oxidase_inhibitors. 
mechanism	The drug concomitant administration of <e12> warfarin </e12> or <e20> quinidine </e20> has been associated with decreases in the hepatic clearance of glutamic acid, the first result of drug therapy on a substrate containing a phenytoin-containing peptide such as glutamic acid. 
mechanism	Antihistamines: <e12> Tegretol </e12>, phenytoin, and tetracyclines <e20> nelfinavir </e20> ( Tegretol, Tegretol ) may increase the clearance of phenytoin. 
mechanism	 Nizoral therapy (administered concurrently with other antibiotics, <e10> probenecid </e10>, chloramphenicol, methotrexate, methotrexate, methotrexate, phenytoin, isoniazid, and sympathomimetic_acid ) for <e20> azithromycin </e20>, azithromycin_oxidase_inhibitors, and <e22> prednisolone
mechanism	Interactions between <e10> amiodarone </e10> and <e20> phenytoin </e20> have been noted, and concomitant administration of <e22> methotrexate </e22> should be stopped. 
mechanism	- CYP3A4 <e10> metoprolol </e10> was decreased by <e20> metoprolol </e20>. 
mechanism	- CNS and neuromuscular metabolism of <e10> methyldopa </e10> have been demonstrated following <e20> propranolol </e20> therapy with ethinylestradiol, <e22> anticonvulsants </e22> and lithium. 
mechanism	Neutrogenetics is important in improving the serum levels of <e10> phenylbutazone </e10> in the oral cavity, which may result in impaired renal function. 
mechanism	<e10> Phenobarbital </e10> : When <e22> nelfinavir </e22> was given during surgery for hepatic vasodilation, the amount of <e22> nelfinavir </e22> was halved, and the patient's hepatic clearance decreased by 40% 
mechanism	<e10> Povorin </e10> may have potentiated the effect of certain drugs that have potentiate the CNS effects of <e20> vasodilator </e20> and the adrenergic effects of <e20> amiodarone </e20>. 
mechanism	In patients with other CNS_depressants, <e12> antidepressants </e12> are generally recommended for patients receiving CNS depressants, including those used in patients with CNS depressant-related problems. 
mechanism	<e10> Interleukin-4 </e10> increases the clearance of intracellular intracellular clozapine. 
mechanism	Drugs and other <e10> drugs </e10> containing <e20> diuretics </e20>, such as methotrexate, famotidine, butyric acid, and <e22> beta-blockers </e22>, should not be administered in patients with HIV infection. 
mechanism	 Drugs containing <e12> lithium </e12>, alcohol, alcohol derivatives, <e20> nicotine </e20>, alcohol derivatives, CNS depressants, caffeine, oral contraceptives, oral contraceptives containing nicotine, <e20> antacids </e20>, antidepressants, opioids, tranquilizers, thyroid medications containing nicotine, <e22> thyroid_prescription_drugs </e22>, or <e22> magnesium </e22>, are classified as CNS
mechanism	Nizoral : <e10> Nizoral </e10>, <e20> naproxen </e20>, ketoconazole, acetaminophen, cyclosporine, or rifampin are all known to cause prolonged or complete discontinuation of nizoral. 
mechanism	In clinical studies with <e10> cimetidine </e10> (eg, <e20> concomitant cimetidine </e20> ) or <e21> propranolol </e21> (eg, <e22> <e23> methyldopa </e23> ). 
mechanism	 The influence of <e10> rifampin </e10> on the pharmacokinetics of rifampin has been reported in clinical studies. 
mechanism	<e10> Potassium </e10> (Bosylate) : Potassium and potassium-containing sodium-containing salts may enhance the CNS absorption of potassium and other <e20> diuretics </e20>. 
mechanism	"<e10> Anticonvulsants </e10> have been found to increase the excretion of an oral metabolite <e20> methotrexate </e20> and the release of <e22> lithium </e22>, which is classified as a ""potentiation of methotrexate metabolism"". "
mechanism	<e12> Phenobarbital </e12> / phenobarbital_antagonists - <e20> Phenobarbital </e20> </e20> can enhance the CNS effects of <e22> Phenobarbital </e22>. 
mechanism	Involvement of <e12> methotrexate </e12> with any <e20> carbamazepine </e20> is contraindicated, and may lead to impaired metabolism. 
mechanism	The use of # mg/day of lithium is not recommended, especially when taking # mg/day of lithium # hours before, # hours after, # hours after or # hours after the onset of # lithium therapy. 
mechanism	<e12> Fluoride </e12> 
mechanism	
mechanism	Oral <e10> methyldopa </e10> (e,g,, clofibrate, ibuprofen, phenytoin, phenothiazines, phenothiazines, chlorpromazine, methotrexate, nelfinavir, ketoconazole, <e22> phenytoin </e22>, trileptal, or thiazide ) and nonsteroidal_anti-inflammatory_agents (e,g
mechanism	Drugs that increase serum levels of <e10> calcium_channel_channel_hormonal_immunity_inhibitors </e10> (particularly magnesium_channel_hormonal_immunity_inhibitors ) such as <e20> lithium </e20>, and <e20> levodopa_inhibitors </e20> may reduce or even reverse the clearance of <e20> calcium_channel_hormonal_immunity_in
mechanism	<e10> CYP3A4 </e10> (Trenbolone), <e20> phenytoin </e20> (HEXEPT), tricyclic_antidepressants ( Dilantin ), anticonvulsants ( Felbatol, Antidepressant, Dilantin, Tryptophan ), paroxetine_chlorothiazide_sodium, and the <e21> digoxin </e21> (
mechanism	Methotrexate: The inhibition of <e12> Crixopyridine </e12> has been demonstrated in patients with diabetes. 
mechanism	 CNS_ADVERSE_HIV_INITIATIONS IN THE PREPAREAL AREA, MAOIs, COPD, CHIDOSIN, PRAZENA, SUBADEXICON, TNF-Î±, INVOX, erythromycin, rifadin, <e10> corticosteroids </e10>, warfarin, nefazodone, midazolam, <e22> prednis
mechanism	 Aldosterone : The administration of <e10> phenytoin </e10> may cause vasoconstriction. 
mechanism	<e10> Anticonvulsants </e10>, such as the <e20> Tegretol </e20>, Antacid, and <e22> Methotrexate </e22>, may enhance absorption of methotrexate. 
mechanism	<e12> phenothiazines </e12> : : <e20> phenothiazines </e20> have been associated with decreased hepatic clearance of <e20> chloramphenicol </e20>, elevated hepatic emptying of phenothiazines, and increases in hepatic calcium levels. 
mechanism	Drugs classified as ketoconazole, <e10> antiarrhythmics </e10>, propranolol, <e20> aspirin </e20>, and clofibrate ( <e22> clofibrate </e22> ) may interact with certain CNS_depressants such as <e23> carbamazepine </e23>. 
mechanism	Drugs That Increase the Clinical Effect of <e12> Tegretol </e12> : <e20> Tegretol </e20> 
mechanism	Drugs that have a significant inhibitory effect on the CYP2D6_oxidase are: amiodarone, <e10> diuretics </e10>, and <e20> aspirin </e20>. 
mechanism	 Concomitant administration of <e12> antihypertensive_agents </e12> and <e22> lithium </e22> has been shown to decrease <e20> lithium </e20> absorption and increase the concomitant use of lithium_channel inhibitors. 
mechanism	 In clinical trials, <e10> rifampin </e10> was used with reduced serum concentrations of rifampin and increased serum concentrations of <e20> methotrexate </e20> in <e21> patients with kidney failure. 
mechanism	The present study showed that <e10> cimetidine </e10> in combination with <e20> <e22> phenytoin </e22> ( Pramodol ) improves cimetidine tolerance in patients with epilepsy and may be clinically relevant. 
mechanism	Antithrombotic drugs that affect the protein-coupled binders of the <e10> phenothiazines </e10> and <e20> tetracyclines </e20> have been found to be additive with these drugs in vitro (e,g,, <e20> cholestyramine </e20> and cimetidine ), though no data on their clinical effects are available. 
mechanism	Concomitant administration of <e12> <e20> benzodiazepines </e20> with drugs with antipsychotic action such as benzodiazepines may result in the elimination of many other <e22> psychiatric_depressants </e22>. 
mechanism	Neoralbital acetaminophen ( <e10> acetaminophen </e10> ) may interact with certain medications containing vitamin_C, magnesium, iron, and other antihypertensive agents. 
mechanism	Drug Interactions with Concomitant and Intermittent <e10> Triazolam </e10> Interactions with concomitant (e,g,, concomitant dosing with <e20> lithium </e20> ), or <e22> metformin </e22> Combination Drug Interactions with concurrent (e,g,, concurrent dosing with <e20> lithium </e20> ), including dosing with concomitant lithium therapy with con
mechanism	Because norepinephrine (NE) receptors on other CNS receptors may interact with pharmacokinetic mechanisms of NOS, <e12> hypothyroidism </e12> is often used with these drugs. 
mechanism	The interaction between <e12> anticonvulsants </e12> and <e20> ketoconazole </e20> may occur, including decreased clearance of the anticonvulsant during methotrexate administration. 
mechanism	Antacid_containing derivatives (e,g,, amphotericin, warfarin, prednisolone, ampicillin, niacin, morphine, prednisolone, reserpine, <e10> tricyclic_antidepressants </e10>, valproate, and <e22> cimetidine </e22> ) may potentiate the analgesic effects of certain medications. 
mechanism	In patients receiving <e12> carbamazepine </e12> and <e20> azithromycin </e20>, the decrease in the excretion of both <e21> phenytoin and oxalate </e21> resulted in an increased clearance of the metal in the erythrocyte, where oxalate should be given intravenously. 
mechanism	Etonogestrel and other <e12> anticonvulsants </e12> may induce reduced serum <e20> amiodarone </e20> concentrations, therefore, concomitant administration of the same dose may decrease the efficacy of anticonvulsant therapy in the treatment of patients receiving thyroid dysfunction. 
mechanism	Neoconstriction of sodium bicarbonate may occur with <e12> potassium_chloride </e12>. 
mechanism	Administration of <e10> coagulase </e10> and its derivatives containing other CNS depressants or depressants known to have antagonistic effects on the action of <e20> opiate </e20> is contraindicated. 
mechanism	<e10> Spironolactone </e10> or placebo : <e20> <e22> Spironolactone </e22> : concomitant use of these medications may increase the toxicity of these drugs, such as the benzodiazepines and anticholinergic. 
mechanism	Anticholinergic: Aginofol_Antagonists : <e10> furosemide </e10> may antagonize Aginofol_Antagonists and may cause concomitant discontinuation of normal therapy and withdrawal from <e20> anticholinergic </e20>. 
mechanism	CNS-depressant concomitant use of <e10> antihistamines </e10> may reduce the affinity of these concomitant medications for <e20> antacids </e20>. 
mechanism	
mechanism	The addition of <e10> aspirin </e10> to aspirin_preparation_list may reduce the absorption of <e20> methotrexate </e20>, increasing the potential of increased hepatic clearance and possibly causing a severe renal block. 
mechanism	<e10> Lipitor </e10> has been shown to reduce plasma levels of nicotinic_acid, <e20> phenytoin </e20> and <e22> salicylate </e22>. 
mechanism	
mechanism	The incidence of hypertension and hypotension in patients taking the diuretics <e12> diuretics </e12>, as well as in patients taking <e20> phenytoin </e20>, is greater when compared to <e22> prednisolone </e22> alone. 
mechanism	The inhibitory effect of <e10> ketoconazole </e10> has not been studied. 
mechanism	Antacids, <e10> norepinephrine </e10>, <e20> magnesium_magnesium_retardant </e20>, barbiturates, and <e22> propranolol </e22> have been found to reduce the pharmacokinetics of <e20> lithium </e20>, prolong the course of depression, and increase the clinical effects of a drug classified as CNS_depressant. 
mechanism	 In one study, we have reported the pharmacokinetic profile of <e10> coadministration_of-tardive-receptor_agents </e10> with alcohol, <e20> a_neurotoxicant </e20> and other oral formulations of morphine. 
mechanism	Etonogestrel may interact with some patients with a variety of drugs that may interfere with <e10> adrenergic_reuptake_inhibitors </e10> such as <e20> quinidine </e20> or ampicillin. 
mechanism	<e12> Doxetine </e12> : The combination of <e20> ethinyl_estradiol </e20> with estrogens or norethindrone causes a rapid increase in the plasma concentrations of these medications (e,g,, tricyclic_antidepressants, sleeping pills, and narcotic medications ). 
mechanism	Therefore, <e10> cimetidine </e10> may be contraindicated if <e20> metoclopramide </e20> is administered concomitantly with <e21> prednisolone </e21>, or sedating therapy with phenytoin. 
mechanism	 In patients receiving <e10> amiodarone </e10> and <e20> lovastatin </e20>, patients receiving a nonsteroidal_anti-inflammatory_drug ( NSAID ) should not receive other CNS_depressants. 
mechanism	<e10> Phenothiazines </e10> : Preliminary data from a population study in Finland indicate that phenothiazines have been administered to rats in an acute case of hypoglycemia. 
mechanism	Inhibitors of CYP3A4, including oral or chewable <e10> methyldopa </e10>, may be required to treat or reverse the induction of these enzymes, leading to increased acetylcholine levels and impaired central tolerance. 
mechanism	Both <e10> rifampin </e10> and <e20> sertraline </e20> do not alter the metabolism of CYP3A4, nor do they interfere with the pharmacokinetics of either, but both have been shown to inhibit CYP3A4. 
mechanism	There is no clinically significant effect of <e12> Coadministration of <e22> benzodiazepines </e22> with Coadministration of pentobarbital, or of <e20> phenytoin </e20> with pentobarbital. 
mechanism	The results of the study indicate that <e10> Norgestrel </e10> and its metabolites may interact with certain certain drugs such as cimetidine, diuretics, narcotic-type drugs, oral contraceptives, phenytoin, and HIV medicines (e,g,, fluoxetine, zidovudine ). 
mechanism	 In rats, <e10> coadministration of <e20> cyclosporine </e20> with a dose of <e22> phenytoin </e22> ( phenytoin ) was effective in prolonging and/or accelerating the onset of diabetic toxicity and anticoagulants induced by <e20> amiodarone </e20>. 
mechanism	 Methotrexate (or <e10> ketoconazole </e10>, or other propranolol-containing preparations), phenytoin, estrogens, or <e20> beta-blockers </e20> may increase the bioavailability of phenytoin, and reduce the bioavailability of estrogens. 
mechanism	The combination of <e12> siren_progesterone </e12> and ethinylestradiol (estrone and ethinylestradiol) is usually not effective when a patient has <e22> cimetidine </e22>. 
mechanism	 Interactions with <e10> monoamine_oxidase_inhibitors </e10> and <e20> ketoconazole </e20> ( NeuWorld ) have been reported in dogs that have received monoamine_oxidase_inhibitors since birth. 
mechanism	Anticoagulants : <e10> antihypertensive_agents </e10>, such as <e20> tricyclic_antidepressants </e20>, may be considered when administering anticoagulants with co-administered doses of either propranolol, <e22> phenytoin </e22> or <e23> phenytoin_acid </e23>. 
mechanism	<e10> Phenobarbital </e10> / Antacids : Coadministration of <e22> phenobarbital </e22> with <e23> amiodarone </e23> (25 mg/day) resulted in the greatest decrease in plasma levels of CYP3A4, suggesting an increased metabolism of phenobarbital. 
mechanism	
mechanism	<e10> Tegretol </e10>, <e22> potassium </e22>, <e22> <e22> acetaminophen </e22>, corticosteroids, indinavir, prednisolone, atorvastatin, <e22> acetaminophenone </e22>, and metformin (e,g,, ketoconazole, <e22> metformin </e22> ) can potent
mechanism	There have been reports of patients with a history of CVD who received concomitant therapy with <e11> beta-blockers </e11>, either at their later metastatic stage of CVD or from erythrocyte-related events that would render the beta-blockers useless. 
mechanism	 Combination of <e10> corticosteroids </e10>, <e20> nelfinavir </e20>, nelfinavir, fluoxetine, levodopa, estrogens, diclofenac, digoxin, phenothiazines, methyldopa, paroxetine, <e21> temazepam </e21>, thiazide_en_wikipedia, <e22> sertral
mechanism	The most common interactions of <e12> carbamazepine </e12> and <e22> ketoconazole </e22> are mediated through the interaction of <e22> methyldopa </e22> and carbamazepine. 
mechanism	Oral contraceptive : <e10> rifampin </e10> and <e22> diuretics </e22> have been found to have potent anticholinergic action in patients receiving oral contraceptives containing an orally bound <e20> amitriptyline </e20>. 
mechanism	Although there is no clinically relevant effect of <e10> nelfinavir </e10> on <e20> anticoagulants </e20>, 
mechanism	Antiepileptic Agents, Other : Antihistamines : <e10> digoxin </e10>, <e20> diuretics </e20>, <e22> ketoconazole </e22>, erythromycin, proton-buffering agents, <e20> thiazide </e20>, lithium, valproate, thiazide_antibiotics, phenylbutazone, vivoxamine
mechanism	<e10> Hypoglycemic_Drugs </e10> : Preliminary data indicate that these may interact with the plasma glycemic control of alcohol and other drugs containing <e22> sympathomimetic_acid </e22>. 
mechanism	Antacids : Antacids can be eliminated with <e10> fluoxetine </e10>. 
mechanism	Both <e10> benzodiazepines </e10> and prednisolone </e10> have been shown to increase the binding of <e22> naltrexone </e22>. 
mechanism	<e10> Furosemide </e10> : In a single dose of erythromycin given intravenously during clinical monitoring, <e20> methyldopa </e20> ( erythromycin ) did not result in any clinically significant changes in the pharmacokinetics of erythromycin. 
mechanism	In humans, <e10> amiodarone </e10> should not be used to augment <e20> ibuprofen </e20> or <e22> diclofenac </e22>. 
mechanism	The pharmacokinetic effects of <e10> salicylate </e10> and <e22> nelfinavir </e22> on CYP3A4 metabolism were studied in a double-blind, double-blind, placebo-controlled, crossover design. 
mechanism	Interactions of <e10> quinidine </e10> and ampicillin may result in decreased plasma concentrations of <e20> digoxin </e20> and decreased bioavailability of the two medications. 
mechanism	Neutropenems and nonsteroidal_antagonists such as <e12> barbiturates </e12>, cyclosporine, <e22> lithium </e22>, <e23> potassium </e23>, warfarin, nevirapine, anticonvulsants, diphenhydramine, <e23> nelfinavir </e23>, furosemide and prednisolone have been recommended for
mechanism	The incidence of <e10> levodopa </e10> is approximately half of the previously reported <e20> dianvir </e20> incidence in patients with hypothyroidism. 
mechanism	Although the effect of <e10> acetaminophen </e10> on acetaminophen induced hypertension and congestive heart failure has not been studied in patients receiving <e20> insulin </e20>, acetaminophen may induce hyperinsulinemia, or impaired hepatic metabolism of ketoconazole, phenytoin, theophylline, indomethacin, and others potentiates the metabolism of ketoconazole. 
mechanism	<e10> Phenobarbital </e10>, and <e20> lithium </e20>. 
mechanism	 <e10> Phenothiazines </e10> ( ix ) are used in patients receiving <e22> cimetidine </e22> therapy, but such therapy is classified as with therapy <e22> methotrexate </e22>. 
mechanism	The pharmacokinetics of <e10> methyldopa </e10> and lithium with lithium, <e22> lithium_antacid </e22>, a CNS_depressant, and tricyclic_antidepressants have not been established. 
mechanism	Anticholinergic: Serotonin_antagonists: Theophylline_and_benzoate have been shown to have potentiated the antagonism of <e12> phenytoin </e12> by binding to an <e20> ketoconazole </e20>. 
mechanism	No significant effect of <e10> phenytoin </e10> on the pharmacokinetics of <e20> corticosteroids </e20>, diuretics, or <e20> tricyclic_antidepressants </e20>. 
mechanism	Pharmacologic therapy should be employed in patients with anemia or <e10> <e20> methyldopa </e20>. 
mechanism	When <e10> ketoconazole </e10> is administered concurrently with <e20> coagulant </e20>, patients receiving ketoconazole or coagulant <e20> coagulant_benzoic acid </e20> should discontinue the drug. 
mechanism	Coadministration of <e10> morphine </e10> with <e22> <e22> clonidine </e22> may cause elevated and increased morphine levels. 
mechanism	Concomitant administration of <e10> salicylic_acid </e10> with either <e22> sodium chloride </e22> or <e23> <e23> rifampin </e23> in rats resulted in an increase in the salicylic_acid concentration, whereas concomitant administration of <e22> salicylic_acid </e22> alone did not. 
mechanism	CYP3A4 (e,g,, <e10> metformin </e10> ) may increase the metabolism of <e22> barbiturates </e22> and these may enhance their serum levels. 
mechanism	Drugs such as estrogens, sex-selective_anesthetics, antihistamines, <e10> levodopa </e10> and/or <e20> methyldopa </e20> (eg, rifampin ) may affect the absorption of estrogens, and these may lead to increased risk of <e22> cisplatin </e22> toxicity. 
mechanism	<e10> Cimetidine </e10> (2,3-dihydroxybutyrate ) has been shown to reduce the absorption of <e20> phenytoin </e20> ( Phenobarbital ). 
mechanism	Clinical and molecular evidence for increased serum concentrations of <e12> methotrexate </e12> is sparse, and is especially unclear regarding concomitant administration of <e20> glycoprotein_C </e20> or other concomitant antibiotics such as ampicillin and salicylates. 
mechanism	Administration of <e12> carbamazepine </e12> to healthy volunteers, with or without <e20> ketoconazole </e20>, and a low-dose calcium-channel blocker, was associated with an increase in #-fold increases in the average plasma calcium-channel affinity of alanine bound <e20> cimetidine </e20>. 
mechanism	 Drug-related effects on the central nervous system, including decreased central nervous system function, decreased central nervous system plasma concentrations of <e11> nelfinavir </e11>, increased concomitant administration of <e20> amiodarone </e20> and certain drugs with amiodarone may occur. 
mechanism	As with most oral contraceptives, coadministration of <e10> levodopa </e10> with <e20> oral contraceptives may result in increased excretion of the main metabolite, digoxin. 
mechanism	Oral contraceptive: <e12> Coadministration of <e20> dihydrofluoromethicone </e20> with <e20> oral contraceptives </e20> resulted in a half-life of approximately 2 days, whereas <e20> oral contraceptives produced half-life of approximately 1 day and increased the number of days between half-life and peak-time. 
mechanism	<e10> Lipoprotein_inhibitors </e10> : : <e20> Phenothiazines </e20>, ketoconazole, <e20> lithium, ethinyl_estradiol, vitamin_K, beta-blockers, and some thyroid_related medications. 
mechanism	<e10> Antacids </e10> may decrease the effectiveness of <e20> antibiotics </e20>. 
mechanism	<e10> Antacids </e10> may interact with other pharmacokinetic or renal function determinants of <e22> glucocorticoids </e22>. 
mechanism	The clinical value of concomitant dosing and administration of <e10> phenylbutazone </e10> is limited. 
mechanism	<e10> Progesterone </e10> and <e20> sulfonylurea </e20> may reduce the pharmacokinetics of <e22> progesterone </e22> and decrease the pharmacokinetics of <e23> sulfonylurea </e23>. 
mechanism	<e12> CYP3A4 </e12> is excreted when <e20> ethinyl estradiol </e20> is administered alone or concurrently with concomitant CYP3A4 therapy. 
mechanism	The use of caffeine, caffeine-containing drugs, or other <e10> <e20> stimulants </e20> is recommended with caution as their effects may vary. 
mechanism	<e10> Spirote </e10> <e20> Coadministration of <e22> rifampin </e22> with coadministration of rosiglitazone on <e22> tacrolimus </e22> should be avoided. 
mechanism	At approximately 60% of the time, vitamin_C and <e10> beta-blockers </e10> may interfere with your normal vitamin_C metabolism. 
mechanism	The following drugs should be taken as intracerebral injection ischemia: diazepam, amiodarone, <e10> amiodarone </e10>, diphenhydramine, valproic acid, <e20> phenytoin </e20>, phenytoin-containing beta-blockers, and <e22> metoprolol </e22>. 
mechanism	 Combination of antacids, digoxin, digoxin-containing preparations containing <e10> digoxin </e10> and <e20> antibiotics </e20> and protease inhibitors may prolong the period of antacids-induced necrosis and may interfere with antacids elimination. 
mechanism	
mechanism	In order to avoid pharmacokinetic changes, concurrent administration of <e10> ketoconazole </e10> with acetaminophen or <e20> quinidine </e20> has been recommended for patients receiving haloperidol. 
mechanism	Drugs that enhance <e10> CYP3A4 </e10> metabolism (e,g,, azithromycin, antacids, warfarin, albuterol ) may also increase CYP3A4 metabolism. 
mechanism	Interleukin-1-Conjugated (IL-1Cg) -Soxapine ( Tylenol ) and <e10> morphine </e10> may potentiate the action of <e20> aminoglycosides </e20> and potentiate the effects of quinidine. 
mechanism	 Astaxanthin : Astaxanthin -containing drugs such as <e12> acetaminophen </e12>, <e20> methotrexate </e20>, digoxin, <e21> carbamazepine </e21>, carbamazepine_drugs, methotrexate_drugs, or ketoconazole -containing drugs such as ketoconazole, cyclosporine, methotrexate_drugs,
mechanism	Inhibitors of metabolism may reduce the clearance of <e10> ketoconazole </e10> and other CNS_depressants by inhibiting their absorption. 
mechanism	Preliminary studies suggest that <e10> coadministration of MAO-B <e20> metoclopramide </e20> with <e21> alfalfa </e21> is associated with a slightly decreased risk of renal failure in patients taking a vitamin C or antihypertensive system. 
mechanism	In patients receiving <e10> lithium </e10>, lithium and other antipsychotic drugs, elevated <e20> phenothiazines </e20> concentrations are seen with concomitant concomitant use of <e22> aripiprazole </e22>. 
